
<html lang="en"     class="pb-page"  data-request-id="ae0109ab-efb4-4825-94ff-d82ba56ee9e9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2013.56.issue-16;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm400778d"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives" /></meta><meta name="dc.Creator" content="Masanori  Okaniwa" /></meta><meta name="dc.Creator" content="Masaaki  Hirose" /></meta><meta name="dc.Creator" content="Takeo  Arita" /></meta><meta name="dc.Creator" content="Masato  Yabuki" /></meta><meta name="dc.Creator" content="Akito  Nakamura" /></meta><meta name="dc.Creator" content="Terufumi  Takagi" /></meta><meta name="dc.Creator" content="Tomohiro  Kawamoto" /></meta><meta name="dc.Creator" content="Noriko  Uchiyama" /></meta><meta name="dc.Creator" content="Akihiko  Sumita" /></meta><meta name="dc.Creator" content="Shunichirou  Tsutsumi" /></meta><meta name="dc.Creator" content="Tsuneaki  Tottori" /></meta><meta name="dc.Creator" content="Yoshitaka  Inui" /></meta><meta name="dc.Creator" content="Bi-Ching  Sang" /></meta><meta name="dc.Creator" content="Jason  Yano" /></meta><meta name="dc.Creator" content="Kathleen  Aertgeerts" /></meta><meta name="dc.Creator" content="Sei  Yoshida" /></meta><meta name="dc.Creator" content="Tomoyasu  Ishikawa" /></meta><meta name="dc.Description" content="With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 i..." /></meta><meta name="Description" content="With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 i..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 1, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400778d" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400778d" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400778d" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400778d" /></link>
        
    
    

<title>Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400778d" /></meta><meta property="og:title" content="Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0019.jpeg" /></meta><meta property="og:description" content="With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor 1 and developed a regioselective cyclization methodology for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines. Eventually, we selected 7-cyano derivative 8B (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF. Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2. Reflecting its potent pan-RAF inhibition and slow off-rate profile, 8B demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines. Furthermore, in both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, 8B demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body weight loss." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400778d"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400778d">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400778d&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400778d&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400778d&amp;href=/doi/10.1021/jm400778d" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 6478-6494</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm4007565" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400807n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of <i>C</i>-7-Substituted 1,3-Benzothiazole Derivatives</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masanori++Okaniwa">Masanori Okaniwa</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masaaki++Hirose">Masaaki Hirose</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takeo++Arita">Takeo Arita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masato++Yabuki">Masato Yabuki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akito++Nakamura">Akito Nakamura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Terufumi++Takagi">Terufumi Takagi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomohiro++Kawamoto">Tomohiro Kawamoto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Noriko++Uchiyama">Noriko Uchiyama</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akihiko++Sumita">Akihiko Sumita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shunichirou++Tsutsumi">Shunichirou Tsutsumi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tsuneaki++Tottori">Tsuneaki Tottori</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoshitaka++Inui">Yoshitaka Inui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bi-Ching++Sang">Bi-Ching Sang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Yano">Jason Yano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Aertgeerts">Kathleen Aertgeerts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sei++Yoshida">Sei Yoshida</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomoyasu++Ishikawa">Tomoyasu Ishikawa</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">CMC Center, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Structural Biology, Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>(M.O.) Phone: +81-466-32-1158. Fax: +81-466-29-4448. E-mail: <a href="/cdn-cgi/l/email-protection#137e7260727d7c617a3d7c78727d7a6472536772787677723d707c7e"><span class="__cf_email__" data-cfemail="7d101c0e1c13120f145312161c13140a1c3d091c1618191c531e1210">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>(M.H.) Phone: +81-466-32-1029. Fax: +81-466-29-4448. E-mail: <a href="/cdn-cgi/l/email-protection#fd909c8e9c9c9694d395948f928e98bd899c9698999cd39e9290"><span class="__cf_email__" data-cfemail="9ef3ffedfffff5f7b0f6f7ecf1edfbdeeafff5fbfaffb0fdf1f3">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>(T.I.) Phone: +81-466-32-1155. Fax: +81-466-29-4449. E-mail: <a href="/cdn-cgi/l/email-protection#02766d6f6d7b6371772c6b716a6b69637563427663696766632c616d6f"><span class="__cf_email__" data-cfemail="14607b797b6d7567613a7d677c7d7f7563755460757f7170753a777b79">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400778d&amp;href=/doi/10.1021%2Fjm400778d" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 6478–6494</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 1, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 May 2013</li><li><span class="item_label"><b>Published</b> online</span>1 August 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 August 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400778d" title="DOI URL">https://doi.org/10.1021/jm400778d</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6478%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMasanori%2BOkaniwa%252C%2BMasaaki%2BHirose%252C%2BTakeo%2BArita%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D16%26contentID%3Djm400778d%26title%3DDiscovery%2Bof%2Ba%2BSelective%2BKinase%2BInhibitor%2B%2528TAK-632%2529%2BTargeting%2BPan-RAF%2BInhibition%253A%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BC-7-Substituted%2B1%252C3-Benzothiazole%2BDerivatives%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6494%26publicationDate%3DAugust%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400778d"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4204</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">62</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400778d" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Masanori&quot;,&quot;last_name&quot;:&quot;Okaniwa&quot;},{&quot;first_name&quot;:&quot;Masaaki&quot;,&quot;last_name&quot;:&quot;Hirose&quot;},{&quot;first_name&quot;:&quot;Takeo&quot;,&quot;last_name&quot;:&quot;Arita&quot;},{&quot;first_name&quot;:&quot;Masato&quot;,&quot;last_name&quot;:&quot;Yabuki&quot;},{&quot;first_name&quot;:&quot;Akito&quot;,&quot;last_name&quot;:&quot;Nakamura&quot;},{&quot;first_name&quot;:&quot;Terufumi&quot;,&quot;last_name&quot;:&quot;Takagi&quot;},{&quot;first_name&quot;:&quot;Tomohiro&quot;,&quot;last_name&quot;:&quot;Kawamoto&quot;},{&quot;first_name&quot;:&quot;Noriko&quot;,&quot;last_name&quot;:&quot;Uchiyama&quot;},{&quot;first_name&quot;:&quot;Akihiko&quot;,&quot;last_name&quot;:&quot;Sumita&quot;},{&quot;first_name&quot;:&quot;Shunichirou&quot;,&quot;last_name&quot;:&quot;Tsutsumi&quot;},{&quot;first_name&quot;:&quot;Tsuneaki&quot;,&quot;last_name&quot;:&quot;Tottori&quot;},{&quot;first_name&quot;:&quot;Yoshitaka&quot;,&quot;last_name&quot;:&quot;Inui&quot;},{&quot;first_name&quot;:&quot;Bi-Ching&quot;,&quot;last_name&quot;:&quot;Sang&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Yano&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Aertgeerts&quot;},{&quot;first_name&quot;:&quot;Sei&quot;,&quot;last_name&quot;:&quot;Yoshida&quot;},{&quot;first_name&quot;:&quot;Tomoyasu&quot;,&quot;last_name&quot;:&quot;Ishikawa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;6478-6494&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400778d&quot;},&quot;abstract&quot;:&quot;With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor 1 and developed a regioselective cyclization methodology for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines. Eventually, we selected 7-cyano derivative 8B (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF. Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2. Reflecting its potent pan-RAF inhibition and slow off-rate profile, 8B demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines. Furthermore, in both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, 8B demonstrated reg&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400778d&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400778d" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400778d&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400778d" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400778d&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400778d" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400778d&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400778d&amp;href=/doi/10.1021/jm400778d" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400778d" /></input><a href="/doi/pdf/10.1021/jm400778d" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26pmid%3D23906342%26genre%3Darticle%26aulast%3DOkaniwa%26date%3D2013%26atitle%3DDiscovery%2Bof%2Ba%2BSelective%2BKinase%2BInhibitor%2B%2528TAK-632%2529%2BTargeting%2BPan-RAF%2BInhibition%253A%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BC-7-Substituted%2B1%252C3-Benzothiazole%2BDerivatives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D16%26spage%3D6478%26epage%3D6494%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jmcmar.2013.56.issue-16/production/jmcmar.2013.56.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-<i>b</i>]pyridine class RAF/VEGFR2 inhibitor <b>1</b> and developed a regioselective cyclization methodology for the <i>C</i>-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines. Eventually, we selected 7-cyano derivative <b>8B</b> (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF. Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2. Reflecting its potent pan-RAF inhibition and slow off-rate profile, <b>8B</b> demonstrated significant cellular activity against mutated <i>BRAF</i> or mutated <i>NRAS</i> cancer cell lines. Furthermore, in both A375 (<i>BRAF</i><sup>V600E</sup>) and HMVII (<i>NRAS</i><sup>Q61K</sup>) xenograft models in rats, <b>8B</b> demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body weight loss.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80073" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80073" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The RAF family of protein kinases plays critical roles in cancer progression.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Recently, BRAF selective inhibitors such as vemurafenib (PLX4032)<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> and dabrafenib (GSK2118436)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> have shown significant clinical efficacy in melanoma patients bearing oncogenic <i>BRAF</i><sup>V600E</sup> mutation (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). However, adverse events such as rapid development of squamous cell carcinoma (SCC) and keratoacanthoma have been reported.<a onclick="showRef(event, 'ref3 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref3 ref5 ref6 ref7 ref8">(3, 5-8)</a> These observations were thought to be caused by paradoxical activation of the MAPK pathway by BRAF selective inhibitors in cells bearing wild-type <i>BRAF</i> (<i>BRAF</i><sup>wt</sup>).<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> Recent studies<a onclick="showRef(event, 'ref10 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref12 ref13">(10, 12, 13)</a> on this paradoxical activation reported that RAF inhibitors instinctively transactivate RAF homodimers (CRAF–CRAF) or heterodimers (CRAF–BRAF(wt)) and activate RAS dependent MAPK signaling. Hence, it has been reported that selective BRAF(V600E) inhibitors, like vemurafenib, have not shown potent antiproliferative activity against cancer cell lines such as <i>NRAS</i> mutant melanoma in which RAS dependent MAPK signaling is activated.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of RAF inhibitors including [1,3]thiazolo[5,4-<i>b</i>]pyridine derivative <b>1</b> and 1,3-benzothiazole derivative <b>2</b> as lead compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To analyze this, our initial investigation (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>, Table S1) revealed that the feedback activation in fibroblast CsFb cells (<i>BRAF</i><sup>wt</sup>) was significantly suppressed by our DFG-out type pan-RAF inhibitor, but not by DFG-in type inhibitors, which significantly induced the phosphorylation of downstream MEK and ERK in CsFb cells. On the basis of these results, our interest was directed toward DFG-out type pan-RAF inhibitors to treat cancer patients including oncogenic <i>BRAF</i><sup>V600E</sup> as well as <i>NRAS</i> mutant in which BRAF (wt) and CRAF are being involved in aberrant signal transduction. Therefore, we initiated a drug discovery program aimed at targeting DFG-out type pan-RAF inhibitors.</div><div class="NLM_p">We have previously reported potent DFG-out type pan-RAF inhibitors<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> and identified the thiazolo[5,4-<i>b</i>]pyridine derivative <b>1</b> as an inhibitor of RAF and VEGFR2 kinases (BRAF(V600E) IC<sub>50</sub>, 5.6 nM; BRAF(wt), 12 nM; CRAF, 1.5 nM) and VEGFR2 (2.8 nM) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Compound <b>1</b> also showed potent cellular activity such as MAPK signal inhibition in various cell lines possessing the <i>BRAF</i><sup>V600E</sup> mutation and VEGFR2 phosphorylation inhibition in 293/KDR cells. In vivo studies in a rat A375 xenograft model demonstrated regressive antitumor efficacy for compound <b>1</b> based on dual inhibition of RAF and VEGFR2. However, a rat toxicological study of <b>1</b> showed pathological changes derived from angiogenesis inhibition but not MAPK inhibition. These results imply that compound <b>1</b> could be exerting antiangiogenesis activity on vascular endothelial cells rather than MAPK inhibition on cancer cells. On the basis of these results, we sought to increase the pan-Raf kinase inhibitory potency relative to that for VEGFR2 kinase.</div><div class="NLM_p">To better understand kinase selectivity, we utilized the X-ray cocrystal structures of compound <b>1</b> bound to BRAF (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a>) and VEGFR2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>), which we previously reported.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The two cocrystal structures were superimposed and analyzed for differences. It was revealed that there is a notable difference between BRAF and VEGFR2 in the conformations of the benzene ring of phenylalanine in the DFG motif (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The benzene ring of Phe595 in BRAF (shown in green) is located below the thiazolo[5,4-<i>b</i>]pyridine scaffold, whereas that of Phe1047 in VEGFR2 (shown in purple) is located in front of the <i>N</i>-7 position of thiazolo[5,4-<i>b</i>]pyridine <b>1</b> with a distance of 3.2 Å. Consequently, we envisioned that the introduction of a suitable substituent at the <i>C</i>-7 position of 1,3-benzothiazole <b>2</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) could reduce VEGFR2 inhibitory activity by steric repulsion between Phe1047 and the 7-substituent (Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). On the basis of this hypothesis to increase BRAF selectivity over VEGFR2, we planned to introduce an R<sup>1</sup> substituent that would be accommodated in this BRAF-selectivity pocket in front of the <i>C</i>-7 position.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural differences in the adenine sites of BRAF and VEGFR2 bound to RAF/VEGFR2 inhibitor <b>1</b>. The BRAF structure (4DBN) is shown in green and the VEGFR2 stucture (3VNT) in purple.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of designed <i>C</i>-7-substituted 1,3-benzothiazole derivatives and their predicted binding mode to the DFG-out conformation of BRAF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design approaches employed for the ring A moiety and the ring B–linker–ring C moiety. (A) Ring A moiety: introduction of an R<sup>1</sup> group at the <i>C</i>-7 position for targeting a BRAF-selectivity pocket adjacent to Phe595. (B) Ring B–linker–ring C moiety targeting the hydrophobic back pocket of BRAF: ureide derivatives <b>4</b>–<b>6</b> (linker: NHCONH) and acetamide derivatives <b>7</b>–<b>9</b> (linker: NHCOCH<sub>2</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additionally, we examined a new ring B–linker–ring C moiety targeting the hydrophobic back pocket of BRAF (Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). According to our crystallographic data, the NHCO amide substructure connected to ring B could apparently form two significant hydrogen bonds with Glu501 and Asp594. Insertion of X (NH or CH<sub>2</sub>) into the linker was an important modification because the additional amine (X = NH) of ureides <b>4</b>–<b>6</b> could form an additional hydrogen bond with the carboxylic acid of Glu501, and the methylene (X = CH<sub>2</sub>) of the acetamides <b>7</b>–<b>9</b> was considered flexible enough that the conformation of ring C could adjust to be accommodated into the hydrophobic back pocket of BRAF.</div><div class="NLM_p">Our synthetic strategy for the preparation of the <i>C</i>-7-substituted 1,3-benzothiazole scaffold is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The <i>C</i>-7 unsubstituted (R<sup>1</sup> = H) 1,3-benzothiazole derivative <b>2</b> was synthesized by Kaufmann’s method<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> from 4-phenoxylated aniline intermediate <b>10</b> (R<sup>1</sup> = H) using potassium thiocyanate (KSCN) and bromine (Br<sub>2</sub>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> For the construction of the 1,3-benzothiazole scaffold, this methodology was frequently applied to symmetrical anilines such as <i>para</i>-substituted anilines<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> or <i>ortho</i>-substituted anilines such as 2-methoxy-4-substituted anilines.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In such cases, regioselectivity of the product formed was either not an issue or was controlled by the presence of an ortho substituent. In general, the electrophilic aromatic substitution occurs in a regioselective manner, and the regioselectivity is generally affected by substituents on the aromatic ring. Consequently, the regioselective cyclization of meta-substituted aniline <b>10</b> with a variety of R<sup>1</sup> substituents (R<sup>1</sup> ≠ H) was of great interest in order to enable the efficient synthesis of desired <i>C</i>-7 isomer <b>11</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). However, to the best of our knowledge, only a few publications describing the preparation of <i>C</i>-7-substituted 1,3-benzothiazoles by cyclization directly from meta-substituted anilines have been reported (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>, Table S2).<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> Therefore, we initiated synthetic studies on this scaffold.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Strategy for the Preparation of <i>C</i>-7-Substituted 1,3-Benzothiazole Intermediates <b>11</b> by the Regioselective Cyclization of Aniline <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this article, we describe the design, synthesis, and structure–activity relationships (SAR) of novel DFG-out type selective kinase inhibitors targeting pan-RAF inhibition. In addition, the characterization of our development candidate <b>8B</b> using surface plasmon resonance (SPR) spectroscopy and its application to human cancer cells harboring either mutant <i>BRAF</i> or mutant <i>NRAS</i> are also discussed.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The precursor anilines <b>10a</b>–<b>d</b> for 1,3-benzothiazole formation were prepared as shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. S<sub>N</sub>Ar displacement of nitrobenzenes <b>14a</b>–<b>c</b> with known phenol derivative <b>13</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> in the presence of potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) gave the phenoxylated compounds <b>15a</b>–<b>c</b> in 70–98% yield. Reduction of the nitro group for <b>15a</b>,<b>c</b> was carried out using reduced iron (Fe(0)) in the presence of calcium dichloride (CaCl<sub>2</sub>) in 90% ethanol/water to avoid side reactions such as defluorination (<b>10a</b>) or nitrile reduction (<b>10c</b>) under hydrogenation conditions using palladium on activated carbon (Pd/C). As a result, the corresponding anilines <b>10a</b>,<b>c</b> were obtained in 82–99% yield. For compound <b>15b</b>, hydrogenation of the nitro group using Pd/C gave the corresponding aniline <b>10b</b> in 92% yield. In this reaction, 1-methylpyrrolidone (NMP) was used as a cosolvent to dissolve substrate <b>15b</b>, which is insoluble in a mixed solvent of tetrahydrofuran (THF) and methanol (MeOH). The aniline derivative <b>10d</b> was directly synthesized from phenol <b>13</b> with 4-fluoro-3-nitroaniline <b>14d</b> (yield: 82%) using cesium carbonate (Cs<sub>2</sub>CO<sub>3</sub>) in DMF.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 25–80 °C, 12–18 h (70–98%); (b) Fe(0), CaCl<sub>2</sub>, EtOH/H<sub>2</sub>O (9:1), 80–100 °C (82–99%); (c) H<sub>2</sub>, 10% Pd/C, NMP/MeOH/THF (2:4:1), room temp., 14 h (92%); (d) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 16 h (82%).</p></p></figure><div class="NLM_p">Next, the regioselective 1,3-benzothiazole formation reaction for anilines <b>10a</b>–<b>d</b> was investigated. We applied Kaufmann’s conditions<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> to this reaction; the results are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. We first determined the optimal amounts of KSCN and Br<sub>2</sub> for this reaction. The optimized stoichiometry was 4 and 1.5 equivalents relative to the anilines <b>10a</b>–<b>d</b>, respectively. Lower amounts of KSCN or bromine caused low yields. The reaction of <b>10a</b> (R<sup>1</sup> = F) under these optimized conditions gave <i>C</i>-5 fluorinated isomer <b>12a</b> in 57% yield. In this experiment, the <i>C</i>-7 isomer <b>11a</b> was not isolated after conventional workup. Although the regioselectivity in <b>10a</b> was undesirable for our design concept, we continued our efforts to achieve the desired regioselectivity using other anilines <b>10b</b>–<b>d</b> possessing various R<sup>1</sup> substituents. Interestingly, the ring formation reactions of <b>10b</b> (R<sup>1</sup> = CO<sub>2</sub>Me), <b>10c</b> (R<sup>1</sup> = CN), and <b>10d</b> (R<sup>1</sup> = NO<sub>2</sub>) provided <i>C</i>-7 isomers <b>11b</b>–<b>d</b> with our desired regioselectivity in 73–90% isolated yields. Although the reaction of <b>10b</b> (R<sup>1</sup> = CO<sub>2</sub>Me) provided the <i>C</i>-5 isomer in 5% yield, the reaction of <b>10c</b> (R<sup>1</sup> = CN) and <b>10d</b> (R<sup>1</sup> = NO<sub>2</sub>) did not provide <i>C</i>-5 isomers. The change of regioselectivity between F and other R<sup>1</sup> groups such as NO<sub>2</sub> was also of great interest. This regioselectivity, <i>meta</i>-fluoroaniline provides a <i>C</i>-5 isomer<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and <i>meta</i>-nitroaniline provides a <i>C</i>-7 isomer,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> is consistent with other groups’ reports (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>, Table S2). The ring formation reaction of thioureide derivatives using bromine is also known as an alternative method to prepare the 1,3-benzothiazole ring. Some groups have reported that meta-substituted thioureides can provide <i>C</i>-5 or <i>C</i>-7 benzothiazoles in a regioselective manner (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>, Table S3).<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25-28)</a> Interestingly, the tendency for regioselectivity between both reactions is the same, and the direction of cyclization is determined by an R<sup>1</sup> substituent at the meta-position (F, <i>C</i>-5, CO<sub>2</sub>Me; NO<sub>2</sub>, <i>C</i>-7). Regarding the cyano group, our result is the first example that 7-cyano-1,3-benzothiazole can be prepared using the corresponding <i>meta</i>-cyanoaniline in a regioselective manner.</div><div class="NLM_table-wrap" id="tbl1">Table 1<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0014.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">yield<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">substrate<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" colspan="2" align="center"><i>C</i>-7 isomer <b>11</b></th><th class="colsep0 rowsep0" colspan="2" align="center"><i>C</i>-5 isomer <b>12</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">CO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">R<sup>4</sup> means the 3-(1-cyano-1-methylethyl)benzamide moiety.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Isolated yield after conventional workup. Not optimized.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Not detected.</p></div></div></div><div class="NLM_p">The synthesis of 1,3-benzothiazole derivatives <b>3b</b>–<b>f</b> is shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The acylation of 2-amino-1,3-benzothiazoles <b>11b</b>–<b>d</b> with cyclopropanecarbonyl chloride in pyridine gave the desired compounds <b>3b</b>–<b>d</b> in 68–79% yield. Hydrolysis of the methyl ester in <b>3b</b> with lithium hydroxide monohydrate (LiOH·H<sub>2</sub>O) gave the corresponding carboxylic acid <b>3e</b> in 54% yield. Reduction of the carboxyl group in <b>3e</b> was achieved via a mixed anhydride produced by the treatment of <i>iso</i>-butyl chloroformate with <b>3e</b> in the presence of triethylamine (Et<sub>3</sub>N). The subsequent reduction of the obtained anhydride with sodium borohydride (NaBH<sub>4</sub>) gave the desired hydroxymethyl derivative <b>3f</b> in 55% yield over 2 steps.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopropanecarbonyl chloride, pyridine, room temp., 2–4 h (68–79%); (b) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, room temp., 12 h (54%); (c) <i>iso</i>-butyl chloroformate, Et<sub>3</sub>N, THF, 0°C, 0.5 h; then, NaBH<sub>4</sub>, THF, MeOH, room temp., 2 h (55% in 2 steps).</p></p></figure><div class="NLM_p">The synthesis of <i>C</i>-7 cyanated 1,3-benzothiazoles <b>4</b>–<b>9</b> possessing various ring B–linker–ring C moieties is shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. This route was planned for optimization of the back pocket moiety. Therefore, we set the aniline derivatives <b>22A</b>,<b>B</b> as key intermediates for the synthesis of substituted phenyl ureides <b>4</b>–<b>6</b> and phenyl acetamides <b>7</b>–<b>9</b> in the last step in the route. The S<sub>N</sub>Ar displacement of 2-fluoro-5-nitrobenzonitrile <b>14c</b> with phenol <b>16A</b> in the presence of K<sub>2</sub>CO<sub>3</sub> gave the phenoxylated aniline <b>17A</b> in 66% yield. Protection of the amine in <b>17A</b> by a trifluoroacetyl group was achieved in 67% yield using trifluoroacetic anhydride (TFAA), followed by reduction of the nitro group in <b>18A</b> under palladium-mediated hydrogenation conditions in a mixed solvent of NMP/MeOH to give the desired compound <b>19A</b> in 99% yield. The 1,3-benzothiazole formation reaction of <b>19A</b> using KSCN and bromine successfully provided the desired 7-cyano-2-amino-1,3-benzothiazole derivative <b>20A</b> in 81% yield. The acylation of <b>20A</b> with cyclopropanecarbonyl chloride (82% yield) and subsequent trifluoroacetyl cleavage from the resulting compound <b>21A</b> with LiOH·H<sub>2</sub>O gave key intermediate <b>22A</b> in 95% yield.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>16A</b>,<b>B</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 25–60 °C, 2–4 h (66–100%); (b) TFAA, THF, room temp., 1–1.5 h (67–93%); (c) H<sub>2</sub>, 10% Pd/C, MeOH, room temp., 2–8 h (99%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp., 12 h (81–85%); (e) cyclopropanecarbonyl chloride, pyridine, THF room temp., 6–16 h (55–82%); (f) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (1:1:1), room temp., 18 h (95%); (g) NaBH<sub>4</sub>, MeOH (2.4 v/v%), EtOH, room temp., 0.5 h (85%); (h) phenyl isocyanate, DMF, room temp., 12 h (28–94%); (i) phenyl acetic acid, HATU, pyridine, 85 °C, 4 h (57–74%).</p></p></figure><div class="NLM_p">The corresponding fluorinated key intermediate <b>22B</b> (R<sup>2</sup> = F) was prepared by a method similar to that used in the preparation of <b>22A</b> (R<sup>2</sup> = H). Reaction of <b>14c</b> with commercially available <b>16B</b> in the presence of K<sub>2</sub>CO<sub>3</sub> followed by protection of the amino group using TFAA gave the desired compound <b>18B</b> in 93% in 2 steps. Reduction of the nitro group of <b>18B</b> by hydrogenation in the presence of Pd/C was carefully conducted, while monitoring the formation of defluorinated compound <b>19A</b>. Ultimately, this reaction gave the desired aniline <b>19B</b> in 99% yield without the contamination with <b>19A</b>. The 1,3-benzothiazole cyclization reaction of <b>19B</b> also successfully provided the desired isomer <b>20B</b> in 85% yield. The acylation of <b>20B</b> with cyclopropanecarbonyl chloride in the presence of pyridine in THF gave <b>21B</b> in comparatively lower yield (55%) than that for the preparation of <b>21A</b>. The reason for the reduced yield in this reaction is thought to result from cleavage of the trifluoroacetyl group in <b>20B</b>. Introduction of a fluorine atom at the ortho-position of anilide <b>20B</b> enhances the acidity of the trifluoroacetamide moiety, which may activate the nucleophilicity of the amide in its reaction with cyclopropanecarbonyl chloride to provide an asymmetrical imide at the anilino moiety (ring B). The postulated asymmetrical imide formed in situ should be easily cleaved under aqueous workup conditions to give the corresponding bis-cyclopropanecarbonylated compound as a significant byproduct. This contaminating byproduct, fortunately, could be removed by conventional silica gel column chromatography to give purified <b>21B</b>. Since the trifluoroacetamide of <b>21B</b> was highly resistant against the conventional alkaline hydrolysis conditions due to the presence of the <i>ortho</i>-fluorine group, hydride conditions using NaBH<sub>4</sub> were applied for cleavage of the trifluoroacetyl group. At first, deprotection using NaBH<sub>4</sub> was found to be very slow in EtOH. Optimal conditions were obtained by using 2–10 v/v% MeOH as an additive to accelerate the reaction. Use of greater than 10 v/v% of MeOH lowered yields due to undesirable hydrolysis of the cyclopropane carboxamide moiety at the 2-position. Ultimately, cleavage of the trifluoroacetyl group from <b>21B</b> using NaBH<sub>4</sub> in the presence of 2.4 v/v% MeOH in EtOH gave deprotected aniline <b>22B</b> in 85% yield.</div><div class="NLM_p last">Ureide formation from intermediate anilines <b>22A</b>,<b>B</b> with the corresponding isocyanate reagents was accomplished under conventional conditions to give the desired ureide derivatives <b>4A</b>, <b>5A</b>,<b>B</b>, and <b>6A</b>,<b>B</b> in 28–94% yield. Condensation of anilines <b>22A</b>,<b>B</b> with the corresponding phenyl acetic acids using hexafluorophosphate, <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium (HATU), as a coupling reagent in the presence of pyridine provided the desired acetamide derivatives <b>7A</b>, <b>8A</b>,<b>B</b>, and <b>9A</b> in 57–74% yield.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The 1,3-benzothiazoles <b>3b</b>–<b>f</b> that possess various R<sup>1</sup> substituents at the <i>C</i>-7 position were evaluated, and the SAR of <b>3b</b>–<b>f</b> compared to <i>C</i>-7 unsubstituted <b>2</b> (R<sup>1</sup> = H) is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Nitro derivative <b>3b</b> (R<sup>1</sup> = NO<sub>2</sub>) retained potent BRAF inhibition (IC<sub>50</sub> = 25 nM), while demonstrating a 5-fold reduction in VEGFR2 inhibitory activity (IC<sub>50</sub> = 70 nM) compared to that of compound <b>2</b>. The ratio of VEGFR2 IC<sub>50</sub> to BRAF IC<sub>50</sub> (V/B ratio) is a useful metric in discussing the selectivity of our BRAF inhibitors. Introduction of a nitro group at the <i>C</i>-7 position (<b>3b</b>) improved BRAF selectivity (V/B ratio for NO<sub>2</sub>, 2.8; for H, 0.56). Furthermore, the cellular inhibitory activity of <b>3b</b> toward MEK phosphorylation (IC<sub>50</sub> = 29 nM) was approximately 8-fold more potent than that for <b>2</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship for <i>C</i>-7-Substituted 1,3-Benzothiazoles (R<sup>1</sup>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0015.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">kinase IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">BRAF (V600E)</th><th class="colsep0 rowsep0" align="center">VEGFR2</th><th class="colsep0 rowsep0" align="center">ratio VEGFR2/BRAF (V600E)</th><th class="colsep0 rowsep0" align="center">cellular pMEK<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> IC<sub>50</sub> (nmol/L)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">25 (23–28)</td><td class="colsep0 rowsep0" align="left">14 (13–16)</td><td class="colsep0 rowsep0" align="left">0.56</td><td class="colsep0 rowsep0" align="left">240</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3b</b></td><td class="colsep0 rowsep0" align="left">NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">25 (19–32)</td><td class="colsep0 rowsep0" align="left">70 (62–79)</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3c</b></td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">13 (11–16)</td><td class="colsep0 rowsep0" align="left">76 (52–110)</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="left">CO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">12 (9.6–15)</td><td class="colsep0 rowsep0" align="left">33 (30–36)</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3e</b></td><td class="colsep0 rowsep0" align="left">CO<sub>2</sub>H</td><td class="colsep0 rowsep0" align="left">290 (160–500)</td><td class="colsep0 rowsep0" align="left">15 (13–17)</td><td class="colsep0 rowsep0" align="left">0.051</td><td class="colsep0 rowsep0" align="left">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3f</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">24 (22–26)</td><td class="colsep0 rowsep0" align="left">7.4 (6.8–8.2)</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">170</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last"><i>n</i> = 2. 95% confidence intervals are shown in parentheses.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Cellular phosphorylation level of the downstream MEK (pMEK) was evaluated in HT-29 colon cancer cells (<i>n</i> = 1).</p></div></div></div><div class="NLM_p">Next, we evaluated the cyano derivative <b>3c</b> (R<sup>1</sup> = CN) and the methoxycarbonyl derivative <b>3d</b> (R<sup>1</sup> = CO<sub>2</sub>Me). Compounds <b>3c</b> and <b>3d</b> showed a 2-fold increase in BRAF inhibitory potency (<b>3c</b>, 13 nM; <b>3d</b>, 12 nM) compared with that of the nitro derivative <b>3b</b>. The V/B ratio of <b>3c</b> is about 2-fold that of <b>3d</b> (V/B ratio for <b>3c</b>, 5.8; for <b>3d</b>, 2.8). The cellular pMEK inhibitory activity of compounds <b>3c</b>,<b>d</b> was equal to that of <b>3b</b> with an IC<sub>50</sub> range of 24–34 nM. However, carboxylic acid derivative <b>3e</b> (R<sup>1</sup> = CO<sub>2</sub>H) and hydroxymethyl derivative <b>3f</b> (R<sup>1</sup> = CH<sub>2</sub>OH) showed different SAR. Compound <b>3e</b> showed reduced BRAF inhibitory activity (IC<sub>50</sub> = 290 nM), whereas compound <b>3f</b> retained BRAF inhibition with an IC<sub>50</sub> value of 24 nM but with reduced cellular pMEK inhibition (IC<sub>50</sub> = 170 nM). In addition, the V/B ratios of <b>3e</b> and <b>3f</b> dropped to 0.051 and 0.31, respectively. As a result, we found the <i>C</i>-7 position to be significant in modulating the V/B ratio, and nitro (<b>3b</b>), cyano (<b>3c</b>), and methoxycarbonyl (<b>3d</b>) derivatives demonstrated high V/B ratios as well as potent cellular pMEK inhibition. The cyano derivative <b>3c</b> had the highest V/B ratio and was selected for further optimization.</div><div class="NLM_p">In order to improve the V/B ratio further, we conducted chemical modification of the ring B–linker–ring C portion of <b>3c</b> to explore appropriate linkers (X) targeted for selective RAF inhibitors. First, we evaluated the ureide derivatives (X = NH, R<sup>2</sup> = H) possessing a trifluoromethyl group with various substitution positions such as <i>o</i>-CF<sub>3</sub> (<b>4A</b>), <i>m</i>-CF<sub>3</sub> (<b>5A</b>), and <i>p</i>-CF<sub>3</sub> (<b>6A</b>) (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Among them, the <i>m</i>-CF<sub>3</sub> (<b>5A</b>) and <i>p</i>-CF<sub>3</sub> (<b>6A</b>) derivatives showed improved V/B ratios (V/B ratio for <i>m</i>-, 19; for <i>p</i>-, 18) compared with that of the <i>o</i>-CF<sub>3</sub> derivative (V/B ratio for <b>4A</b>: 6.3). Thus, we selected <i>m-</i> and <i>p-</i>CF<sub>3</sub> groups on ring C and attempted to introduce a fluorine group at the metabolically labile site of ring B on the basis of our previous work.<a onclick="showRef(event, 'ref15 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref17">(15, 17)</a> Compound <b>5B</b> (R<sup>2</sup> = F, R<sup>3</sup> = <i>m</i>-CF<sub>3</sub>) and <b>6B</b> (R<sup>2</sup> = F, R<sup>3</sup> = <i>p</i>-CF<sub>3</sub>) showed comparable or slightly weaker BRAF inhibition (<b>5B</b> IC<sub>50</sub>, 49 nM; <b>6B</b>, 26 nM) and V/B ratios similar to those of the corresponding unsubstituted (R<sup>2</sup> = H) derivatives <b>5A</b> or <b>6A</b>. Interestingly, the cellular pMEK inhibitory potency of these fluorinated compounds <b>5B</b> and <b>6B</b> increased, giving IC<sub>50</sub> values of 22 and 81 nM, respectively. However, in spite of attractive cellular activity with improved BRAF selectivity, oral absorption for the ureide series was found to be extremely low with AUC<sub>0–8 h</sub> values of 0.058–0.431 μg h/kg at a dose of 10 mg/kg in mice.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationship for Ureide Derivatives <b>4</b>–<b>6</b> Compared with that of Amide <b>3c</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0016.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep1" colspan="3" align="center">kinase IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep0" align="center"> </th></tr><tr valign="bottom"><th class="colsep0 rowsep0" align="center" valign="top"> </th><th class="colsep0 rowsep0" align="center" valign="bottom">X</th><th class="colsep0 rowsep0" align="center" valign="bottom">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" valign="bottom">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" valign="bottom">BRAF (V600E)</th><th class="colsep0 rowsep0" align="center" valign="bottom">VEGFR2</th><th class="colsep0 rowsep0" align="center" valign="bottom">ratio VEGFR2/BRAF (V600E)</th><th class="colsep0 rowsep0" align="center" valign="bottom">cellular pMEK<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> IC<sub>50</sub> (nmol/L)</th><th class="rowsep0" align="center" valign="bottom">PO AUC<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> mice (μg h/kg)</th></tr></thead><tbody><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>3c</b></td><td class="colsep0 rowsep0" align="left">bond</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>m</i>-C(CH<sub>3</sub>)<sub>2</sub>CN</td><td class="colsep0 rowsep0" align="left">13 (11–16)</td><td class="colsep0 rowsep0" align="left">76 (52–110)</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">34</td><td class="rowsep0" align="left">0.149</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>4A</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>o</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">19 (16–23)</td><td class="colsep0 rowsep0" align="left">120 (82–170)</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">>500</td><td class="rowsep0" align="left">0.058</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>5A</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>m</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">18 (5.6–58)</td><td class="colsep0 rowsep0" align="left">350 (310–410)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">75</td><td class="rowsep0" align="left">0.099</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>6A</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>p</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">18 (12–26)</td><td class="colsep0 rowsep0" align="left">330 (250–430)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">110</td><td class="rowsep0" align="left">0.431</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>5B</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left"><i>m</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">49 (17–140)</td><td class="colsep0 rowsep0" align="left">730 (650–810)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">22</td><td class="rowsep0" align="left">N.D.</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>6B</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left"><i>p</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">26 (13–51)</td><td class="colsep0 rowsep0" align="left">660 (530–830)</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">81</td><td class="rowsep0" align="left">0.158</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last"><i>n</i> = 2. 95% confidence intervals are shown in parentheses.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Cellular phosphorylation level of the downstream MEK (pMEK) was evaluated in HT-29 colon cancer cells (<i>n</i> = 1).</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Mean AUC<sub>0–8 h</sub> values are shown (<i>n</i> = 2). Cassette dosing was of five compounds. Compounds (10 mg/kg) were administered in 0.5% methyl cellulose in distilled water.</p></div></div></div><div class="NLM_p">Next, we evaluated the acetamide derivatives (X = CH<sub>2</sub>, R<sup>2</sup> = H) having a CF<sub>3</sub> group in three different positions as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Meta-substitution of the CF<sub>3</sub> group (<b>8A</b>) showed notably enhanced BRAF inhibition, with potency at least 7-fold greater than that for the ortho (<b>7A</b>)- and para-substituted (<b>9A</b>) derivatives (IC<sub>50</sub> values: <i>m</i>-, 1.3 nM; <i>p</i>-, 9.5 nM; <i>o</i>-, 14 nM). Reflecting the remarkable increase in BRAF inhibitory potency for <b>8A</b>, we observed that the V/B ratio increased to 120. These results encouraged us to synthesize fluorine derivative <b>8B</b> (R<sup>2</sup> = F). As we expected, compound <b>8B</b> showed a promising enzymatic profile for both BRAF inhibition (IC<sub>50</sub>: 2.4 nM) and BRAF selectivity (V/B ratio: 67). In addition, this fluorinated derivative also exhibited potent cellular pMEK activity with an IC<sub>50</sub> value of 75 nM. Furthermore, the pharmacokinetic (PK) evaluation of <i>m</i>-CF<sub>3</sub> derivatives <b>8A</b>,<b>B</b> showed significantly improved oral absorption with respective AUC values of 3.782 and 2.482 μg h/kg in mice, compared with those of the <i>o</i>- and <i>p</i>-CF<sub>3</sub> derivatives. On the basis of promising BRAF potency, selectivity, and good PK, compound <b>8B</b> was selected for further evaluation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure–Activity Relationship for Acetamide Derivatives <b>7</b>–<b>9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0018.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">kinase IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">BRAF (V600E)</th><th class="colsep0 rowsep0" align="center">VEGFR2</th><th class="colsep0 rowsep0" align="center">ratio VEGFR2/BRAF (V600E)</th><th class="colsep0 rowsep0" align="center">cellular pMEK<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (nmol/L)</th><th class="colsep0 rowsep0" align="center">PO AUC<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> mice  (μg h/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7A</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>o</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">14 (9.2–20)</td><td class="colsep0 rowsep0" align="left">100 (89–110)</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">0.255</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8A</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>m</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">1.3 (0.68–2.6)</td><td class="colsep0 rowsep0" align="left">150 (130–190)</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">360</td><td class="colsep0 rowsep0" align="left">3.782</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9A</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>p</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">9.5 (7.9–11)</td><td class="colsep0 rowsep0" align="left">190 (160–230)</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">0.123</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8B</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left"><i>m</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.4 (0.45–12)</td><td class="colsep0 rowsep0" align="left">160 (140–180)</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">2.482</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><i>n</i> = 2. 95% confidence intervals are shown in parentheses.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Cellular phosphorylation level of the downstream MEK (pMEK) was evaluated in HT-29 colon cancer cells (<i>n</i> = 1).</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Mean AUC<sub>0–8 h</sub> values are shown (<i>n</i> = 2). Cassette dosing was of five compounds. Compounds (10 mg/kg) were administered in 0.5% methyl cellulose in distilled water.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> X-ray Cocrystal Structural Analysis of <b>8B</b> with BRAF</h3><div class="NLM_p">We determined the X-ray cocrystal structure of <b>8B</b> bound to BRAF kinase (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The BRAF cocrystal structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>) revealed that the optimal compound <b>8B</b> is accommodated by the DFG-out conformation of BRAF, as we expected. Within the adenine site, the 1,3-benzothiazole-2-amide moiety forms two hydrogen bonds between the carbonyl of Cys532 and the NH of the 2-amide (3.0 Å), and between the NH of Cys532 and the <i>N</i>-3 nitrogen (3.4 Å). Since the measured distance between the carbonyl oxygen of the 2-amide and the <i>S</i>-1 sulfur (2.9 Å) is shorter than the sum of the corresponding van der Waals radii of the oxygen and sulfur atoms (3.32 Å),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the conformation of the 2-amide with respect to the 1,3-benzothiazole scaffold is held in a planar conformation by the sulfur–carbonyl interaction. These results for <b>8B</b> are consistent with those for <b>1</b> that we previously reported.<a onclick="showRef(event, 'ref15 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref18">(15, 18)</a> Furthermore, it was also shown that the phenylacetamide linker of <b>8B</b> forms significant hydrogen bonds between the carboxylate of Glu501 and the NH of the acetamide (3.1 Å), and between the NH of Asp594 and the carbonyl of the acetamide (2.8 Å). The methylene of the phenylacetamide linker X in <b>8B</b> seems to be important for providing enough flexibility to fit into the back pocket of BRAF.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray cocrystal structure of <b>8B</b> bound to BRAF (2.93 Å resolution).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To clarify the importance of the phenylacetamide linker in <b>8B</b>, we also obtained an X-ray cocrystal structure of ureide <b>5B</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSQ">4KSQ</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The only difference between <b>8B</b> and <b>5B</b> is the linker X (<b>8B</b>, CH<sub>2</sub>; <b>5B</b>, NH) (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). This single change resulted in an approximately 20-fold increase in BRAF inhibitory activity for <b>8B</b> (IC<sub>50</sub>: 2.4 nM) compared with that for <b>5B</b> (IC<sub>50</sub>: 49 nM). The cocrystal structural analysis revealed that the <i>m</i>-CF<sub>3</sub>-substituted benzene moieties of both <b>8B</b> and <b>5B</b> bind to the hydrophobic back pocket as we had envisioned (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A,B). In the cocrystal structure of <b>8B</b>, the phenylacetamide linker anchors the benzene moiety into a twisted orthogonal conformation with a dihedral angle of 88° at the CH<sub>2</sub> position (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C). However, the ureide <b>5B</b> shows a decreased dihedral angle of 20° at the corresponding NH position (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>D). Since it is known that the acetamide linker provides more flexible conformations in a protein than the ureide moiety does,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> the flexibility of phenylacetamide derivative <b>8B</b> allows optimal hydrophobic interaction between an 88° twisted <i>m</i>-CF<sub>3</sub>-substituted benzene and a hydrophobic back pocket. We assume that this conformational change could account for the increase in RAF inhibition for <b>8B</b>.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray cocrystal structures of BRAF bound to acetamide derivative <b>8B</b> and of BRAF bound to the corresponding ureide derivative <b>5B</b>. (A) Trifluoromethyl-substituted benzene of <b>8B</b> in the back pocket region. (B) Trifluoromethyl-substituted benzene of the corresponding ureide <b>5B</b> in the back pocket region. (C) Binding mode of acetamide <b>8B</b> with Glu501 and Asp594 (2.93 Å resolution). (D) Binding mode of ureide <b>5B</b> with Glu501 and Asp594 (3.30 Å resolution).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Kinase Inhibitory Profiles of Compound <b>8B</b></h3><div class="NLM_p">The kinase inhibitory profile of compound <b>8B</b> against 26 different kinases is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Compound <b>8B</b> showed potent single-digit nanomolar inhibitory activity against BRAF(wt) and CRAF (BRAF(wt) IC<sub>50</sub>, 8.3 nM; CRAF, 1.4 nM). In addition, compound <b>8B</b> inhibited Aurora B with an IC<sub>50</sub> value of 66 nM. Another 8 out of 26 kinases, such as PDGFRβ, FGFR3, GSK3β, CDK2, P38α, PDGFRα, TIE2, and CDK1 were inhibited by <b>8B</b> with a range of IC<sub>50</sub> values from 120–790 nM. CHK1, IKKβ, and MEK1 were inhibited over an IC<sub>50</sub> range of 1400–1700 nM. No significant inhibition was observed against the other 12 kinases assayed. On the basis of these preclinical results, compound <b>8B</b> was found to be a selective kinase inhibitor targeting the RAF family kinases.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity of Compound <b>8B</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF (wt)</td><td class="colsep0 rowsep0" align="left">8.3 (4.9–14)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C-RAF</td><td class="colsep0 rowsep0" align="left">1.4 (0.75–2.6)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">PKCθ</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="left">280</td><td class="colsep0 rowsep0" align="left">CHK1</td><td class="colsep0 rowsep0" align="left">1400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left">CK1δ</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">ERK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="left">790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Her2</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">580</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TIE2</td><td class="colsep0 rowsep0" align="left">740</td><td class="colsep0 rowsep0" align="left">Aurora B</td><td class="colsep0 rowsep0" align="left">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">p38α</td><td class="colsep0 rowsep0" align="left">600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">JNK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">GSK3β</td><td class="colsep0 rowsep0" align="left">500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IR</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="left">3700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IKKβ</td><td class="colsep0 rowsep0" align="left">3700</td><td class="colsep0 rowsep0" align="left">MEKK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">95% confidence intervals are in parentheses.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Dissociation Kinetics of Compound <b>8B</b> Using Surface Plasmon Resonance Technology</h3><div class="NLM_p">To determine affinities and kinetic rate constants, compound <b>8B</b> was injected over immobilized BRAF(V600E) or CRAF, and surface plasmon resonance (SPR) was used to analyze the interaction (Biacore T100, <a href="http://www.biacore.com/" class="extLink">http://www.biacore.com/</a>). Compound <b>8B</b> showed similar equilibrium dissociation constants (<i>K</i><sub>D</sub>) against both BRAF and CRAF by SPR (BRAF <i>K</i><sub>D</sub>, 1.6 × 10<sup>–9</sup>; CRAF, 0.52 × 10<sup>–9</sup>; Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). The dissociation rate constant (<i>k</i><sub>off</sub>) and the residence time (<i>t</i><sub>1/2</sub>) of <b>8B</b> were 1.9 × 10<sup>–5</sup> s<sup>–1</sup> and 602 min for BRAF, 9.0 × 10<sup>–5</sup> s<sup>–1</sup> and 129 min for CRAF (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). The dissociation parameters indicate that <b>8B</b> has slow dissociation kinetics (low <i>k</i><sub>off</sub>) along with long residence time binding to both BRAF and CRAF. In contrast, PLX4720,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> a precursor analogue of vemurafenib (PLX4032), showed fast dissociation kinetics and short residence time under the same assay conditions (BRAF, <i>k</i><sub>off</sub> = 3.3 × 10<sup>–2</sup> s<sup>–1</sup>; <i>t</i><sub>1/2</sub> = 21 s; CRAF, <i>k</i><sub>off (1)</sub> = 2.2 × 10<sup>–3</sup> s<sup>–1</sup>; <i>t</i><sub>1/2 (1)</sub> = 5.3 min; <i>k</i><sub>off (2)</sub> = 1.2 × 10<sup>–1</sup> s<sup>–1</sup>; <i>t</i><sub>1/2 (2)</sub> = 5.8 s). These results suggested that <b>8B</b> is a slow off-rate, pan-RAF inhibitor.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Dissociation Kinetics of <b>8B</b> Measured by SPR</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">apparent <i>k</i><sub>off</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (sec<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">dissociation half-life (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF</td><td class="colsep0 rowsep0" align="left">1.6 × 10<sup>–9</sup></td><td class="colsep0 rowsep0" align="left">1.9 × 10<sup>–5</sup></td><td class="colsep0 rowsep0" align="left">602</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CRAF:</td><td class="colsep0 rowsep0" align="left">5.2 × 10<sup>–10</sup></td><td class="colsep0 rowsep0" align="left">9.0 × 10<sup>–5</sup></td><td class="colsep0 rowsep0" align="left">129</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>K</i><sub>D</sub>: equilibrium dissociation constant,</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last"><i>K</i><sub>off</sub>: dissociation rate constant.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Time Dependent Inhibition Properties of <b>8B</b> against BRAF and CRAF</h3><div class="NLM_p">Some reported kinase inhibitors have been recognized as slow off-rate inhibitors with long residence times bound to the target protein.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> These long residence times have been used to explain the potent drug properties found for these compounds.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">We evaluated the biochemical activity of <b>8B</b> against BRAF and CRAF at two different ATP concentrations of <i>K</i>m (low) and 1.0 mM (high, corresponding to 200-times the BRAF <i>K</i><sub>m</sub> and 2000-times the CRAF <i>K</i><sub>m</sub>) and two preincubation times (0 and 1 h) (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). With 1 h of preincubation time, <b>8B</b> inhibited BRAF and CRAF in an ATP competitive manner (at low ATP concentrations BRAF IC<sub>50</sub>: 15 nM; CRAF: 8.1 nM). The respective biochemical activity of <b>8B</b> against BRAF and CRAF reduced to IC<sub>50</sub> values of 58 nM and 62 nM at high ATP concentrations.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Biochemical Activities of <b>8B</b> against BRAF(V600E) and CRAF with Differing Preincubation Times (0 or 1 h) and under Different ATP Concentrations: <i>K</i><sub>m</sub> (Low) or 1000 μM (High)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">kinase IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">preincubation time:</th><th class="rowsep1 colsep0" colspan="2" align="center">0 h</th><th class="rowsep1 colsep0" colspan="2" align="center">1 h</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ATP concentration:</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>m</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1000 μM</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>m</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1000 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF(V600E):</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CRAF:</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">5.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last"><i>K</i><sub>m</sub> concentration of ATP; BRAF(V600E), [ATP] = 5 μM. CRAF: [ATP] = 0.5 μM.</p></div></div></div><div class="NLM_p last">Next, we examined the activity of <b>8B</b> with 1 h of preincubation time for the assay. At low ATP concentration, the inhibitory activity of <b>8B</b> increased in a time-dependent manner (BRAF IC<sub>50</sub>, 2.2 nM; CRAF, 1.5 nM). At high ATP concentration, <b>8B</b> showed still potent inhibitory activity for both BRAF and CRAF (IC<sub>50</sub>: 3.3 nM and 5.0 nM, respectively). These time-dependent inhibition properties with long residence times suggested that <b>8B</b> has the potential to demonstrate efficient inhibition of both BRAF and CRAF in cells.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vitro Pharmacology of Compound <b>8B</b></h3><div class="NLM_p">Reflecting the potent BRAF (V600E) inhibitory activity in vitro, compound <b>8B</b> inhibited phosphorylation of MEK (pMEK) in melanoma A375 cells (<i>BRAF</i><sup>V600E</sup>) with an IC<sub>50</sub> value of 12 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Downstream inhibition of ERK phosphorylation (pERK) was also observed in A375 cells with an IC<sub>50</sub> value of 16 nM. Next, we also evaluated the cellular activity of <b>8B</b> against human melanoma HMVII cells (<i>NRAS</i><sup>Q61K</sup>/<i>BRAF</i><sup>G469V</sup>), which have been reported to be insensitive to selective BRAF(V600E) inhibitors such as vemurafenib.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In HMVII cells, signal transduction of the MAPK cascade is thought to be activated by mutated <i>NRAS</i> through the downstream BRAF(wt) and CRAF. However, continuous inhibition of BRAF or CRAF by the corresponding siRNA has been shown to induce downstream inhibition in cells with <i>RAS</i> mutation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Interestingly, <b>8B</b> demonstrated strong inhibition of pMEK and pERK in HMVII cells with IC<sub>50</sub> values of 49 nM and 50 nM, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Furthermore, antiproliferative activity of <b>8B</b> was potent in both A375 and HMVII cells with GI<sub>50</sub> values of 66 nM and 200 nM, respectively. On the basis of these preclinical results, compound <b>8B</b> was identified as an antitumor drug development candidate for patients with either <i>BRAF</i><sup>V600E</sup> or <i>NRAS</i> mutation, based on its apparent suppression of RAF dimer feedback activation presumably caused by its slow off-rate and pan-RAF inhibitory profile.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cellular Activities of pan-RAF Inhibitor <b>8B</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">mutation status<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">mean IC<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><i>BRAF</i></th><th class="colsep0 rowsep0" align="center"><i>NRAS</i></th><th class="colsep0 rowsep0" align="center">pMEK</th><th class="colsep0 rowsep0" align="center">pERK</th><th class="colsep0 rowsep0" align="center">proliferation GI<sub>50</sub> (nmol/L)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A375</td><td class="colsep0 rowsep0" align="left">V600E</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HMVII</td><td class="colsep0 rowsep0" align="left">G469V</td><td class="colsep0 rowsep0" align="left">Q61K</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">200</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Mutational status determined from the Sanger Institute database.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Numbers represent average IC<sub>50</sub> values derived from a Western blot assay after 2 h of <b>8B</b> administration. (<i>n</i> = 2).</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Numbers represent average GI<sub>50</sub> derived from a ATPlite cell proliferation assay after 72 h of <b>8B</b> administration. (<i>n</i> = 3).</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Pharmacokinetic Profile and in Vivo Studies of Compound <b>8B</b> in Rats</h3><div class="NLM_p">In a pharmacokinetic study, compound <b>8B</b> was administered using a solid dispersion (SD) formulation based on our previous research<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> because <b>8B</b> showed low solubility (<0.02 μg/mL) in pH 6.8 phosphate buffer.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> An SD formulation of <b>8B</b> demonstrated dramatically improved solubility (740 μg/mL) in pH 6.8 phosphate buffer and exhibited significant oral absorption (at a dose of 25 mg/kg, AUC, 32.47 μg h/mL; <i>F</i>, 51.7%) in rats (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). In a dog PK study, 10 mg/kg administration of the SD formulation of <b>8B</b> also showed superior oral bioavailability (<i>F</i>: 108%).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Mean<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a> Pharmacokinetic Parameters for Compound <b>8B</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">animal</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center"><i>CL</i><sub>total</sub> (mL/h/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>dss</sub> (mL/kg)</th><th class="colsep0 rowsep0" align="center">MRT (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–24h</sub> (μg h/mL)</th><th class="colsep0 rowsep0" align="center">% <i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">400 ± 29</td><td class="colsep0 rowsep0" align="left">1872 ± 71</td><td class="colsep0 rowsep0" align="left">4.69 ± 0.25</td><td class="colsep0 rowsep0" align="left">2.512 ± 0.18</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">25<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.27 ± 0.37</td><td class="colsep0 rowsep0" align="left">32.47 ± 4.68</td><td class="colsep0 rowsep0" align="left">51.7 ± 8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">704 ± 68</td><td class="colsep0 rowsep0" align="left">1568 ± 226</td><td class="colsep0 rowsep0" align="left">2.23 ± 0.27</td><td class="colsep0 rowsep0" align="left">1.429 ± 0.13</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.12 ± 0.76</td><td class="colsep0 rowsep0" align="left">15.48 ± 2.00</td><td class="colsep0 rowsep0" align="left">108 ± 8.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Values shown are the mean ± SD of data (<i>n</i> = 3).</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Delivered in 1,3-butane-diol/DMA (1:1).</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">Delivered as a solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate = 20:80).</p></div></div></div><div class="NLM_p">In vivo efficacy of <b>8B</b> was evaluated using an SD formulation in a human melanoma A375 (<i>BRAF</i><sup>V600E</sup>) xenograft model in F344 nude rats. Reflecting the potent in vitro pMEK inhibition, oral single administration of <b>8B</b> inhibited pERK in tumors at 8 h after its administration over a dose range of 1.9–24.1 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). In particular, 9.7–24.1 mg/kg dosing with <b>8B</b> strongly inhibited pERK levels to 11% of the control. We examined the antitumor efficacy of <b>8B</b> administered twice daily for 14 days in an A375 xenograft model in rats (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Compound <b>8B</b> exhibited dose-dependent antitumor efficacy without severe body weight reduction over a dose range of 3.9–24.1 mg/kg. Significant tumor regression was observed at 9.7 mg/kg and 24.1 mg/kg (<i>T</i>/<i>C</i> = −2.1% and −12.1%, respectively).</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mean (<i>n</i> = 3; *<i>P</i> ≤ 0.025 compared with vehicle by the Shirley–Williams’ test) phosphorylated ERK1/2 levels in the tumor in a human melanoma A375 (<i>BRAF</i><sup>V600E</sup> mutant) xenograft model in rats, at 8 h after oral administration of <b>8B</b>. Data were detected by Western blotting. The solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate = 20:80) was delivered in distilled water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antitumor activity of a solid dispersion of <b>8B</b> (p.o., b.i.d.) in human melanoma A375 (<i>BRAF</i><sup>V600E</sup> mutant) bearing F344 nude rats (A) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) tumor volumes. (B) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) body weight change. The solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate =20:80) was delievered in distilled water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, antitumor effects of <b>8B</b> in a human melanoma HMVII (<i>NRAS</i><sup>Q61K</sup>/<i>BRAF</i><sup>G469V</sup>) xenograft model were evaluated in rats (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). In this study, <b>8B</b> was orally administered as an SD formulation and suppressed the growth of HMVII tumors with <i>T</i>/<i>C</i> values of 52%, 26%, and 0% at doses of 3.9 mg/kg, 9.7 mg/kg, and 24.1 mg/kg, respectively. This antitumor efficacy was dose-dependent and significant (<i>p</i> < 0.025) compared with that of the vehicle control at all three doses. In this model, the HMVII tumor induced cancer cachexia and resulted in approximately 6% body weight loss in the vehicle control group over the 14-day administration period (body weight change: −8.6 g for the vehicle and +16.5 g for nontumor bearing). Interestingly, dose-dependent recovery of body weight loss was observed. In particular, the group at 24.1 mg/kg showed no signs of body weight loss (body weight change: +28.4 g). Recently, other DFG-out type (Type II) inhibitors were reported to have the potential to induce RAF dimerization and feedback activation in <i>BRAF</i><sup>wt</sup> cells, similar to DFG-in type (Type I) inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Some inhibitors are not able to inhibit activated MAPK signaling in <i>BRAF</i><sup>wt</sup> normal cells at their projected efficacious doses and induce hyperplasia in animal models.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> However, a study of our DFG-out type inhibitor <b>8B</b> using an A375 (<i>BRAF</i><sup>V600E</sup>) xenograft model indicated that administration of <b>8B</b> did not induce pERK activation in normal skin tissues (<i>BRAF</i><sup>wt</sup>) at projected efficacious doses but slightly inhibited pERK at higher doses of 25 and 50 mg/kg (<a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>, Figure S1). Further characterization of how <b>8B</b> inhibits the feedback activation in <i>BRAF</i><sup>wt</sup> cells is of great interest. The results of detailed biological studies of our compounds will be reported in due course.</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antitumor activity of a solid dispersion of <b>8B</b> in human melanoma HMVII (<i>NRAS</i><sup>Q61K</sup>/<i>BRAF</i><sup>G469V</sup> mutant) bearing F344 nude rats (A) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) tumor volumes. (B) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) body weight change. The solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate = 20:80) was delievered in distilled water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We designed and synthesized selective kinase inhibitors targeting pan-RAF kinase activity. On the basis of the X-ray cocrystal structures of compound <b>1</b> with both BRAF (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a>) and VEGFR2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>), <i>C</i>-7 substitution of lead compound <b>2</b> proved to be a fruitful approach to enhancing RAF inhibitory potency relative to VEGFR2. These novel compounds were efficiently prepared by the regioselective <i>C</i>-7-substituted 1,3-benzothiazole ring formation reaction of meta-substituted anilines with KSCN and bromine. Various substituents, such as NO<sub>2</sub>, CN, and CO<sub>2</sub>Me, provided good regioselectivity. Among these scaffolds, the 7-cyano derivatives showed enhanced BRAF selectivity over VEGFR2 as well as potent cellular pMEK inhibitory activity.</div><div class="NLM_p">Subsequent optimization of the ring B–linker–ring C domain provided the <i>m-</i>CF<sub>3</sub>-substituted phenylacetamide derivative <b>8B</b> as a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC<sub>50</sub>, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A375) IC<sub>50</sub>, 12 nM; pMEK (HMVII), 49 nM; V/B ratio, 67). In addition, compound <b>8B</b> was shown preclinically to be a selective kinase inhibitor targeting pan-RAF kinase activity by testing against a panel of kinases. X-ray cocrystal structure analysis revealed that <b>8B</b> occupies the ATP site of BRAF in the DFG-out conformation. Furthermore, the flexible acetamide linker provides a more twisted conformation for ring C that can interact more effectively with the hydrophobic back pocket than is observed for the ureide derivative (dihedral angles of 88° for the acetamide linker and 20° for the ureide linker).</div><div class="NLM_p">An SPR study revealed that compound <b>8B</b> is a slow off-rate inhibitor of both BRAF and CRAF. Reflecting the slow off-rate property, compound <b>8B</b> demonstrated potent inhibitory activity even at high ATP concentration (BRAF(V600E) IC<sub>50</sub>, 3.3 nM; CRAF, 5.0 nM) with 1 h of preincubation in a biochemical assay.</div><div class="NLM_p">In vitro pharmacological studies revealed that compound <b>8B</b> possesses significant cellular activity against <i>BRAF</i><sup>V600E</sup> and <i>NRAS</i> mutated cancer cell lines. In vivo pharmacological evaluation in a melanoma A375 (<i>BRAF</i><sup>V600E</sup>) xenograft model in rats revealed potent inhibition of the MAPK cascade in tumor cells after a single oral administration of <b>8B</b> at doses of 4–25 mg/kg. Furthermore, twice daily, 14 days of repetitive administration of <b>8B</b> demonstrated regressive antitumor efficacy at doses of 4–25 mg/kg without body weight changes. Moreover, compound <b>8B</b> induced regression in HMVII (<i>NRAS</i><sup>Q61K</sup>) tumors and restored body weight loss derived from HMVII tumor-induced cachexia.</div><div class="NLM_p last">These results suggested that slow off-rate pan-RAF inhibitors could represent a second generation of RAF inhibitors to be tested in the clinic for the treatment of human cancer harboring either <i>BRAF</i><sup>V600E</sup> or <i>NRAS</i> mutation. Along with another pan-RAF inhibitor MLN2480 under phase I clinical study by Takeda,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> we selected compound <b>8B</b> (TAK-632) as an alternative development candidate.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Chemistry Information</h3><div class="NLM_p">The starting materials, reagents, and solvents for reactions were of reagent grade and were used as purchased. Thin-layer chromatography (TLC) was carried out using Merck Kieselgel 60, 63–200 mesh, F254 plates, or Fuji Silysia Chemical Ltd., 100–200 mesh, NH plates. Chromatographic purification was carried out using silica gel (Merck, 70–230 mesh) or basic silica gel (Fuji Silysia Chemical Ltd., DM1020, 100–200 mesh). Melting points were obtained using an OptiMelt melting point apparatus MPA100 and are uncorrected. Proton nuclear magnetic resonance <sup>1</sup>H NMR spectra were recorded using a Bruker AVANCE II (300 MHz) spectrometer with tetramethylsilane (TMS) as an internal standard. The NMR data are given as follows: chemical shift (δ) in ppm, multiplicity (where applicable), coupling constants (<i>J)</i> in Hz (where applicable), and integration (where applicable). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), dt, (doublet of triplets), ddd (doublet of doublet of doublets), br s (broad singlet), or m (multiplet). MS spectra were collected with a Waters LC-MS system (ZMD-1) and were used to confirm ≥95% purity of each compound. The column used was an L-column 2 ODS (3.0 × 50 mm I.D., CERI, Japan) with a temperature of 40 °C and a flow rate of 1.2 mL/min. Mobile phase A was 0.05% TFA in ultrapure water. Mobile phase B was 0.05% TFA in acetonitrile, which was increased linearly from 5% to 90% over 2 min and 90% over the next 1.5 min, after which the column was equilibrated to 5% for 0.5 min. Elemental analyses (Anal.) and high-resolution mass spectroscopy (HRMS) were carried out at Takeda Analytical Laboratories, Ltd. Yields were not optimized.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Methyl 6-[3-({[3-(1-Cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]-2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazole-7-carboxylate (<b>3b</b>)</h4><div class="NLM_p last">To a solution of methyl 2-amino-6-[3-({[3-(1-cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]-1,3-benzothiazole-7-carboxylate <b>11b</b> (0.92 g, 1.88 mmol) in pyridine (5 mL) was added cyclopropanecarbonyl chloride (371 μL, 4.1 mmol), and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The obtained residue was diluted with EtOAc (100 mL), washed with water (100 mL) and brine (100 mL), successively, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was suspended in MeOH (10 mL), and Na<sub>2</sub>CO<sub>3</sub> (250 mg) was added to the mixture. The mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with EtOAc (100 mL), washed with water (100 mL) and brine (100 mL), successively, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was successively purified by basic silica gel column chromatography (40–100% EtOAc in <i>n</i>-hexane) and silica gel column chromatography (40–60% EtOAc in <i>n</i>-hexane), and the obtained solution was concentrated under reduced pressure. The residue was recrystallized from EtOAc/<i>n</i>-hexane to give <b>3b</b> (706 mg, 68%) as pale-yellow crystals; mp 143–145 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.98 (d, <i>J</i> = 4.2 Hz, 4H), 1.73 (s, 6H), 1.96–2.08 (m, 1H), 3.81 (s, 3H), 6.72–6.79 (m, 1H), 7.25 (d, <i>J</i> = 8.7 Hz, 1H), 7.31–7.42 (m, 2H), 7.49–7.63 (m, 2H), 7.69–7.77 (m, 1H), 7.88 (dt, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.97 (t, <i>J</i> = 1.7 Hz, 1H), 8.01 (d, <i>J</i> = 8.7 Hz, 1H), 10.31 (s, 1H), 12.69 (br s, 1H). MS (ESI+) <i>m</i>/<i>z</i> 555.25 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>30</sub>H<sub>26</sub>N<sub>4</sub>O<sub>5</sub>S·0.4H<sub>2</sub>O: C, 64.13; H, 4.81; N, 9.97. Found: C, 64.17; H, 4.81; N, 9.84.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-[3-({7-Cyano-2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}oxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (<b>3c</b>)</h4><div class="NLM_p">To a solution of <i>N</i>-{3-[(2-amino-7-cyano-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide <b>11c</b> (150 mg, 0.33 mmol) in pyridine (2 mL) was added cyclopropanecarbonyl chloride (59 μL, 0.66 mmol), and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was suspended in EtOAc (50 mL), washed with 5% aqueous NaHCO<sub>3</sub> solution (50 mL) and brine (50 mL), successively, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (30–100% EtOAc in <i>n</i>-hexane), and the obtained solution was concentrated under reduced pressure. The residue was recrystallized from EtOAc to give <b>3c</b> (119 mg, 69%) as colorless crystals; mp 273–275 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–1.09 (m, 4H), 1.74 (s, 6H), 1.96–2.10 (m, 1H), 6.93 (dd, <i>J</i> = 2.1, 7.7 Hz, 1H), 7.20 (d, <i>J</i> = 8.9 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.54–7.68 (m, 3H), 7.70–7.81 (m, 1H), 7.91 (d, <i>J</i> = 7.9 Hz, 1H), 8.00 (t, <i>J</i> = 1.7 Hz, 1H), 8.05 (d, <i>J</i> = 8.9 Hz, 1H), 10.43 (s, 1H), 13.01 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 522.25 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>29</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S: C, 66.78; H, 4.44; N, 13.43. Found: C, 66.57; H, 4.46; N, 13.40.</div><div class="NLM_p last">The following compounds (<b>3d</b>) were prepared from the corresponding 2-amino-1,3-benzothiazole derivatives (<b>11d</b>) with cyclopropanecarbonyl chloride by a method similar to that described for <b>3c</b>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-7-nitro-1,3-benzothiazol-6-yl}oxy)phenyl]benzamide (<b>3d</b>)</h4><div class="NLM_p last">Yield 79%, yellow crystals (recrystallized from EtOAc/<i>n</i>-hexane), mp 223–225 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.95–1.05 (m, 4H), 1.73 (s, 6H), 1.98–2.09 (m, 1H), 6.81–6.92 (m, 1H), 7.33–7.47 (m, 2H), 7.49–7.65 (m, 3H), 7.71–7.78 (m, 1H), 7.90 (dt, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.99 (t, <i>J</i> = 1.7 Hz, 1H), 8.15 (d, <i>J</i> = 8.7 Hz, 1H), 10.38 (s, 1H), 12.90 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 542.25 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>28</sub>H<sub>23</sub>N<sub>5</sub>O<sub>5</sub>S: C, 62.10; H, 4.28; N, 12.93. Found: C, 61.83; H, 4.36; N, 12.70.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 6-[3-({[3-(1-Cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]-2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazole-7-carboxylic Acid (<b>3e</b>)</h4><div class="NLM_p last">To a solution of <b>3b</b> (570 mg, 1.02 mmol) in a mixed solvent of THF/MeOH/H<sub>2</sub>O (3:1:1, 10 mL) was added LiOH·H<sub>2</sub>O (150 mg, 3.66 mmol), and the mixture was stirred at room temperature for 12 h. The reaction mixture was neutralized with 1 N HCl, diluted with EtOAc/THF (1:1, 200 mL), and washed with water (100 mL). The organic layer was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (0–10% MeOH in EtOAc), and the obtained solution was concentrated under reduced pressure to give <b>3e</b> (300 mg, 54%) as a colorless amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–1.01 (m, 4H), 1.72 (s, 6H), 1.94–2.09 (m, 1H), 6.70 (dd, <i>J</i> = 2.0, 8.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.7 Hz, 1H), 7.27–7.36 (m, 2H), 7.47–7.61 (m, 2H), 7.68–7.77 (m, 1H), 7.87 (d, <i>J</i> = 7.7 Hz, 1H), 7.92–7.99 (m, 2H), 10.30 (s, 1H), 12.61 (s, 1H), 13.55 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 541.25 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>29</sub>H<sub>24</sub>N<sub>4</sub>O<sub>5</sub>S·0.8H<sub>2</sub>O: C, 62.76; H, 4.65; N, 10.09. Found: C, 62.75; H, 4.58; N, 9.93.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-7-(hydroxymethyl)-1,3-benzothiazol-6-yl}oxy)phenyl]benzamide (<b>3f</b>)</h4><div class="NLM_p last">To a solution of <b>3e</b> (200 mg, 0.369 mmol) in THF (8 mL) were added triethylamine (101 μL, 0.738 mmol) and <i>iso</i>-butyl chloroformate (96 μL, 0.738 mmol) at 4 °C, and the mixture was stirred at 4 °C for 30 min. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in THF (2 mL), and to the mixture were added NaBH<sub>4</sub> (42 mg, 1.10 mmol) and MeOH (2 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The obtained residue was diluted with EtOAc (20 mL), washed with 1 N HCl (5 mL), 5% aqueous NaHCO<sub>3</sub> solution (10 mL) and brine (5 mL), successively, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (20–60% EtOAc in <i>n</i>-hexane), and the obtained solution was concentrated under reduced pressure to give <b>3f</b> (108 mg, 55%) as pale yellow crystals; mp 152–153 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 0.90–1.00 (m, 4H), 1.73 (s, 6H), 1.93–2.07 (m, 1H), 4.74 (d, <i>J</i> = 5.1 Hz, 2H), 5.65 (t, <i>J</i> = 5.3 Hz, 1H), 6.66–6.77 (m, 1H), 7.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.33 (t, <i>J</i> = 8.2 Hz, 1H), 7.37 (t, <i>J</i> = 2.2 Hz, 1H), 7.51 (dd, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.65 (d, <i>J</i> = 8.7 Hz, 1H), 7.69–7.79 (m, 1H), 7.83–7.92 (m, 1H), 7.97 (t, <i>J</i> = 1.8 Hz, 1H), 10.33 (s, 1H), 12.51 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 527.20 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>29</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>S·0.25H<sub>2</sub>O: C, 65.58; H, 5.03; N, 10.55. Found: C, 65.65; H, 5.16; N, 10.42.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-{7-Cyano-6-[3-({[2-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>4A</b>)</h4><div class="NLM_p">To a solution of 1-isocyanato-2-(trifluoromethyl)benzene (63 μL, 0.44 mmol) in DMF (2 mL) was added <i>N</i>-[6-(3-aminophenoxy)-7-cyano-1,3-benzothiazol-2-yl]cyclopropanecarboxamide <b>22A</b> (120 mg, 0.34 mmol) at room temperature. The mixture was stirred at room temperature for 12 h and was diluted with EtOAc (10 mL). The mixture was washed with 5% aqueous NaHCO<sub>3</sub> (5 mL) and brine (5 mL), successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The resulting material was purified by basic silica gel column chromatography (60–100% EtOAc in <i>n</i>-hexane). Desired fractions were combined and evaporated in vacuo. The oily residue was crystallized from EtOAc (4 mL). The crystalline solid was collected by filtration using 50% EtOAc in <i>n</i>-hexane to give <b>4A</b> (107 mg, 58%) as colorless crystals; mp 181–183 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.89–1.07 (m, 4H), 1.93–2.13 (m, 1H), 6.64–6.90 (m, 1H), 7.10–7.23 (m, 2H), 7.24–7.33 (m, 1H), 7.32–7.43 (m, 2H), 7.62 (t, <i>J</i> = 7.6 Hz, 1H), 7.67 (d, <i>J</i> = 7.9 Hz, 1H), 7.88 (d, <i>J</i> = 8.1 Hz, 1H), 8.03 (d, <i>J</i> = 9.1 Hz, 1H), 8.10 (s, 1H), 9.53 (s, 1H), 13.00 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 538.2 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>26</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S·0.5H<sub>2</sub>O: C, 57.14; H, 3.50; N, 12.81, Found: C, 57.43; H, 3.79; N, 12.42.</div><div class="NLM_p last">The following compounds (<b>5A</b>,<b>B</b> and <b>6A</b>,<b>B</b>) were prepared from the corresponding aniline derivatives (<b>22A</b>,<b>B</b>) with the corresponding isocyanate reagents by a method similar to that described for <b>4A</b>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-{7-Cyano-6-[3-({[3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>5A</b>)</h4><div class="NLM_p last">Yield 28%, colorless crystals (recrystallized from EtOAc/<i>n</i>-hexane), mp 269–270 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.83–1.12 (m, 4H), 1.91–2.16 (m, 1H), 6.77 (dd, <i>J</i> = 2.0, 8.0 Hz, 1H), 7.15 (d, <i>J</i> = 9.0 Hz, 1H), 7.20–7.44 (m, 4H), 7.44–7.66 (m, 2H), 7.96 (s, 1H), 8.03 (d, <i>J</i> = 9.0 Hz, 1H), 9.01 (s, 1H), 9.08 (s, 1H), 12.99 (s, 1H). HRMS (ESI) calcd for C<sub>26</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S: 538.1155 [M + H]<sup>+</sup>. Found: 538.1117.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-{7-Cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>5B</b>)</h4><div class="NLM_p last">Yield 85%, colorless crystals (recrystallized from EtOAc/<i>n</i>-hexane), mp 252–254 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.98 (d, <i>J</i> = 4.9 Hz, 4H), 2.00 (br s, 1H), 6.69–6.94 (m, 1H), 7.09 (d, <i>J</i> = 8.9 Hz, 1H), 7.22–7.43 (m, 2H), 7.52 (d, <i>J</i> = 5.1 Hz, 2H), 7.85–8.10 (m, 3H), 8.85 (s, 1H), 9.46 (s, 1H), 12.97 (br s, 1H). HRMS (ESI) calcd for C<sub>26</sub>H<sub>17</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub>S: 556.1061 [M + H]<sup>+</sup>. Found: 556.1049.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-{7-Cyano-6-[3-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>6A</b>)</h4><div class="NLM_p last">Yield 94%, colorless crystals (recrystallized from EtOAc), mp 217–218 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.93–1.08 (m, 4H), 1.99–2.07 (m, 1H), 6.74–6.85 (m, 1H), 7.17 (d, <i>J</i> = 9.0 Hz, 1H), 7.20–7.28 (m, 1H), 7.32–7.45 (m, 2H), 7.62 (s, 4H), 8.05 (d, <i>J</i> = 9.0 Hz, 1H), 9.01 (s, 1H), 9.13 (s, 1H), 13.00 (s, 1H). HRMS (ESI) calcd for C<sub>26</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S 538.1155 [M + H]<sup>+</sup>. Found: 538.1107.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-{7-Cyano-6-[4-fluoro-3-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>6B</b>)</h4><div class="NLM_p last">Yield 51%, colorless crystals (recrystallized from acetone/<i>n</i>-hexane), mp 176–177 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.84–1.22 (m, 4H), 1.86–2.07 (m, 1H), 6.68–6.92 (m, 1H), 7.13 (d, <i>J</i> = 8.9 Hz, 1H), 7.36 (dd, <i>J</i> = 9.1, 11.0 Hz, 1H), 7.55–7.73 (m, 4H), 7.91–8.13 (m, 2H), 8.87 (d, <i>J</i> = 2.5 Hz, 1H), 9.51 (s, 1H), 12.99 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 556.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>26</sub>H<sub>17</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub>S·1.0H<sub>2</sub>O: C, 54.45; H, 3.34; N, 12.21. Found: C, 54.69; H, 3.23; N, 12.09.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-{7-Cyano-6-[3-({[2-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>7A</b>)</h4><div class="NLM_p">To a solution of 2-(2-(trifluoromethyl)phenyl)acetic acid (138 mg, 0.68 mmol) in DMF (2 mL) was added <b>22A</b> (120 mg, 0.34 mmol) at room temperature. The mixture was stirred at room temperature for 12 h and was diluted with EtOAc (10 mL). The mixture was washed with aqueous 5% NaHCO<sub>3</sub> solution (5 mL) and brine (5 mL), successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (30–100% EtOAc in <i>n</i>-hexane). Desired fractions were combined and evaporated in vacuo. The crude material was crystallized from EtOAc to give <b>7A</b> (135 mg, 74%) as colorless crystals; mp 205–206 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.82–1.12 (m, 4H), 1.94–2.14 (m, 1H), 3.90 (s, 2H), 6.85 (td, <i>J</i> = 4.5, 2.5 Hz, 1H), 7.16 (d, <i>J</i> = 9.1 Hz, 1H), 7.28–7.57 (m, 5H), 7.57–7.78 (m, 2H), 8.02 (d, <i>J</i> = 8.9 Hz, 1H), 10.35 (s, 1H), 12.98 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 537.2 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S: C, 60.44; H, 3.57; N, 10.44. Found: C, 60.28; H, 3.63; N, 10.42.</div><div class="NLM_p last">The following compounds (<b>8A</b>,<b>B</b> and <b>9A</b>) were prepared from the corresponding aniline derivatives (<b>22A</b>,<b>B</b>) with the corresponding phenylacetic acids by a method similar to that described for <b>7A</b>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-{7-Cyano-6-[3-({[3-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>8A</b>)</h4><div class="NLM_p last">Yield 57%, colorless crystals (recrystallized from EtOAc/n-heptane), mp 183–184 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.91–1.11 (m, 4H), 1.93–2.11 (m, 1H), 3.77 (s, 2H), 6.79–6.91 (m, 1H), 7.15 (d, <i>J</i> = 9.0 Hz, 1H), 7.31–7.43 (m, 2H), 7.43–7.48 (m, 1H), 7.50–7.65 (m, 3H), 7.67 (s, 1H), 8.02 (d, <i>J</i> = 9.0 Hz, 1H), 10.38 (s, 1H), 12.99 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 537.0 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S: C, 60.44; H, 3.57; N, 10.44. Found: C, 60.28; H, 3.59; N, 10.42.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-{7-Cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>8B</b>)</h4><div class="NLM_p last">Yield 60%, colorless crystals (recrystallized from EtOAc/<i>n</i>-heptane), mp 209–210 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.89–1.05 (m, 4H), 1.97–2.13 (m, 1H), 3.88 (s, 2H), 6.97 (dt, <i>J</i> = 8.7, 3.6 Hz, 1H), 7.08 (d, <i>J</i> = 9.0 Hz, 1H), 7.37 (dd, <i>J</i> = 9.1, 10.6 Hz, 1H), 7.49–7.64 (m, 3H), 7.68 (s, 1H), 7.83 (dd, <i>J</i> = 3.0, 6.4 Hz, 1H), 7.99 (d, <i>J</i> = 9.0 Hz, 1H), 10.21 (s, 1H), 12.97 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 555.50 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>18</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>S: C, 58.48; H, 3.27; N, 10.10. Found: C, 58.40; H, 3.18; N, 9.99.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-{7-Cyano-6-[3-({[4-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (<b>9A</b>)</h4><div class="NLM_p last">Yield 69%, colorless crystals (recrystallized from EtOAc), mp 233–235 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–1.08 (m, 4H), 1.86–2.19 (m, 1H), 3.76 (s, 2H), 6.70–6.99 (m, 1H), 7.15 (d, <i>J</i> = 9.1 Hz, 1H), 7.30–7.41 (m, 2H), 7.45 (d, <i>J</i> = 1.7 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 2H), 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 8.03 (d, <i>J</i> = 9.1 Hz, 1H), 10.39 (s, 1H), 13.00 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 537.2 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S: C, 60.44; H, 3.57; N, 10.44, Found: C, 60.35; H, 3.81; N, 10.20.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-[3-(4-Amino-2-fluorophenoxy)phenyl]-3-(2-cyanopropan-2-yl)benzamide (<b>10a</b>)</h4><div class="NLM_p last">To a solution of 3-(2-cyanopropan-2-yl)-<i>N</i>-[3-(2-fluoro-4-nitrophenoxy)phenyl]benzamide <b>15a</b> (2.03 g, 4.83 mmol) in 90% EtOH in water were added Fe(0) (2.97 g, 53.1 mmol) and CaCl<sub>2</sub> (95%, 1.41 g, 12.1 mmol). The mixture was refluxed for 12 h, and was then cooled and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was partitioned between EtOAc (300 mL) and 5% aqueous NaHCO<sub>3</sub> solution (300 mL). The organic layer was washed with water (2 × 200 mL) and brine (200 mL), successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (30–100% EtOAc in <i>n</i>-hexane). Desired fractions were combined and evaporated to give <b>10a</b> (1.94 g, 99%) as yellow crystals; mp 77–78 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 5.34 (s, 2H), 6.35–6.44 (m, 1H), 6.49 (dd, <i>J</i> = 2.4, 13.2 Hz, 1H), 6.61–6.73 (m, 1H), 6.80–7.03 (m, 1H), 7.28 (t, <i>J</i> = 8.1 Hz, 1H), 7.36 (t, <i>J</i> = 2.1 Hz, 1H), 7.41–7.50 (m, 1H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.67–7.79 (m, 1H), 7.83–7.94 (m, 1H), 7.99 (t, <i>J</i> = 1.8 Hz, 1H), 10.31 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 390.05 (M + H)<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Methyl 5-amino-2-[3-({[3-(1-cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]benzoate (<b>10b</b>)</h4><div class="NLM_p">To a solution of methyl 2-[3-({[3-(1-cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]-5-nitrobenzoate <b>15b</b> (4.00 g, 8.70 mmol) in NMP/MeOH/THF (2:4:1) (70 mL) was added 10% Pd/C (400 mg), and the mixture was stirred at room temperature for 14 h under a hydrogen atmosphere (1 atm). Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was diluted with EtOAc (200 mL), washed successively with water (2 × 100 mL) and brine (2 × 100 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (eluate: EtOAc), and the obtained solution was concentrated under reduced pressure to give <b>10b</b> (3.42 g, 92%) as a pale yellow oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 2.69 (s, 3H), 5.33 (s, 2H), 6.44–6.63 (m, 1H), 6.71–6.96 (m, 2H), 7.07 (d, <i>J</i> = 2.6 Hz, 1H), 7.19–7.32 (m, 2H), 7.39–7.44 (m, 1H), 7.57 (t, <i>J</i> = 7.7 Hz, 1H), 7.68–7.80 (m, 1H), 7.83–7.94 (m, 1H), 7.98 (t, <i>J</i> = 1.7 Hz, 1H), 10.28 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 430.20 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The following compounds (<b>10c</b>) were prepared from the corresponding nitro derivatives (<b>15c</b>) using Fe(0) and CaCl<sub>2</sub> by a method similar to that described for <b>10a</b>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-[3-(4-Amino-2-cyanophenoxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (<b>10c</b>)</h4><div class="NLM_p last">Yield 82%, yellow oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 5.48–5.66 (br s, 2H), 6.65–6.80 (m, 1H), 6.86–7.05 (m, 3H), 7.34 (t, <i>J</i> = 8.1 Hz, 1H), 7.42 (t, <i>J</i> = 2.1 Hz, 1H), 7.48–7.55 (m, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.69–7.81 (m, 1H), 7.84–7.94 (m, 1H), 8.00 (t, <i>J</i> = 1.7 Hz, 1H), 10.35 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 397.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-[3-(4-Amino-2-nitrophenoxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (<b>10d</b>)</h4><div class="NLM_p last">To a mixture of 3-(1-cyano-1-methylethyl)-<i>N</i>-(3-hydroxyphenyl)benzamide <b>13</b> (20 g, 71.3 mmol) and 4-fluoro-3-nitroaniline <b>14d</b> (10.9 g, 69.9 mmol) in DMF (150 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (33.8 g, 104 mmol), and the mixture was stirred at 80 °C for 16 h. The reaction mixture was cooled to room temperature, and insoluble material was filtered off and washed with EtOAc. The filtrate and washings were combined, and the mixture was concentrated under reduced pressure. The obtained residue was diluted with EtOAc (300 mL), washed successively with water (300 mL) and brine (2 × 150 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (eluate: EtOAc), and the obtained solution was concentrated under reduced pressure. The residue was crystallized from EtOAc/<i>n</i>-hexane to give <b>10d</b> (23.8 g, 82%) as red-orange crystals; mp 137–138 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 5.71 (s, 2H), 6.61–6.74 (m, 1H), 6.93 (dd, <i>J</i> = 2.7, 8.7 Hz, 1H), 7.06 (d, <i>J</i> = 8.7 Hz, 1H), 7.20 (d, <i>J</i> = 2.7 Hz, 1H), 7.31 (t, <i>J</i> = 8.1 Hz, 1H), 7.39 (t, <i>J</i> = 2.1 Hz, 1H), 7.45–7.52 (m, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.68–7.79 (m, 1H), 7.90 (dt, <i>J</i> = 1.5, 7.8 Hz, 1H), 7.99 (t, <i>J</i> = 1.8 Hz, 1H), 10.33 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 417.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Methyl 2-amino-6-[3-({[3-(1-cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]-1,3-benzothiazole-7-carboxylate (<b>11b</b>)</h4><div class="NLM_p">Potassium thiocyanate (1.02 g, 10.5 mmol) was suspended in AcOH (10 mL), and the mixture was stirred at room temperature for 10 min. A solution of <b>10b</b> (1.13 g, 2.62 mmol) in AcOH (10 mL) was added to the obtained solution, and the mixture was further stirred at room temperature for 10 min. A solution of bromine (460 mg, 2.88 mmol) in AcOH (5 mL) was slowly added dropwise to the obtained solution, and the mixture was stirred at room temperature for 3 h. The resulting yellow insoluble material was filtered off and washed with AcOH. The filtrate and washings were combined, and the mixture was concentrated under reduced pressure. The obtained residue was suspended in EtOAc (200 mL), washed successively with saturated aqueous NaHCO<sub>3</sub> solution (100 mL) and brine (2 × 100 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (40–100% EtOAc in <i>n</i>-hexane), and the obtained solution was concentrated under reduced pressure to give <b>11b</b> (1.15 g, 90%) as a colorless solid; mp 115–116 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 1.73 (s, 6H), 3.74 (s, 3H), 6.65–6.73 (m, 1H), 7.06 (d, <i>J</i> = 8.7 Hz, 1H), 7.25–7.38 (m, 2H), 7.44–7.63 (m, 5H), 7.67–7.77 (m, 1H), 7.82–7.91 (m, 1H), 7.97 (t, <i>J</i> = 1.7 Hz, 1H), 10.29 (s, 1H). HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>S: 487.1435 [M + H]<sup>+</sup>. Found: 487.1406.</div><div class="NLM_p last">The following compounds (<b>11c</b>,<b>d</b> and <b>12a</b>) were prepared from the corresponding aniline derivatives (<b>10a</b>,<b>c</b>,<b>d</b>) using KSCN, Br<sub>2</sub>, and AcOH by a method similar to that described for <b>11b</b>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-{3-[(2-Amino-7-cyano-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>11c</b>)</h4><div class="NLM_p last">Yield 81%, yellow solid, mp 179–182 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 6.81–6.91 (m, 1H), 7.04 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (t, <i>J</i> = 8.1 Hz, 1H), 7.49–7.67 (m, 4H), 7.69–7.80 (m, 1H), 7.84–7.95 (m, 3H), 8.00 (t, <i>J</i> = 1.7 Hz, 1H), 10.39 (s, 1H). HRMS (ESI) calcd for C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>S: 454.1332 [M + H]<sup>+</sup>. Found: 454.1306.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-{3-[(2-Amino-7-nitro-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>11d</b>)</h4><div class="NLM_p last">Yield 73%, yellow solid; mp 202–204 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.73 (s, 6H), 6.71–6.88 (m, 1H), 7.21 (d, <i>J</i> = 8.7 Hz, 1H), 7.36 (t, <i>J</i> = 8.2 Hz, 1H), 7.44 (t, <i>J</i> = 2.1 Hz, 1H), 7.51–7.63 (m, 2H), 7.67–7.78 (m, 2H), 7.83–7.93 (m, 3H), 7.98 (t, <i>J</i> = 1.7 Hz, 1H), 10.34 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 474.20 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>24</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub>S·0.2H<sub>2</sub>O: C, 60.42; H, 4.10; N, 14.68. Found: C, 60.48; H, 4.14; N, 14.49.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-{3-[(2-Amino-5-fluoro-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(2-cyanopropan-2-yl)benzamide (<b>12a</b>)</h4><div class="NLM_p last">Yield 57%, yellow crystals, mp 112–113 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.73 (s, 6H), 6.74 (dd, <i>J</i> = 2.0, 7.8 Hz, 1H), 7.25–7.37 (m, 2H), 7.40 (t, <i>J</i> = 2.0 Hz, 1H), 7.49–7.55 (m, 1H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.61–7.69 (m, 3H), 7.70–7.78 (m, 1H), 7.85–7.92 (m, 1H), 7.98 (t, <i>J</i> = 1.6 Hz, 1H), 10.32 (s, 1H). HRMS (ESI) calcd for C<sub>24</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>S: 447.1286 [M + H]<sup>+</sup>. Found: 447.1250.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-(2-fluoro-4-nitrophenoxy)phenyl]benzamide (<b>15a</b>)</h4><div class="NLM_p">To a mixture of <b>13</b> (2.0 g, 7.13 mmol) and 3,4-difluoronitrobenzene <b>14a</b> (1.19 g, 7.49 mmol) in DMF (15 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.48 g, 10.7 mmol) at room temperature. The mixture was stirred at 80 °C for 18 h, and the mixture was partitioned between EtOAc (200 mL) and water (200 mL). The organic layer was washed with water (200 mL) and brine (200 mL), successively, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (EtOAc/<i>n</i>-hexane), and the obtained solution was concentrated under reduced pressure to give <b>15a</b> (2.09 g, 70%) as a yellow oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.60–1.65 (m, 2H), 1.80–1.84 (m, 2H), 6.52 (dt, <i>J</i> = 6.6, 2.4 Hz, 1H), 7.09–7.14 (m, 2H), 7.32–7.33 (m, 1H), 7.54–7.56 (m, 2H), 7.80 (s, 1H), 7.84–7.88 (m, 1H), 9.43 (s, 1H), 10.16 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 420.10 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The following compounds (<b>15b</b>,<b>c</b> and <b>17A</b>,<b>B</b>) were prepared from the 4-fluoronitrobenzene derivatives (<b>14b</b>,<b>c</b>) and the corresponding phenols (<b>13</b> and <b>16A</b>,<b>B</b>) using K<sub>2</sub>CO<sub>3</sub> and DMF by a method similar to that described for <b>15a</b>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Methyl 2-[3-({[3-(1-Cyano-1-methylethyl)phenyl]carbonyl}amino)phenoxy]-5-nitrobenzoate (<b>15b</b>)</h4><div class="NLM_p last">Yield 98%, colorless crystals, mp 144–145 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.75 (s, 6H), 3.88 (s, 3H), 6.90–6.99 (m, 1H), 7.14 (d, <i>J</i> = 9.3 Hz, 1H), 7.43–7.53 (m, 1H), 7.55–7.64 (m, 1H), 7.64–7.71 (m, 2H), 7.72–7.81 (m, 1H), 7.88–7.95 (m, 1H), 8.02 (t, <i>J</i> = 1.7 Hz, 1H), 8.41 (dd, <i>J</i> = 3.0, 9.3 Hz, 1H), 8.64 (d, <i>J</i> = 3.0 Hz, 1H), 10.49 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 460 (M + H)<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-(2-cyano-4-nitrophenoxy)phenyl]benzamide (<b>15c</b>)</h4><div class="NLM_p last">Yield 94%, yellow oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.75 (s, 6H), 7.01–7.19 (m, 2H), 7.55 (t, <i>J</i> = 8.1 Hz, 1H), 7.61 (t, <i>J</i> = 7.8 Hz, 1H), 7.68–7.80 (m, 2H), 7.81 (t, <i>J</i> = 2.1 Hz, 1H), 7.89–7.99 (m, 1H), 8.03 (t, <i>J</i> = 1.7 Hz, 1H), 8.48 (dd, <i>J</i> = 2.8, 9.4 Hz, 1H), 8.88 (d, <i>J</i> = 2.8 Hz, 1H), 10.56 (1H, s). MS (ESI) <i>m</i>/<i>z</i> 427 (M + H)<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-(3-Aminophenoxy)-5-nitrobenzonitrile (<b>17A</b>)</h4><div class="NLM_p last">Yield 66%, yellow crystals (recrystallized from EtOAc/<i>n</i>-hexane), mp 131–133 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.48 (s, 2H), 6.31–6.37 (m, 1H), 6.38 (t, <i>J</i> = 2.2 Hz, 1H), 6.51–6.58 (m, 1H), 7.03 (d, <i>J</i> = 9.4 Hz, 1H), 7.11–7.20 (m, 1H), 8.45 (dd, <i>J</i> = 2.8, 9.4 Hz, 1H), 8.82 (d, <i>J</i> = 2.8 Hz, 1H). MS (ESI) <i>m</i>/<i>z</i> 255.95 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>13</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>:C, 61.18; H, 3.55; N, 16.46. Found: C, 61.12; H, 3.46; N, 16.63.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-(3-Amino-4-fluorophenoxy)-5-nitrobenzonitrile (<b>17B</b>)</h4><div class="NLM_p last">Yield 100%, beige crystals, mp 140–141 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.55 (s, 2H), 6.33–6.46 (m, 1H), 6.60 (dd, <i>J</i> = 3.0, 7.6 Hz, 1H), 7.02 (d, <i>J</i> = 9.4 Hz, 1H), 7.13 (dd, <i>J</i> = 8.7, 11.1 Hz, 1H), 8.44 (dd, <i>J</i> = 2.7, 9.4 Hz, 1H), 8.83 (d, <i>J</i> = 2.7 Hz, 1H). MS (ESI) <i>m</i>/<i>z</i> 273.95 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>13</sub>H<sub>8</sub>FN<sub>3</sub>O<sub>3</sub>: C, 57.15; H, 2.95; N, 15.38. Found: C, 57.22; H, 2.96; N, 15.34.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-[3-(2-Cyano-4-nitrophenoxy)phenyl]-2,2,2-trifluoroacetamide (<b>18A</b>)</h4><div class="NLM_p">To a solution of <b>17A</b> (18 g, 70.5 mmol) in THF (150 mL) was added trifluoroacetic anhydride (11.8 mL, 84.9 mmol) at 0 °C, and the mixture was stirred at room temperature for 1.5 h. The reaction mixture was diluted with EtOAc (500 mL), washed successively with water (150 mL), 5% aqueous NaHCO<sub>3</sub> solution (500 mL), and brine (500 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (10–40% EtOAc in <i>n</i>-hexane), and the obtained solution was concentrated under reduced pressure to give <b>18A</b> (16.6 g, 67%) as beige crystals; mp 190–191 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 7.09 (d, <i>J</i> = 9.3 Hz, 1H), 7.17–7.22 (m, 1H), 7.54–7.63 (m, 1H), 7.63–7.72 (m, 2H), 8.42–8.49 (m, 1H), 8.89 (d, <i>J</i> = 2.6 Hz, 1H), 11.46 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 351 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>15</sub>H<sub>8</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>: C, 51.29; H, 2.30; N, 11.96. Found: C, 51.46; H, 2.33; N, 12.04.</div><div class="NLM_p last">The following compound (<b>18B</b>) was prepared from the aniline derivative (<b>17B</b>) using trifluoroacetic anhydride by a method similar to that described for <b>18A</b>.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-[5-(2-Cyano-4-nitrophenoxy)-2-fluorophenyl]-2,2,2-trifluoroacetamide (<b>18B</b>)</h4><div class="NLM_p">Yield 93%, colorless crystals, mp 168–169 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.06 (d, <i>J</i> = 9.4 Hz, 1H), 7.35–7.45 (m, 1H), 7.51–7.63 (m, 2H), 8.47 (dd, <i>J</i> = 2.8, 9.4 Hz, 1H), 8.88 (d, <i>J</i> = 2.8 Hz, 1H), 11.51 (s, 1H). Anal. Calcd for C<sub>15</sub>H<sub>7</sub>F<sub>4</sub>N<sub>3</sub>O<sub>4</sub>: C, 48.79; H, 1.91; N, 11.38. Found: C, 48.85; H, 2.02; N, 11.30.</div><div class="NLM_p last">The following compounds (<b>19A</b>,<b>B</b>) was prepared from the nitro derivatives (<b>18A</b>,<b>B</b>) using H<sub>2</sub> and 10% Pd/C by a method similar to that described for <b>10b</b>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-[3-(4-Amino-2-cyanophenoxy)phenyl]-2,2,2-trifluoroacetamide (<b>19A</b>)</h4><div class="NLM_p last">Yield 99%, pale yellow oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.55 (s, 2H), 6.81 (d, <i>J</i> = 8.1 Hz, 1H), 6.88–6.94 (m, 2H), 6.96–7.03 (m, 1H), 7.22 (t, <i>J</i> = 2.1 Hz, 1H), 7.32–7.42 (m, 1H), 7.41–7.50 (m, 1H), 11.28 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 321.95 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>: C, 56.08; H, 3.14; N, 13.08. Found: C, 56.28; H, 3.17; N, 13.13.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-[5-(4-Amino-2-cyanophenoxy)-2-fluorophenyl]-2,2,2-trifluoroacetamide (<b>19B</b>)</h4><div class="NLM_p">Yield 99%, gray crystals, mp 136–137 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.53 (s, 2H), 6.84–7.00 (m, 4H), 7.09 (dd, <i>J</i> = 3.2, 6.2 Hz, 1H), 7.33 (t, <i>J</i> = 9.5 Hz, 1H), 11.20 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 340.00 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>15</sub>H<sub>9</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>: C, 53.11; H, 2.67; N, 12.39. Found: C, 52.92; H, 2.80; N, 12.13.</div><div class="NLM_p last">The following compounds (<b>20A</b>,<b>B</b>) were prepared from the corresponding aniline derivatives (<b>19A</b>,<b>B</b>) using KSCN, Br<sub>2</sub>, and AcOH by a method similar to that described for <b>11b</b>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-{3-[(2-Amino-7-cyano-1,3-benzothiazol-6-yl)oxy]phenyl}-2,2,2-trifluoroacetamide (<b>20A</b>)</h4><div class="NLM_p last">Yield 81%, yellow crystals, mp 263–264 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.89–7.00 (m, 1H), 7.06 (d, <i>J</i> = 8.9 Hz, 1H), 7.35 (t, <i>J</i> = 2.1 Hz, 1H), 7.44 (t, <i>J</i> = 8.1 Hz, 1H), 7.51–7.59 (m, 1H), 7.63 (d, <i>J</i> = 8.9 Hz, 1H), 7.92 (s, 2H), 11.30 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 379 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>16</sub>H<sub>9</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S·0.5H<sub>2</sub>O: C, 49.61; H, 2.60; N, 14.46. Found: C, 49.65; H, 2.86; N, 14.30.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-{5-[(2-Amino-7-cyano-1,3-benzothiazol-6-yl)oxy]-2-fluorophenyl}-2,2,2-trifluoroacetamide (<b>20B</b>)</h4><div class="NLM_p">Yield 85%, pale yellow crystals, mp 251–253 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.00 (d, <i>J</i> = 8.9 Hz, 1H), 7.10–7.19 (m, 1H), 7.26 (dd, <i>J</i> = 3.1, 6.1 Hz, 1H), 7.42 (t, <i>J</i> = 9.5 Hz, 1H), 7.62 (d, <i>J</i> = 8.9 Hz, 1H), 7.91 (s, 2H), 11.34 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 397 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>16</sub>H<sub>8</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S: C, 48.49; H, 2.03; N, 14.14. Found: C, 48.26; H, 2.26; N, 13.78.</div><div class="NLM_p last">The following compounds (<b>21A</b>,<b>B</b>) were prepared from the corresponding 2-amino-1,3-benzothiazole derivatives (<b>20A</b>,<b>B</b>) with cyclopropanecarbonyl chloride by a method similar to that described for <b>3c</b>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(7-Cyano-6-{3-[(trifluoroacetyl)amino]phenoxy}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide (<b>21A</b>)</h4><div class="NLM_p last">Yield 82%, colorless crystals (recrystallized from EtOAc), mp 243–244 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.80–1.13 (m, 4H), 1.92–2.11 (m, 1H), 6.93–7.15 (m, 1H), 7.22 (d, <i>J</i> = 8.9 Hz, 1H), 7.35–7.73 (m, 3H), 8.06 (d, <i>J</i> = 9.0 Hz, 1H), 11.0–12.1 (br s, 1H), 12.2–13.4 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 446.95 (M + H)<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(7-Cyano-6-{4-fluoro-3-[(trifluoroacetyl)amino]phenoxy}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide (<b>21B</b>)</h4><div class="NLM_p last">Yield 55%, colorless crystals (recrystallized from EtOAc/<i>n</i>-hexane), mp 242–243 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.95–1.05 (m, 4H), 1.97–2.09 (m, 1H), 7.16 (d, <i>J</i> = 9.0 Hz, 1H), 7.19–7.28 (m, 1H), 7.36 (dd, <i>J</i> = 3.0, 6.2 Hz, 1H), 7.46 (t, <i>J</i> = 9.5 Hz, 1H), 8.05 (d, <i>J</i> = 9.0 Hz, 1H), 11.36 (s, 1H), 12.99 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 465.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>20</sub>H<sub>12</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>S: C, 51.73; H, 2.60; N, 12.06. Found: C, 52.11; H, 2.85; N, 12.08.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-[6-(3-Aminophenoxy)-7-cyano-1,3-benzothiazol-2-yl]cyclopropanecarboxamide (<b>22A</b>)</h4><div class="NLM_p last">Compound <b>21A</b> (1.06 g, 2.37 mmol) was dissolved in a mixed solvent of THF/MeOH/H<sub>2</sub>O (1:1:1) (75 mL), LiOH·H<sub>2</sub>O (1.05 g, 25.7 mmol) was added, and the mixture was stirred at room temperature for 18 h. The reaction mixture was neutralized with 1 N HCl and concentrated under reduced pressure. The obtained precipitates were repeatedly washed with water to give <b>22A</b> (0.79 g, 95%) as colorless crystals; mp 233–234 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–1.14 (m, 4H), 1.96–2.11 (m, 1H), 5.33 (s, 2H), 6.18–6.30 (m, 2H), 6.37–6.49 (m, 1H), 6.98–7.07 (m, 1H), 7.10 (d, <i>J</i> = 9.1 Hz, 1H), 8.00 (d, <i>J</i> = 9.1 Hz, 1H), 12.96 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 351.05 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S·0.5H<sub>2</sub>O: C, 60.15; H, 4.21; N, 15.59. Found: C, 60.31; H, 4.19; N, 15.57.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-[6-(3-Amino-4-fluorophenoxy)-7-cyano-1,3-benzothiazol-2-yl]cyclopropanecarboxamide (<b>22B</b>)</h4><div class="NLM_p last">To a solution of NaBH<sub>4</sub> (1.46 g, 38.6 mmol) in EtOH (20 mL) was added MeOH (0.5 mL). To this suspension was added <b>21B</b> (900 mg, 1.93 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h then at room temperature for 0.5 h. The mixture was diluted with EtOAc (20 mL), and the resulting mixture was concentrated in vacuo. The resulting residue was diluted with EtOAc (200 mL), washed successively with 5% aqueous NaHCO<sub>3</sub> solution (100 mL) and brine (2 × 100 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (eluent: EtOAc), and the obtained solution was concentrated under reduced pressure. The residue was recrystallized from EtOAc/<i>n</i>-hexane to give <b>22B</b> (611 mg, 85%) as colorless crystals; mp 196–197 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.89–1.07 (m, 4H), 1.95–2.08 (m, 1H), 5.40 (s, 2H), 6.16–6.35 (m, 1H), 6.49 (dd, <i>J</i> = 3.0, 7.6 Hz, 1H), 6.96–7.11 (m, 2H), 8.00 (d, <i>J</i> = 8.9 Hz, 1H), 12.94 (br s, 1H). MS (ESI) <i>m</i>/<i>z</i> 369.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>2</sub>S: C, 58.69; H, 3.56; N, 15.21. Found: C, 58.63; H, 3.58; N, 15.00.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60"><a href="/doi/suppl/10.1021/jm400778d">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Information related to the feedback activation in fibroblast CsFb cells, reported regioselective/nonselective <i>C</i>-7 substituted 1,3-benzothiazole ring formation reaction of meta-substituted anilines and regioselective cyclization of meta-substituted thioureides, and assay protocols used in kinase enzyme assays, cellular assays, SPR assay, in vivo studies, solubility study, pharmacokinetic studies, and structural biology studies. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400778d/suppl_file/jm400778d_si_001.pdf">jm400778d_si_001.pdf (381.5 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB accession codes are 4KSP for BRAF with <b>8B</b> and 4KSQ for BRAF with <b>5B</b>.</p><div class="testing" data-doi="10.1021/jm400778d" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55285" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55285" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masanori Okaniwa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b0ddd1c3d1dedfc2d99edfdbd1ded9c7d1f0c4d1dbd5d4d19ed3dfdd"><span class="__cf_email__" data-cfemail="f69b9785979899849fd8999d97989f8197b682979d939297d895999b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masaaki Hirose</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7d101c0e1c1c16145315140f120e183d091c1618191c531e1210"><span class="__cf_email__" data-cfemail="a4c9c5d7c5c5cfcd8acccdd6cbd7c1e4d0c5cfc1c0c58ac7cbc9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomoyasu Ishikawa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#72061d1f1d0b1301075c1b011a1b19130513320613191716135c111d1f"><span class="__cf_email__" data-cfemail="f1859e9c9e88908284df988299989a908690b185909a949590df929e9c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takeo Arita</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masato Yabuki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akito Nakamura</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Terufumi Takagi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomohiro Kawamoto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noriko Uchiyama</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akihiko Sumita</span> - <span class="hlFld-Affiliation affiliation">CMC Center, Takeda
Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-chome,
Yodogawa-ku, Osaka 532-8686, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shunichirou Tsutsumi</span> - <span class="hlFld-Affiliation affiliation">CMC Center, Takeda
Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-chome,
Yodogawa-ku, Osaka 532-8686, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsuneaki Tottori</span> - <span class="hlFld-Affiliation affiliation">CMC Center, Takeda
Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-chome,
Yodogawa-ku, Osaka 532-8686, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshitaka Inui</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bi-Ching Sang</span> - <span class="hlFld-Affiliation affiliation">Structural Biology, Takeda California, Inc., 10410 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Yano</span> - <span class="hlFld-Affiliation affiliation">Structural Biology, Takeda California, Inc., 10410 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Aertgeerts</span> - <span class="hlFld-Affiliation affiliation">Structural Biology, Takeda California, Inc., 10410 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sei Yoshida</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d71e6501-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11251" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11251" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Tohru Miyazaki, and Takashi Imada for their support in the synthesis reactions. We express our gratitude to Yuka Hasegawa, Akiko Nakayama, Kazuyo Kakoi, and Katherine Galvin for their helpful support in biological evaluation. We thank Koji Mori, Shuuhei Yao, Hiroshi Miki, Taeko Yoshida, and Hidehisa Iwata for their assistance in evaluating the kinase inhibitory activities. We thank Yuuki Koudono for his assistance in preparing the SD formulation. We thank Douglas R. Cary for his helpful support in proofreading.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i64" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i64"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i65" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i65"> Abbreviations Used</h2><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the blood concentration–time curve</p></td></tr><tr><td class="NLM_term"><i>CL</i><sub>total</sub></td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectroscopy</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>D</sub></td><td class="NLM_def"><p class="first last">equilibrium dissociation constants</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>off</sub></td><td class="NLM_def"><p class="first last">dissociation rate constant</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectroscopy</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last">1-methylpyrrolidone</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">SCC</td><td class="NLM_def"><p class="first last">squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">solid dispersion</p></td></tr><tr><td class="NLM_term">±SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic anhydride</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">VDss</td><td class="NLM_def"><p class="first last">steady state volume of distribution</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">wt</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Maurer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarini, M.</span><span> </span><span class="NLM_article-title">Raf kinases in cancer-roles and therapeutic opportunities</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3477</span><span class="NLM_x">–</span> <span class="NLM_lpage">3488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=3477-3488&author=G.+Maurerauthor=B.+Tarkowskiauthor=M.+Baccarini&title=Raf+kinases+in+cancer-roles+and+therapeutic+opportunities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DG.%26aulast%3DTarkowski%26aufirst%3DB.%26aulast%3DBaccarini%26aufirst%3DM.%26atitle%3DRaf%2520kinases%2520in%2520cancer-roles%2520and%2520therapeutic%2520opportunities%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D3477%26epage%3D3488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lg9k1ErGvslFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">For the BRIM-3 Study Group. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=For+the+BRIM-3+Study+Group.+Improved+survival+with+Vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0ljKCB01S6okCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DFor%2520the%2520BRIM-3%2520Study%2520Group.%2520Improved%2520survival%2520with%2520Vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">BRAF targeted therapy changes the treatment paradigm in melanoma</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnrclinonc.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=21606968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=426-433&author=A.+Ribasauthor=K.+T.+Flaherty&title=BRAF+targeted+therapy+changes+the+treatment+paradigm+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF targeted therapy changes the treatment paradigm in melanoma</span></div><div class="casAuthors">Ribas, Antoni; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">426-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target.  The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clin. data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.  After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.  The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them.  In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling mol. shown efficacy from early clin. testing.  Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their resp. phase I, II, and III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJ5nnopldxbVg90H21EOLACvtfcHk0ljKCB01S6okCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D&md5=710ef1d3ccb02a0c80bf7f9b3fe935a7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DBRAF%2520targeted%2520therapy%2520changes%2520the%2520treatment%2520paradigm%2520in%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D426%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaempgen, E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Algarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaszewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarion-Sileni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirakhur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckert, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0liPoOGuhkfDfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0liPoOGuhkfDfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Anforth, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumetti, T. C. M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolyer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kossard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Peñas, P.</span><span> </span><span class="NLM_article-title">Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1111%2Fj.1365-2133.2012.11155.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=22804352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ShtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1153-1160&author=R.+M.+Anforthauthor=T.+C.+M.+P.+Blumettiauthor=R.+F.+Keffordauthor=R.+Sharmaauthor=R.+A.+Scolyerauthor=S.+Kossardauthor=G.+V.+Longauthor=P.+Fernandez-Pe%C3%B1as&title=Cutaneous+manifestations+of+dabrafenib+%28GSK2118436%29%3A+a+selective+inhibitor+of+mutant+BRAF+in+patients+with+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma</span></div><div class="casAuthors">Anforth, R. M.; Blumetti, T. C. M. P.; Kefford, R. F.; Sharma, R.; Scolyer, R. A.; Kossard, S.; Long, G. V.; Fernandez-Penas, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1153-1160</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Inhibitors of mutant BRAF are emerging as std. of care in patients with metastatic melanoma carrying relevant oncogenic mutations.  Cutaneous reactions are frequent and significant.  We conducted a systematic prospective dermatol. review of all patients enrolled at a single institution in the phase I/II clin. trial of the mutant BRAF inhibitor dabrafenib (GSK2118436).  Objectives: To identify the cutaneous manifestations of the BRAF inhibitor dabrafenib; to form diagnostic criteria to standardize the diagnosis of verrucal keratotic squamoproliferative lesions; and to bring awareness to the medical community of the importance of dermatol. assessment of patients taking dabrafenib.  Methods: Patients enrolled in the phase I/II trial (n = 43) were monitored for the development of new skin lesions.  Each new lesion was photographed, a clin. diagnosis recorded and, where appropriate, a biopsy taken.  Human papillomavirus (HPV) and p16 immunohistochem. analyses were performed.  Results: The most frequently obsd. lesions were verrucal keratotic squamoproliferative lesions (49%), Grover's disease (27%) and reactive hyperkeratotic lesions on the soles, at points of friction (22%).  Eighteen squamous cell carcinomas (SCCs) occurred in 20% of patients.  Most SCCs appeared between weeks 6 and 24 following commencement of therapy on both sun-damaged and nonsun-damaged skin.  All SCCs were well differentiated, five were of the keratoacanthoma type, and two were SCC in situ.  Other lesions obsd. included seborrhoeic keratoses, epidermal cysts, acneiform eruptions, hair loss and changes in hair structure.  HPV was neg. in 15 of the 16 tissues studied and p16 expression was higher in SCCs compared with verrucal keratoses.  Conclusions: Administration of the mutant BRAF inhibitor dabrafenib is assocd. with induction of keratinocytic proliferation, which in some cases develops features of low-grade malignancy.  Highly oncogenic HPV infection is unlikely to be a contributor to the formation of SCCs or verrucal keratoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJUWGMM-LFa7Vg90H21EOLACvtfcHk0liPoOGuhkfDfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ShtbnP&md5=4f5e528a4419a1711320b82bd85d3478</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2012.11155.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2012.11155.x%26sid%3Dliteratum%253Aachs%26aulast%3DAnforth%26aufirst%3DR.%2BM.%26aulast%3DBlumetti%26aufirst%3DT.%2BC.%2BM.%2BP.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DScolyer%26aufirst%3DR.%2BA.%26aulast%3DKossard%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFernandez-Pe%25C3%25B1as%26aufirst%3DP.%26atitle%3DCutaneous%2520manifestations%2520of%2520dabrafenib%2520%2528GSK2118436%2529%253A%2520a%2520selective%2520inhibitor%2520of%2520mutant%2520BRAF%2520in%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2012%26volume%3D167%26spage%3D1153%26epage%3D1160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Falchook, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span> </span><span class="NLM_article-title">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x"> (</span><span class="NLM_issue">9829</span><span class="NLM_x">) </span> <span class="NLM_fpage">1893</span><span class="NLM_x">–</span> <span class="NLM_lpage">1901</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1893-1901&issue=9829&author=G.+S.+Falchookauthor=G.+V.+Longauthor=R.+Kurzrockauthor=K.+B.+Kimauthor=T.+H.+Arkenauauthor=M.+P.+Brownauthor=O.+Hamidauthor=J.+R.+Infanteauthor=M.+Millwardauthor=A.+C.+Pavlickauthor=S.+J.+O%E2%80%99Dayauthor=S.+C.+Blackmanauthor=C.+M.+Curtisauthor=P.+Lebowitzauthor=B.+Maauthor=D.+Ouelletauthor=R.+F.+Kefford&title=Dabrafenib+in+patients+with+melanoma%2C+untreated+brain+metastases%2C+and+other+solid+tumours%3A+a+phase+1+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DArkenau%26aufirst%3DT.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26aulast%3DCurtis%26aufirst%3DC.%2BM.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26atitle%3DDabrafenib%2520in%2520patients%2520with%2520melanoma%252C%2520untreated%2520brain%2520metastases%252C%2520and%2520other%2520solid%2520tumours%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26issue%3D9829%26spage%3D1893%26epage%3D1901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hall-Jackson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyers, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plant, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedge, P.</span><span> </span><span class="NLM_article-title">Paradoxical activation of Raf by a novel Raf inhibitor</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">568</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1016%2FS1074-5521%2899%2980088-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=10421767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=559-568&author=C.+A.+Hall-Jacksonauthor=P.+A.+Eyersauthor=P.+Cohenauthor=M.+Goedertauthor=F.+T.+Boyleauthor=N.+Hewittauthor=H.+Plantauthor=P.+Hedge&title=Paradoxical+activation+of+Raf+by+a+novel+Raf+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Paradoxical activation of raf by a novel raf inhibitor</span></div><div class="casAuthors">Hall-Jackson, Clare A.; Eyers, Patrick A.; Cohen, Philip; Goedert, Michel; Boyle, F. Tom; Hewitt, Neil; Plant, Helen; Hedge, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-568</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">Raf is a proto-oncogene that is activated in response to growth factors or phorbol esters, and is thought to activate MAP kinase kinase-1 (MKK1) and hence the classical MAP kinase (MAPK) cascade.  The compd. ZM 336372 is identified as a potent and specific inhibitor of Raf isoforms in vitro.  Paradoxically, exposure of cells to ZM 336372 induces > 100-fold activation of c-Raf (measured in the absence of compd.), but without triggering any activation of MKK1 or p42 MAPK/ERK2.  The ZM 336372-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras and is not prevented by inhibition of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase.  ZM 336372 does not prevent growth factor or phorbol ester induced activation of MKK1 or p42 MAPK/ERK2, or reverse the phenotype of Ras- or Raf-transformed cell lines.  The only other protein kinase inhibited by ZM 336372 out of 20 tested was SAPK2/p38.  Although ZM 336372 is structurally unrelated to SB 203580, a potent inhibitor of SAPK2/p38, the mutation of Thr106→Met made SAPK2/p38 insensitive to ZM 336372 as well as to SB 203580.  Raf appears to suppress its own activation by a novel feedback loop, such that inhibition is always counterbalanced by reactivation.  These observations imply that some agonists reported to trigger the cellular activation of c-Raf might actually be inhibitors of this enzyme, and that compds. which inhibit the kinase activity of Raf might not be useful as anticancer drugs.  The binding sites for ZM 336372 and SB 203580 on Raf and SAPK2/p38 are likely to overlap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo23oQKXswmRbVg90H21EOLACvtfcHk0lhdtpAQjiK_Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D&md5=93aa7dbc301a6f798be138df3e5a075c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980088-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980088-X%26sid%3Dliteratum%253Aachs%26aulast%3DHall-Jackson%26aufirst%3DC.%2BA.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DHewitt%26aufirst%3DN.%26aulast%3DPlant%26aufirst%3DH.%26aulast%3DHedge%26aufirst%3DP.%26atitle%3DParadoxical%2520activation%2520of%2520Raf%2520by%2520a%2520novel%2520Raf%2520inhibitor%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26spage%3D559%26epage%3D568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0lhdtpAQjiK_Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signalling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trunzer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spleiss, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kockx, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1056%2FNEJMoa1105358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=22256804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=207-215&issue=3&author=F.+Suauthor=A.+Virosauthor=C.+Milagreauthor=K.+Trunzerauthor=G.+Bollagauthor=O.+Spleissauthor=J.+S.+Reis-Filhoauthor=X.+Kongauthor=R.+C.+Koyaauthor=K.+T.+Flahertyauthor=P.+B.+Chapmanauthor=M.+J.+Kimauthor=R.+Haywardauthor=M.+Martinauthor=H.+Yangauthor=Q.+Wangauthor=H.+Hiltonauthor=J.+S.+Hangauthor=J.+Noeauthor=M.+Lambrosauthor=F.+Geyerauthor=N.+Dhomenauthor=I.+Niculescu-Duvazauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=N.+Preeceauthor=L.+Robertauthor=N.+J.+Otteauthor=S.+Mokauthor=D.+Keeauthor=Y.+Maauthor=C.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=H.+Nguyenauthor=M.+Kockxauthor=L.+Andriesauthor=B.+Lestiniauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=J.+L.+Troyauthor=R.+Gonzalezauthor=T.+E.+Hutsonauthor=I.+Puzanovauthor=B.+Chmielowskiauthor=C.+J.+Springerauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=R.+S.+Loauthor=A.+Ribasauthor=R.+Marais&title=RAS+mutations+in+cutaneous+squamous-cell+carcinomas+in+patients+treated+with+BRAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span></div><div class="casAuthors">Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.  METHODS: We performed a mol. anal. to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.  An anal. of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.  RESULTS: Among 21 tumor samples, 13 had RAS mutations (12 in HRAS).  In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS).  Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L.  Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was assocd. with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription.  In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analog PLX4720 was not an initiator or a.promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor.  CONCLUSIONS: Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.  The mol. mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplrkvSEAdDG7Vg90H21EOLACvtfcHk0lilZlAOiC0k3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D&md5=6c813dc23344a8eedcc7a289d2326f4f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105358%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DF.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DTrunzer%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSpleiss%26aufirst%3DO.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DHayward%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BS.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKockx%26aufirst%3DM.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DTroy%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DRAS%2520mutations%2520in%2520cutaneous%2520squamous-cell%2520carcinomas%2520in%2520patients%2520treated%2520with%2520BRAF%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D3%26spage%3D207%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x"> (</span><span class="NLM_issue">7287</span><span class="NLM_x">) </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lilZlAOiC0k3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Heidorn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&issue=2&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lj6QFyKonU7LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D2%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schostack, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simcox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span> </span><span class="NLM_article-title">RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5518</span><span class="NLM_x">–</span> <span class="NLM_lpage">5527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5518-5527&author=H.+Yangauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=Z.+Goauthor=R.+Iyerauthor=S.+Kolisauthor=S.+Zhaoauthor=R.+Leeauthor=J.+F.+Grippoauthor=K.+Schostackauthor=M.+E.+Simcoxauthor=D.+Heimbrookauthor=G.+Bollagauthor=F.+Su&title=RG7204+%28PLX4032%29%2C+a+selective+BRAFV600E+inhibitor%2C+displays+potent+antitumor+activity+in+preclinical+melanoma+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DGo%26aufirst%3DZ.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DKolis%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DSchostack%26aufirst%3DK.%26aulast%3DSimcox%26aufirst%3DM.%2BE.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DF.%26atitle%3DRG7204%2520%2528PLX4032%2529%252C%2520a%2520selective%2520BRAFV600E%2520inhibitor%252C%2520displays%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520melanoma%2520models%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5518%26epage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. -C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3452</span><span class="NLM_x">–</span> <span class="NLM_lpage">3478</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300126x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3452-3478&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Imadaauthor=T.+Ohashiauthor=Y.+Hayashiauthor=T.+Miyazakiauthor=T.+Aritaauthor=M.+Yabukiauthor=K.+Kakoiauthor=J.+Katoauthor=T.+Takagiauthor=T.+Kawamotoauthor=S.+Yaoauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=H.+Okiauthor=B.+-C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors.+1.+Exploration+of+%5B5%2C6%5D-fused+bicyclic+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm300126x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300126x%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DKakoi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DJ.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2B-C.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors.%25201.%2520Exploration%2520of%2520%255B5%252C6%255D-fused%2520bicyclic%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3452%26epage%3D3478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4680</span><span class="NLM_x">–</span> <span class="NLM_lpage">4692</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4680-4692&author=M.+Okaniwaauthor=T.+Imadaauthor=T.+Ohashiauthor=T.+Miyazakiauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=K.+Higashikawaauthor=T.+Takagiauthor=T.+Kawamotoauthor=Y.+Inuiauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors%3A+2.+Synthesis+and+characterization+of+a+novel+imide-type+prodrug+for+improving+oral+absorption"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DHigashikawa%26aufirst%3DK.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors%253A%25202.%2520Synthesis%2520and%2520characterization%2520of%2520a%2520novel%2520imide-type%2520prodrug%2520for%2520improving%2520oral%2520absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4680%26epage%3D4692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hirose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-<i>d</i>]pyrimidine and thiazolo[5,4-<i>b</i>]pyridine derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5600</span><span class="NLM_x">–</span> <span class="NLM_lpage">5615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5600-5615&author=M.+Hiroseauthor=M.+Okaniwaauthor=T.+Miyazakiauthor=T.+Imadaauthor=T.+Ohashiauthor=Y.+Tanakaauthor=T.+Aritaauthor=M.+Yabukiauthor=T.+Kawamotoauthor=S.+Tsutsumiauthor=A.+Sumitaauthor=T.+Takagiauthor=B.+C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors%3A+3.+Evaluation+of+5-amino-linked+thiazolo%5B5%2C4-d%5Dpyrimidine+and+thiazolo%5B5%2C4-b%5Dpyridine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors%253A%25203.%2520Evaluation%2520of%25205-amino-linked%2520thiazolo%255B5%252C4-d%255Dpyrimidine%2520and%2520thiazolo%255B5%252C4-b%255Dpyridine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D5600%26epage%3D5615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>For BRAF, DOI: <span class="refDoi"> DOI: 10.2210/pdb4dbn/pdb</span> . For VEGFR2, DOI:<span class="refDoi"> DOI: 10.2210/pdb3vnt/pdb</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.2210%2Fpdb4dbn%2Fpdb" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+BRAF%2C+DOI%3A+10.2210%2Fpdb4dbn%2Fpdb.+For+VEGFR2%2C+DOI%3A+10.2210%2Fpdb3vnt%2Fpdb."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2210%2Fpdb4dbn%2Fpdb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.2210%252Fpdb4dbn%252Fpdb%26sid%3Dliteratum%253Aachs%26doi%3D10.2210%2Fpdb4dbn%2Fpdb%26doi%3D10.2210%2Fpdb3vnt%2Fpdb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kaufmann, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span> </span><span class="NLM_article-title">Arzneimittelsynthetische studien IV. Synthese schwefelhaltiger verbindungen</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1929</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1002%2Fardp.19292670304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1929&pages=192-211&author=H.+P.+Kaufmannauthor=E.+Weber&title=Arzneimittelsynthetische+studien+IV.+Synthese+schwefelhaltiger+verbindungen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic drug studies. IV. Synthesis of sulfur-containing preparations</span></div><div class="casAuthors">Kaufmann, H. P.; Weber, E.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft</span>
        (<span class="NLM_cas:date">1929</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-211</span>CODEN:
                <span class="NLM_cas:coden">APBDAJ</span>;
        ISSN:<span class="NLM_cas:issn">0376-0367</span>.
    </div><div class="casAbstract">An exptl. study confined mainly to the introduction of the SCN group into, and the influence of such groups, on certain antipyretics (aniline, phenetidine and phenylhydrazinc) and disinfectants (thymol, cresols and hydroxyquinolines).  The method of introducing SCN into the above compds. involves treatment in a suitable solvent with NaSCN and Br.  Among the new compds. prepd. and characterized were the following: p-rhodanacelanilide, C9H8ON2S, needles m. 188°;  1-amino-2-rhodan-4-ethoxybenzene, C9H10ON2S, silky needles m. 67-8°, easily convertible to 2-amino-6-ethoxybenzthiazol; C9H10ON2S, needles m. 161°;  2-diacetylamino-6-ethoxybenzthiazol, C13H14O3N2S, m. 245°;  bis(1-amino-4-ethoxy)2-disulfide, C16H20O2S2, m. 101°; sym.-formyl-(p-rhodanphenyl) hydrazine, C8H7ON3S, needles m. 132°; sym.-Ac(p-rhodanphenyl), C9H9ON3S, m. 171°; sym.-benzoyl-(p-rhodanphenyl)hydrazine, C14H11ON3S, m. 164°; sym.-phthalyl-(p-rhodanphenyl)hydrazine, C15H9O2N3S, m. 213°; sym.-acetyl-bis(p-rhodanphenyl)hydrazine, C15H12ON4S2, needles m. 160°; sym.-benzoyl-bis(p-rhodanphenyl)hydrazine, C21H14ON4S2, m. 160°; α-hydroxy-γ-rhodanquinoline (4-rhodancarbostyrile), C10H6ON2S, yellowish needles m. 141°; γ-rhodan-o-hydroxyquinoline, C10H6ON2S, m. 134°; 1-methyl-4-isopropyl-3-hydroxy-6-rhodanbenzene (3-methyl-4-rhodan-6-isopropylphenol), needles m. 105°; 1-methyl-2-hydroxy-5-rhodanbenzene (o-methyl-p-rhodanphenol), C8H7ONS, m. 71°; 1-methyl-3-hydroxy-5-rhodanbenzene (o-methyl-m-rhodanphenol), C8H7ONS, needles m. 76°; 1-methyl-4-hydroxy-3-rhodanbenzene, C8H7ONS, m. 105°, yields with alc.  HCl a N-free compd., C8H6O2S, m. 83°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRUByAzB_wf7Vg90H21EOLACvtfcHk0lgEc0DncyN89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D&md5=f514b2d36023e1c8ed30c16b08dfeff8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fardp.19292670304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19292670304%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DH.%2BP.%26aulast%3DWeber%26aufirst%3DE.%26atitle%3DArzneimittelsynthetische%2520studien%2520IV.%2520Synthese%2520schwefelhaltiger%2520verbindungen%26jtitle%3DArch.%2520Pharm.%26date%3D1929%26spage%3D192%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Stuckwisch, C. G.</span><span> </span><span class="NLM_article-title">Derivatives of 2-amino-6-methoxybenzothiazole</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1949</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3417</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja01178a043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1949&pages=3417&author=C.+G.+Stuckwisch&title=Derivatives+of+2-amino-6-methoxybenzothiazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja01178a043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01178a043%26sid%3Dliteratum%253Aachs%26aulast%3DStuckwisch%26aufirst%3DC.%2BG.%26atitle%3DDerivatives%2520of%25202-amino-6-methoxybenzothiazole%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1949%26volume%3D71%26spage%3D3417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ismail, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chedekel, M. R.</span><span> </span><span class="NLM_article-title">Synthesis of benzothiazoles. α-Amino-(4-hydroxy-6-benzothiazolyl)propionic acid</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2243</span><span class="NLM_x">–</span> <span class="NLM_lpage">2246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01299a041" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=2243-2246&author=I.+A.+Ismailauthor=D.+E.+Sharpauthor=M.+R.+Chedekel&title=Synthesis+of+benzothiazoles.+%CE%B1-Amino-%284-hydroxy-6-benzothiazolyl%29propionic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo01299a041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01299a041%26sid%3Dliteratum%253Aachs%26aulast%3DIsmail%26aufirst%3DI.%2BA.%26aulast%3DSharp%26aufirst%3DD.%2BE.%26aulast%3DChedekel%26aufirst%3DM.%2BR.%26atitle%3DSynthesis%2520of%2520benzothiazoles.%2520%25CE%25B1-Amino-%25284-hydroxy-6-benzothiazolyl%2529propionic%2520acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D2243%26epage%3D2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Charris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monasterios, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Castro, N.</span><span> </span><span class="NLM_article-title">Synthesis of some 5-nitro-2-furfurylidene derivatives and their antibacterial and antifungal activities</span> <span class="citation_source-journal">Heterocycl. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1515%2FHC.2002.8.3.275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvFGjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=275-280&issue=3&author=J.+Charrisauthor=M.+Monasteriosauthor=J.+Dominguezauthor=W.+Infanteauthor=N.+De+Castro&title=Synthesis+of+some+5-nitro-2-furfurylidene+derivatives+and+their+antibacterial+and+antifungal+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some 5-nitro-2-furfurylidene derivatives and their antibacterial and antifungal activities</span></div><div class="casAuthors">Charris, Jaime; Monasterios, Melina; Dominguez, Jose; Infante, Wilson; De Castro, Norma</div><div class="citationInfo"><span class="NLM_cas:title">Heterocyclic Communications</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-280</span>CODEN:
                <span class="NLM_cas:coden">HCOMEX</span>;
        ISSN:<span class="NLM_cas:issn">0793-0283</span>.
    
            (<span class="NLM_cas:orgname">Freund Publishing House Ltd.</span>)
        </div><div class="casAbstract">New 5-nitro-2-furfurylidene derivs. I (R1 = Me, Ph; R2 = H, NO2; R3 = H, 6-F, 6-Cl, 6-OMe, 5,6-F2, etc.) were synthesized by reaction of 2-methyl-4-(5-nitro-2-furfurylmethylidene)-Δ2-oxazolin-5-one or 2-phenyl-4-(2-furfurylmethylidene)-Δ2-oxazolin-5-one with 2-aminobenzothiazoles.  The compds. synthesized were identified by 1H-NMR, IR, MS and microanal.  All products were screened for their in vitro antibacterial and antifungal activities against the std. strains: Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, and the yeast Candida albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIH2MfHRtP8bVg90H21EOLACvtfcHk0lhJ_cND7cds-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvFGjurw%253D&md5=3990df645756e422dab165a5d22d85a4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1515%2FHC.2002.8.3.275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FHC.2002.8.3.275%26sid%3Dliteratum%253Aachs%26aulast%3DCharris%26aufirst%3DJ.%26aulast%3DMonasterios%26aufirst%3DM.%26aulast%3DDominguez%26aufirst%3DJ.%26aulast%3DInfante%26aufirst%3DW.%26aulast%3DDe%2BCastro%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520some%25205-nitro-2-furfurylidene%2520derivatives%2520and%2520their%2520antibacterial%2520and%2520antifungal%2520activities%26jtitle%3DHeterocycl.%2520Commun.%26date%3D2002%26volume%3D8%26issue%3D3%26spage%3D275%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Tomasi, A.; Morgan, B. P.; McDonald, A.; Roof, D.; Maxon, M.</span><span> </span><span class="NLM_article-title">Compounds, Compositions, and Methods</span>. WIPO Patent Application WO 2004/098494, Nov 18,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+Tomasi&author=B.+P.+Morgan&author=A.+McDonald&author=D.+Roof&author=M.+Maxon&title=Compounds%2C+Compositions%2C+and+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTomasi%26aufirst%3DA.%26atitle%3DCompounds%252C%2520Compositions%252C%2520and%2520Methods%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Malik, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manvi, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanjwade, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span> </span><span class="NLM_article-title">Synthesis and screening of some new 2-amino substituted-benzothiazole derivatives for antifungal activity</span> <span class="citation_source-journal">Drug Invention Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1eqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=32-34&issue=1&author=J.+K.+Malikauthor=F.+V.+Manviauthor=B.+K.+Nanjwadeauthor=S.+Singh&title=Synthesis+and+screening+of+some+new+2-amino+substituted-benzothiazole+derivatives+for+antifungal+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and screening of some new 2-amino substituted-benzothiazole derivatives for antifungal activity</span></div><div class="casAuthors">Malik, Jitender K.; Manvi, F. V.; Nanjwade, B. K.; Singh, Sanjiv</div><div class="citationInfo"><span class="NLM_cas:title">Drug Invention Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-34</span>CODEN:
                <span class="NLM_cas:coden">DITRCZ</span>;
        ISSN:<span class="NLM_cas:issn">0975-7619</span>.
    
            (<span class="NLM_cas:orgname">Drug Invention Today</span>)
        </div><div class="casAbstract">Some new 2-Amino substituted-benzothiazole were synthesized by treating with KSCN in presence of glacial acetic acid and with different substituted aniline.  Structures of the synthesized compds. were established on the basis of M.p., TLC, and IR spectral data.  The anti-fungal activity of the synthesized compds. was evaluated by disk diffusion method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tsvkyOHXLrVg90H21EOLACvtfcHk0lhJ_cND7cds-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1eqtLs%253D&md5=434175a9fde3bb926ffdf23b4e7f7fec</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DJ.%2BK.%26aulast%3DManvi%26aufirst%3DF.%2BV.%26aulast%3DNanjwade%26aufirst%3DB.%2BK.%26aulast%3DSingh%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520screening%2520of%2520some%2520new%25202-amino%2520substituted-benzothiazole%2520derivatives%2520for%2520antifungal%2520activity%26jtitle%3DDrug%2520Invention%2520Today%26date%3D2009%26volume%3D1%26issue%3D1%26spage%3D32%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Schnur, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fliri, A. F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kajiji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis Lung carcinoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00107a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=914-918&author=R.+C.+Schnurauthor=A.+F.+J.+Fliriauthor=S.+Kajijiauthor=V.+A.+Pollack&title=N-%285-fluorobenzothiazol-2-yl%29-2-guanidinothiazole-4-carboxamide.+A+novel%2C+systemically+active+antitumor+agent+effective+against+3LL+Lewis+Lung+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00107a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00107a007%26sid%3Dliteratum%253Aachs%26aulast%3DSchnur%26aufirst%3DR.%2BC.%26aulast%3DFliri%26aufirst%3DA.%2BF.%2BJ.%26aulast%3DKajiji%26aufirst%3DS.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26atitle%3DN-%25285-fluorobenzothiazol-2-yl%2529-2-guanidinothiazole-4-carboxamide.%2520A%2520novel%252C%2520systemically%2520active%2520antitumor%2520agent%2520effective%2520against%25203LL%2520Lewis%2520Lung%2520carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D914%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sledge, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Q. H.</span><span> </span><span class="NLM_article-title">Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">8599</span><span class="NLM_x">–</span> <span class="NLM_lpage">8607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=8599-8607&issue=24&author=M.+Wangauthor=M.+Gaoauthor=B.+H.+Mockauthor=K.+D.+Millerauthor=G.+W.+Sledgeauthor=G.+D.+Hutchinsauthor=Q.+H.+Zheng&title=Synthesis+of+carbon-11+labeled+fluorinated+2-arylbenzothiazoles+as+novel+potential+PET+cancer+imaging+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMock%26aufirst%3DB.%2BH.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DHutchins%26aufirst%3DG.%2BD.%26aulast%3DZheng%26aufirst%3DQ.%2BH.%26atitle%3DSynthesis%2520of%2520carbon-11%2520labeled%2520fluorinated%25202-arylbenzothiazoles%2520as%2520novel%2520potential%2520PET%2520cancer%2520imaging%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26issue%3D24%26spage%3D8599%26epage%3D8607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wang, M.; Jiang, S.; Hou, X.</span><span> </span><span class="NLM_article-title">[1,2,3] Piazthiole-7-formhydrazide Derivative as I-Type Plant Disease-Resisting Revulsive.</span> SIPO Patent Application CN 1389114, Jan 08,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+Wang&author=S.+Jiang&author=X.+Hou&title=%5B1%2C2%2C3%5D+Piazthiole-7-formhydrazide+Derivative+as+I-Type+Plant+Disease-Resisting+Revulsive."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26atitle%3D%255B1%252C2%252C3%255D%2520Piazthiole-7-formhydrazide%2520Derivative%2520as%2520I-Type%2520Plant%2520Disease-Resisting%2520Revulsive.%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Gyorkos, A. C.; Corrette, C. P.; Cho, S. Y.; Turner, T. M.; Pratt, S. A.; Aso, K.; Kori, M.; Gyoten, M.</span><span> </span><span class="NLM_article-title">Preparation of Nitrogen-Containing Fused Heterocyclic Compounds Like Benzimidazoles and Benzothiazoles as CRF Receptor Antagonists</span>. WIPO Patent Application WO 2005/044793, May 19,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+C.+Gyorkos&author=C.+P.+Corrette&author=S.+Y.+Cho&author=T.+M.+Turner&author=S.+A.+Pratt&author=K.+Aso&author=M.+Kori&author=M.+Gyoten&title=Preparation+of+Nitrogen-Containing+Fused+Heterocyclic+Compounds+Like+Benzimidazoles+and+Benzothiazoles+as+CRF+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGyorkos%26aufirst%3DA.%2BC.%26atitle%3DPreparation%2520of%2520Nitrogen-Containing%2520Fused%2520Heterocyclic%2520Compounds%2520Like%2520Benzimidazoles%2520and%2520Benzothiazoles%2520as%2520CRF%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession code 4KSP for BRAF with <b>8B</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bondi, A.</span><span> </span><span class="NLM_article-title">van der Waals volumes and radii</span> <span class="citation_source-journal">J. Phys. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/doi/10.1021/j100785a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1964&pages=441-451&author=A.+Bondi&title=van+der+Waals+volumes+and+radii"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">van der Waals volumes and radii</span></div><div class="casAuthors">Bondi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-51</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">Intermol. van der Waals radii of the nonmetallic elements were assembled into a list of recommended values for vol. calcns.  These values were arrived at by selecting from the most reliable x-ray diffraction data those which could be reconciled with crystal d. at 0°K. (to give reasonable packing d.), gas kinetic collision cross section, crit. d., and with liquid state properties.  A qual. understanding of the nature of van der Waals radii is provided by correlation with the de Broglie wavelength of the outermost valence electron.  Tentative values for the van der Waals radii of metallic elements in organometallic compds. are proposed.  A list of increments for the vol. of mols. impenetrable to thermal collision, the so-called van der Waals vol., and of the corresponding increments in area per mol. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHeueZoao997Vg90H21EOLACvtfcHk0ljpVrDztORd9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D&md5=0f25964afae4e9f761e0d314151444a5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fj100785a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100785a001%26sid%3Dliteratum%253Aachs%26aulast%3DBondi%26aufirst%3DA.%26atitle%3Dvan%2520der%2520Waals%2520volumes%2520and%2520radii%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1964%26volume%3D68%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession code 4KSQ for BRAF with <b>5B</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci7002494" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1-24&issue=1&author=K.+A.+Brameldauthor=B.+Kuhnauthor=D.+C.+Reuterauthor=M.+Stahl&title=Small+molecule+conformational+preferences+derived+from+crystal+structure+data.+A+medicinal+chemistry+focused+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule conformational preferences derived from crystal structure data. a medicinal chemistry focused analysis</span></div><div class="casAuthors">Brameld, Ken A.; Kuhn, Bernd; Reuter, Deborah C.; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Based on torsion angle distributions of frequently occurring substructures, conformation preferences of druglike mols. are presented, accompanied by a review of the relevant literature.  First, the relevance of the Cambridge Structural Database (CSD) for drug design is demonstrated by comparing substructures present in compds. entering clin. trials with those found in the CSD and protein-bound ligands in the Protein Data Bank (PDB).  Next, we briefly highlight preferred conformations of elementary acyclic systems, followed by a discussion of sulfonamide conformations.  Due to their central role in medicinal chem., we discuss properties of aryl ring substituents in depth, including biaryl systems and systems of two aryl rings connected by two acyclic bonds.  For a subset of torsion motifs, we also compare torsion angle histograms derived from CSD structures with those derived from ligands in the PDB.  Furthermore, selected properties of some six- and seven-membered ring systems are discussed.  The article closes with a section on attractive sulfur-oxygen contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBrdvMrRvKirVg90H21EOLACvtfcHk0ljpVrDztORd9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D&md5=289969338dcb94a145ce736d19d05cf4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fci7002494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci7002494%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DReuter%26aufirst%3DD.%2BC.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DSmall%2520molecule%2520conformational%2520preferences%2520derived%2520from%2520crystal%2520structure%2520data.%2520A%2520medicinal%2520chemistry%2520focused%2520analysis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26issue%3D1%26spage%3D1%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haass, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproesser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+Smalleyauthor=D.+Fongauthor=Y.+L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lgBDFaE7JOgUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%2BL.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">Aunique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=Aunique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DAunique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span> </span><span class="NLM_article-title">Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi101777f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=738-751&author=H.+Iwataauthor=S.+Imamuraauthor=A.+Horiauthor=M.+S.+Hixonauthor=H.+Kimuraauthor=H.+Miki&title=Biochemical+characterization+of+TAK-593%2C+a+novel+VEGFR%2FPDGFR+inhibitor+with+a+two-step+slow+binding+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fbi101777f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi101777f%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHixon%26aufirst%3DM.%2BS.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DBiochemical%2520characterization%2520of%2520TAK-593%252C%2520a%2520novel%2520VEGFR%252FPDGFR%2520inhibitor%2520with%2520a%2520two-step%2520slow%2520binding%2520mechanism%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D738%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&issue=9&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lgBDFaE7JOgUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D9%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">The Ministry of Health, Labour and Welfare</span><span class="NLM_x">. </span><span> </span><span class="NLM_article-title">The Ministry of Health, Labour and Welfare Ministerial Notification No. 285. General Tests/Reagents, Test Solutions</span>.  <span class="citation_source-book">The Japanese Pharmacopoeia</span>, English version, <span class="NLM_publisher-name">Ministry of Health, Labour and Welfare</span>: <span class="NLM_publisher-loc">Tokyo, Japan</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">15</span>, p.  <span class="NLM_fpage">239</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=239&author=The+Ministry+of+Health%2C+Labour+and+Welfare&title=The+Japanese+Pharmacopoeia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520Ministry%2520of%2520Health%252C%2520Labour%2520and%2520Welfare%2520Ministerial%2520Notification%2520No.%2520285.%2520General%2520Tests%252FReagents%252C%2520Test%2520Solutions%26btitle%3DThe%2520Japanese%2520Pharmacopoeia%26pub%3DMinistry%2520of%2520Health%252C%2520Labour%2520and%2520Welfare%26date%3D2006%26volume%3D15%26spage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Lavoie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thevakumaran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavory, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padeganeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, D. Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, M.</span><span> </span><span class="NLM_article-title">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&issue=7&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+L.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+that+stabilize+a+closed+RAF+kinase+domain+conformation+induce+dimerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0lhVWdrNsqHslg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%2BL.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520that%2520stabilize%2520a%2520closed%2520RAF%2520kinase%2520domain%2520conformation%2520induce%2520dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D7%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">2410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-2410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0lhVWdrNsqHslg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Galvin, K.</span>MLN2480: A Novel pan-RAF Inhibitor for Treatment of BRAF Mutant and Wild-Type Tumors, 103rd Annual Meeting of American Association for Cancer Research (AACR), Chicago, IL, Mar 31–Apr 4,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Abstract.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=K.+Galvin&title=MLN2480%3A+A+Novel+pan-RAF+Inhibitor+for+Treatment+of+BRAF+Mutant+and+Wild-Type+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGalvin%26aufirst%3DK.%26jtitle%3DMLN2480%253A%2520A%2520Novel%2520pan-RAF%2520Inhibitor%2520for%2520Treatment%2520of%2520BRAF%2520Mutant%2520and%2520Wild-Type%2520Tumors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':[],'ref30':['cit30'],'ref31':[],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 62 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mohammed S. Abdel-Maksoud, Mohammed I. El-Gamal, Bong S. Lee, Mahmoud M. Gamal El-Din, Hong R. Jeon, Dow Kwon, Usama M. Ammar, Karim I. Mersal, Eslam M. H. Ali, Kyung-Tae Lee, Kyung Ho Yoo, Dong Keun Han, Jae Kyun Lee, Garam Kim, Hong Seok Choi, Young Jik Kwon, Kwan Hyi Lee, <span class="NLM_string-name hlFld-ContribAuthor">Chang Hyun Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6877-6901. <a href="https://doi.org/10.1021/acs.jmedchem.1c00230" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00230%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNew%252BImidazo%25255B2%25252C1-b%25255Dthiazole%252BDerivatives%252Bas%252BPotent%252BPan-RAF%252BInhibitors%252Bwith%252BPromising%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAnti-melanoma%252BActivity%26aulast%3DAbdel-Maksoud%26aufirst%3DMohammed%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05022021%26date%3D17052021%26volume%3D64%26issue%3D10%26spage%3D6877%26epage%3D6901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Chen, Hao Xiong, Jing-Fang Yang, Xiao-Lei Zhu, Ren-Yu Qu, <span class="NLM_string-name hlFld-ContribAuthor">Guang-Fu Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (37)
                                     , 9839-9877. <a href="https://doi.org/10.1021/acs.jafc.0c03369" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c03369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c03369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c03369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DDiaryl%252BEther%25253A%252BA%252BPrivileged%252BScaffold%252Bfor%252BDrug%252Band%252BAgrochemical%252BDiscovery%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27052020%26date%3D11082020%26date%3D11082020%26date%3D29082020%26date%3D11082020%26volume%3D68%26issue%3D37%26spage%3D9839%26epage%3D9877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hao Zhang, Lijuan Xu, Xia Qin, Xiaofei Chen, Hui Cong, Longmiao Hu, Long Chen, Zhenyuan Miao, Wannian Zhang, Zhenyu Cai, <span class="NLM_string-name hlFld-ContribAuthor">Chunlin Zhuang</span>. </span><span class="cited-content_cbyCitation_article-title">N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure–Activity Relationships, and in Vivo Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6665-6681. <a href="https://doi.org/10.1021/acs.jmedchem.9b00611" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00611%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-%2525287-Cyano-6-%2525284-fluoro-3-%2525282-%2525283-%252528trifluoromethyl%252529phenyl%252529acetamido%252529phenoxy%252529benzo%25255Bd%25255Dthiazol-2-yl%252529cyclopropanecarboxamide%252B%252528TAK-632%252529%252BAnalogues%252Bas%252BNovel%252BNecroptosis%252BInhibitors%252Bby%252BTargeting%252BReceptor-Interacting%252BProtein%252BKinase%252B3%252B%252528RIPK3%252529%25253A%252BSynthesis%25252C%252BStructure%2525E2%252580%252593Activity%252BRelationships%25252C%252Band%252Bin%252BVivo%252BEfficacy%26aulast%3DZhang%26aufirst%3DHao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D09042019%26date%3D28052019%26date%3D16052019%26volume%3D62%26issue%3D14%26spage%3D6665%26epage%3D6681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bogos Agianian, <span class="NLM_string-name hlFld-ContribAuthor">Evripidis Gavathiotis</span>. </span><span class="cited-content_cbyCitation_article-title">Current Insights of BRAF Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5775-5793. <a href="https://doi.org/10.1021/acs.jmedchem.7b01306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BInsights%252Bof%252BBRAF%252BInhibitors%252Bin%252BCancer%26aulast%3DAgianian%26aufirst%3DBogos%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01092017%26date%3D06032018%26date%3D20022018%26volume%3D61%26issue%3D14%26spage%3D5775%26epage%3D5793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael Grasso, Michelle A. Estrada, Kiara N. Berrios, Jeffrey D. Winkler, <span class="NLM_string-name hlFld-ContribAuthor">Ronen Marmorstein</span>. </span><span class="cited-content_cbyCitation_article-title">N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (11)
                                     , 5034-5046. <a href="https://doi.org/10.1021/acs.jmedchem.8b00499" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00499%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-%2525287-Cyano-6-%2525284-fluoro-3-%2525282-%2525283-%252528trifluoromethyl%252529phenyl%252529acetamido%252529phenoxy%252529benzo%25255Bd%25255Dthiazol-2-yl%252529cyclopropanecarboxamide%252B%252528TAK632%252529%252BPromotes%252BInhibition%252Bof%252BBRAF%252Bthrough%252Bthe%252BInduction%252Bof%252BInhibited%252BDimers%26aulast%3DGrasso%26aufirst%3DMichael%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D29032018%26date%3D18052018%26date%3D04052018%26volume%3D61%26issue%3D11%26spage%3D5034%26epage%3D5046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Volkamer</span>, <span class="hlFld-ContribAuthor ">Sameh  Eid</span>, <span class="hlFld-ContribAuthor ">Samo  Turk</span>, <span class="hlFld-ContribAuthor ">Friedrich  Rippmann</span>, and <span class="hlFld-ContribAuthor ">Simone  Fulle</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification and Visualization of Kinase-Specific Subpockets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (2)
                                     , 335-346. <a href="https://doi.org/10.1021/acs.jcim.5b00627" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00627</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00627%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Band%252BVisualization%252Bof%252BKinase-Specific%252BSubpockets%26aulast%3DVolkamer%26aufirst%3DAndrea%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D15102015%26date%3D29012016%26date%3D22022016%26date%3D06012016%26volume%3D56%26issue%3D2%26spage%3D335%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James R.  Henry</span>, <span class="hlFld-ContribAuthor ">Michael D.  Kaufman</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>, <span class="hlFld-ContribAuthor ">Yu Mi  Ahn</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Caldwell</span>, <span class="hlFld-ContribAuthor ">Lakshminarayana  Vogeti</span>, <span class="hlFld-ContribAuthor ">Hanumaiah  Telikepalli</span>, <span class="hlFld-ContribAuthor ">Wei-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Molly M.  Hood</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Rutkoski</span>, <span class="hlFld-ContribAuthor ">Bryan D.  Smith</span>, <span class="hlFld-ContribAuthor ">Subha  Vogeti</span>, <span class="hlFld-ContribAuthor ">David  Miller</span>, <span class="hlFld-ContribAuthor ">Scott C.  Wise</span>, <span class="hlFld-ContribAuthor ">Lawrence  Chun</span>, <span class="hlFld-ContribAuthor ">Xiaoyi  Zhang</span>, <span class="hlFld-ContribAuthor ">Youyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Lisa  Kays</span>, <span class="hlFld-ContribAuthor ">Philip A.  Hipskind</span>, <span class="hlFld-ContribAuthor ">Aaron D.  Wrobleski</span>, <span class="hlFld-ContribAuthor ">Karen L.  Lobb</span>, <span class="hlFld-ContribAuthor ">Julia M.  Clay</span>, <span class="hlFld-ContribAuthor ">Jeffrey D.  Cohen</span>, <span class="hlFld-ContribAuthor ">Jennie L.  Walgren</span>, <span class="hlFld-ContribAuthor ">Denis  McCann</span>, <span class="hlFld-ContribAuthor ">Phenil  Patel</span>, <span class="hlFld-ContribAuthor ">David K.  Clawson</span>, <span class="hlFld-ContribAuthor ">Sherry  Guo</span>, <span class="hlFld-ContribAuthor ">Danalyn  Manglicmot</span>, <span class="hlFld-ContribAuthor ">Chris  Groshong</span>, <span class="hlFld-ContribAuthor ">Cheyenne  Logan</span>, <span class="hlFld-ContribAuthor ">James J.  Starling</span>, and <span class="hlFld-ContribAuthor ">Daniel L.  Flynn</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (10)
                                     , 4165-4179. <a href="https://doi.org/10.1021/acs.jmedchem.5b00067" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%2525283%25252C3-Dimethylbutyl%252529-3-%2525282-fluoro-4-methyl-5-%2525287-methyl-2-%252528methylamino%252529pyrido%25255B2%25252C3-d%25255Dpyrimidin-6-yl%252529phenyl%252529urea%252B%252528LY3009120%252529%252Bas%252Ba%252BPan-RAF%252BInhibitor%252Bwith%252BMinimal%252BParadoxical%252BActivation%252Band%252BActivity%252Bagainst%252BBRAF%252Bor%252BRAS%252BMutant%252BTumor%252BCells%26aulast%3DHenry%26aufirst%3DJames%2BR.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D14012015%26date%3D12052015%26date%3D28052015%26volume%3D58%26issue%3D10%26spage%3D4165%26epage%3D4179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rohit  Arora</span>, <span class="hlFld-ContribAuthor ">Michela  Di Michele</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Stes</span>, <span class="hlFld-ContribAuthor ">Elien  Vandermarliere</span>, <span class="hlFld-ContribAuthor ">Lennart  Martens</span>, <span class="hlFld-ContribAuthor ">Kris  Gevaert</span>, <span class="hlFld-ContribAuthor ">Erika  Van Heerde</span>, <span class="hlFld-ContribAuthor ">Joannes T. M.  Linders</span>, <span class="hlFld-ContribAuthor ">Dirk  Brehmer</span>, <span class="hlFld-ContribAuthor ">Edgar  Jacoby</span>, and <span class="hlFld-ContribAuthor ">Pascal  Bonnet</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (4)
                                     , 1818-1831. <a href="https://doi.org/10.1021/jm501667n" title="DOI URL">https://doi.org/10.1021/jm501667n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501667n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501667n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BInvestigation%252Bof%252BB-Raf%252BParadox%252BBreaker%252Band%252BInducer%252BInhibitors%26aulast%3DArora%26aufirst%3DRohit%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D29102014%26date%3D10022015%26date%3D26022015%26date%3D22012015%26volume%3D58%26issue%3D4%26spage%3D1818%26epage%3D1831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Frédéric  Schmidt</span>, <span class="hlFld-ContribAuthor ">Luc  Van Hijfte</span>, and <span class="hlFld-ContribAuthor ">Pascal  George</span>  . </span><span class="cited-content_cbyCitation_article-title">Interfacing Chemical Biology and Drug Discovery: Report from the 50th International Conference on Medicinal Chemistry of the SCT (French Medicinal Chemistry Society), July 2–4, 2014, Rouen, France. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2014,</strong> <em>9 </em>
                                    (12)
                                     , 2702-2707. <a href="https://doi.org/10.1021/cb5009469" title="DOI URL">https://doi.org/10.1021/cb5009469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb5009469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb5009469%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DInterfacing%252BChemical%252BBiology%252Band%252BDrug%252BDiscovery%25253A%252BReport%252Bfrom%252Bthe%252B50th%252BInternational%252BConference%252Bon%252BMedicinal%252BChemistry%252Bof%252Bthe%252BSCT%252B%252528French%252BMedicinal%252BChemistry%252BSociety%252529%25252C%252BJuly%252B2%2525E2%252580%2525934%25252C%252B2014%25252C%252BRouen%25252C%252BFrance%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2014%26date%3D2014%26date%3D02122014%26date%3D05122014%26date%3D19122014%26volume%3D9%26issue%3D12%26spage%3D2702%26epage%3D2707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahim  Ullah</span>, <span class="hlFld-ContribAuthor ">Qing  Yin</span>, <span class="hlFld-ContribAuthor ">Aidan H.  Snell</span>, <span class="hlFld-ContribAuthor ">Lixin  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">RAF-MEK-ERK pathway in cancer evolution and treatment. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>84 </em><a href="https://doi.org/10.1016/j.semcancer.2021.05.010" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DRAF-MEK-ERK%252Bpathway%252Bin%252Bcancer%252Bevolution%252Band%252Btreatment%26aulast%3DUllah%26aufirst%3DRahim%26date%3D2021%26volume%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Zhu</span>, <span class="hlFld-ContribAuthor ">Meng  Xin</span>, <span class="hlFld-ContribAuthor ">Congcong  Xu</span>, <span class="hlFld-ContribAuthor ">Yuan  He</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhibin  Wang</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>184 </em><a href="https://doi.org/10.1016/j.apsb.2021.05.017" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.05.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.05.017%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DLigand-based%252Bsubstituent-anchoring%252Bdesign%252Bof%252Bselective%252Breceptor-interacting%252Bprotein%252Bkinase%252B1%252Bnecroptosis%252Binhibitors%252Bfor%252Bulcerative%252Bcolitis%252Btherapy%26aulast%3DZhu%26aufirst%3DJing%26date%3D2021%26volume%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christos  Adamopoulos</span>, <span class="hlFld-ContribAuthor ">Tamer A.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Maxwell R.  Tucker</span>, <span class="hlFld-ContribAuthor ">Peter M.U.  Ung</span>, <span class="hlFld-ContribAuthor ">Min  Xiao</span>, <span class="hlFld-ContribAuthor ">Zoi  Karoulia</span>, <span class="hlFld-ContribAuthor ">Angelo  Amabile</span>, <span class="hlFld-ContribAuthor ">Xuewei  Wu</span>, <span class="hlFld-ContribAuthor ">Stuart A.  Aaronson</span>, <span class="hlFld-ContribAuthor ">Celina  Ang</span>, <span class="hlFld-ContribAuthor ">Vito W.  Rebecca</span>, <span class="hlFld-ContribAuthor ">Brian D.  Brown</span>, <span class="hlFld-ContribAuthor ">Avner  Schlessinger</span>, <span class="hlFld-ContribAuthor ">Meenhard  Herlyn</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">David E.  Shaw</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1158/2159-8290.CD-20-1351" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-20-1351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-20-1351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-20-1351%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DExploiting%252BAllosteric%252BProperties%252Bof%252BRAF%252Band%252BMEK%252BInhibitors%252Bto%252BTarget%252BTherapy-Resistant%252BTumors%252BDriven%252Bby%252BOncogenic%252BBRAF%252BSignaling%26aulast%3DAdamopoulos%26aufirst%3DChristos%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Marilia  Barreca</span>, <span class="hlFld-ContribAuthor ">Roberta  Rocca</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>, <span class="hlFld-ContribAuthor ">Ruoli  Bai</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>, <span class="hlFld-ContribAuthor ">Maria Valeria  Raimondi</span>, <span class="hlFld-ContribAuthor ">Antonio Palumbo  Piccionello</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113122. <a href="https://doi.org/10.1016/j.ejmech.2020.113122" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113122%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInsight%252Bon%252B%25255B1%25252C3%25255Dthiazolo%25255B4%25252C5-e%25255Disoindoles%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2021%26volume%3D212%26spage%3D113122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiomaris M.  Cotto-Rios</span>, <span class="hlFld-ContribAuthor ">Bogos  Agianian</span>, <span class="hlFld-ContribAuthor ">Nadege  Gitego</span>, <span class="hlFld-ContribAuthor ">Emmanouil  Zacharioudakis</span>, <span class="hlFld-ContribAuthor ">Orsi  Giricz</span>, <span class="hlFld-ContribAuthor ">Yang  Wu</span>, <span class="hlFld-ContribAuthor ">Yiyu  Zou</span>, <span class="hlFld-ContribAuthor ">Amit  Verma</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>, <span class="hlFld-ContribAuthor ">Evripidis  Gavathiotis</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of BRAF dimers using an allosteric site. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-18123-2" title="DOI URL">https://doi.org/10.1038/s41467-020-18123-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-18123-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-18123-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DInhibitors%252Bof%252BBRAF%252Bdimers%252Busing%252Ban%252Ballosteric%252Bsite%26aulast%3DCotto-Rios%26aufirst%3DXiomaris%2BM.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thuraya  Al-Harthy</span>, <span class="hlFld-ContribAuthor ">Wajdi  Zoghaib</span>, <span class="hlFld-ContribAuthor ">Raid  Abdel-Jalil</span>. </span><span class="cited-content_cbyCitation_article-title">Importance of Fluorine in Benzazole Compounds. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4677. <a href="https://doi.org/10.3390/molecules25204677" title="DOI URL">https://doi.org/10.3390/molecules25204677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204677%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImportance%252Bof%252BFluorine%252Bin%252BBenzazole%252BCompounds%26aulast%3DAl-Harthy%26aufirst%3DThuraya%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kristina  Riegel</span>, <span class="hlFld-ContribAuthor ">Krishnaraj  Rajalingam</span>. </span><span class="cited-content_cbyCitation_article-title">The non-linearity of RAF-MEK signaling in dendritic cells. </span><span class="cited-content_cbyCitation_journal-name">Cell Cycle</span><span> <strong>2020,</strong> <em>19 </em>
                                    (18)
                                     , 2249-2259. <a href="https://doi.org/10.1080/15384101.2020.1795990" title="DOI URL">https://doi.org/10.1080/15384101.2020.1795990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384101.2020.1795990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384101.2020.1795990%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Cycle%26atitle%3DThe%252Bnon-linearity%252Bof%252BRAF-MEK%252Bsignaling%252Bin%252Bdendritic%252Bcells%26aulast%3DRiegel%26aufirst%3DKristina%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D18%26spage%3D2249%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fazal  Shirazi</span>, <span class="hlFld-ContribAuthor ">Richard J.  Jones</span>, <span class="hlFld-ContribAuthor ">Ram K.  Singh</span>, <span class="hlFld-ContribAuthor ">Jianxuan  Zou</span>, <span class="hlFld-ContribAuthor ">Isere  Kuiatse</span>, <span class="hlFld-ContribAuthor ">Zuzana  Berkova</span>, <span class="hlFld-ContribAuthor ">Hua  Wang</span>, <span class="hlFld-ContribAuthor ">Hans C.  Lee</span>, <span class="hlFld-ContribAuthor ">Samuel  Hong</span>, <span class="hlFld-ContribAuthor ">Larry  Dick</span>, <span class="hlFld-ContribAuthor ">Nibedita  Chattopadhyay</span>, <span class="hlFld-ContribAuthor ">Robert Z.  Orlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Activating
              KRAS
              ,
              NRAS
              , and
              BRAF
              mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2020,</strong> <em>117 </em>
                                    (33)
                                     , 20004-20014. <a href="https://doi.org/10.1073/pnas.2005052117" title="DOI URL">https://doi.org/10.1073/pnas.2005052117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.2005052117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.2005052117%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DActivating%252BKRAS%252B%25252C%252BNRAS%252B%25252C%252Band%252BBRAF%252Bmutants%252Benhance%252Bproteasome%252Bcapacity%252Band%252Breduce%252Bendoplasmic%252Breticulum%252Bstress%252Bin%252Bmultiple%252Bmyeloma%26aulast%3DShirazi%26aufirst%3DFazal%26date%3D2020%26date%3D2020%26volume%3D117%26issue%3D33%26spage%3D20004%26epage%3D20014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda R.  Moore</span>, <span class="hlFld-ContribAuthor ">Scott C.  Rosenberg</span>, <span class="hlFld-ContribAuthor ">Frank  McCormick</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>. </span><span class="cited-content_cbyCitation_article-title">RAS-targeted therapies: is the undruggable drugged?. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2020,</strong> <em>19 </em>
                                    (8)
                                     , 533-552. <a href="https://doi.org/10.1038/s41573-020-0068-6" title="DOI URL">https://doi.org/10.1038/s41573-020-0068-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-0068-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-0068-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DRAS-targeted%252Btherapies%25253A%252Bis%252Bthe%252Bundruggable%252Bdrugged%25253F%26aulast%3DMoore%26aufirst%3DAmanda%2BR.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D8%26spage%3D533%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Qin</span>, <span class="hlFld-ContribAuthor ">Longmiao  Hu</span>, <span class="hlFld-ContribAuthor ">Shen-nan  Shi</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Chen</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Siriporn  Jitkaew</span>, <span class="hlFld-ContribAuthor ">Xiufeng  Pang</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Yu</span>, <span class="hlFld-ContribAuthor ">Ye-xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Hong-yang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>, 113947. <a href="https://doi.org/10.1016/j.bcp.2020.113947" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.113947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.113947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.113947%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252BBcr-Abl%252Binhibitor%252BGNF-7%252Binhibits%252Bnecroptosis%252Band%252Bameliorates%252Bacute%252Bkidney%252Binjury%252Bby%252Btargeting%252BRIPK1%252Band%252BRIPK3%252Bkinases%26aulast%3DQin%26aufirst%3DXia%26date%3D2020%26volume%3D177%26spage%3D113947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephan  Mokesch</span>, <span class="hlFld-ContribAuthor ">Klaudia  Cseh</span>, <span class="hlFld-ContribAuthor ">Heiko  Geisler</span>, <span class="hlFld-ContribAuthor ">Michaela  Hejl</span>, <span class="hlFld-ContribAuthor ">Matthias H. M.  Klose</span>, <span class="hlFld-ContribAuthor ">Alexander  Roller</span>, <span class="hlFld-ContribAuthor ">Samuel M.  Meier-Menches</span>, <span class="hlFld-ContribAuthor ">Michael A.  Jakupec</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Kandioller</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>. </span><span class="cited-content_cbyCitation_article-title">Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00209" title="DOI URL">https://doi.org/10.3389/fchem.2020.00209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00209%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DInvestigations%252Bon%252Bthe%252BAnticancer%252BPotential%252Bof%252BBenzothiazole-Based%252BMetallacycles%26aulast%3DMokesch%26aufirst%3DStephan%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evan R.  Abt</span>, <span class="hlFld-ContribAuthor ">Ethan W.  Rosser</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Durst</span>, <span class="hlFld-ContribAuthor ">Vincent  Lok</span>, <span class="hlFld-ContribAuthor ">Soumya  Poddar</span>, <span class="hlFld-ContribAuthor ">Thuc M.  Le</span>, <span class="hlFld-ContribAuthor ">Arthur  Cho</span>, <span class="hlFld-ContribAuthor ">Woosuk  Kim</span>, <span class="hlFld-ContribAuthor ">Liu  Wei</span>, <span class="hlFld-ContribAuthor ">Janet  Song</span>, <span class="hlFld-ContribAuthor ">Joseph R.  Capri</span>, <span class="hlFld-ContribAuthor ">Shili  Xu</span>, <span class="hlFld-ContribAuthor ">Nanping  Wu</span>, <span class="hlFld-ContribAuthor ">Roger  Slavik</span>, <span class="hlFld-ContribAuthor ">Michael E.  Jung</span>, <span class="hlFld-ContribAuthor ">Robert  Damoiseaux</span>, <span class="hlFld-ContribAuthor ">Johannes  Czernin</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Donahue</span>, <span class="hlFld-ContribAuthor ">Arnon  Lavie</span>, <span class="hlFld-ContribAuthor ">Caius G.  Radu</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (2)
                                     , 197-205.e6. <a href="https://doi.org/10.1016/j.chembiol.2019.10.012" title="DOI URL">https://doi.org/10.1016/j.chembiol.2019.10.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2019.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2019.10.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DMetabolic%252BModifier%252BScreen%252BReveals%252BSecondary%252BTargets%252Bof%252BProtein%252BKinase%252BInhibitors%252Bwithin%252BNucleotide%252BMetabolism%26aulast%3DAbt%26aufirst%3DEvan%2BR.%26date%3D2020%26volume%3D27%26issue%3D2%26spage%3D197%26epage%3D205.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ufuk  Degirmenci</span>, <span class="hlFld-ContribAuthor ">Mei  Wang</span>, <span class="hlFld-ContribAuthor ">Jiancheng  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (1)
                                     , 198. <a href="https://doi.org/10.3390/cells9010198" title="DOI URL">https://doi.org/10.3390/cells9010198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9010198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9010198%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DTargeting%252BAberrant%252BRAS%25252FRAF%25252FMEK%25252FERK%252BSignaling%252Bfor%252BCancer%252BTherapy%26aulast%3DDegirmenci%26aufirst%3DUfuk%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D1%26spage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Mubeen</span>, <span class="hlFld-ContribAuthor ">Suvarna Ganesh  Kini</span>, <span class="hlFld-ContribAuthor ">Avinash  Kumar</span>, <span class="hlFld-ContribAuthor ">Karkala Sreedhara Ranganath  Pai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Biological Evaluation and In Silico Studies of Few Novel 2-Substituted Benzothiazole Derivatives as Potential EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2019,</strong> <em>16 </em>
                                    (8)
                                     , 961-971. <a href="https://doi.org/10.2174/1570180816666181108112228" title="DOI URL">https://doi.org/10.2174/1570180816666181108112228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180816666181108112228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180816666181108112228%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BBiological%252BEvaluation%252Band%252BIn%252BSilico%252BStudies%252Bof%252BFew%252BNovel%252B2-Substituted%252BBenzothiazole%252BDerivatives%252Bas%252BPotential%252BEGFR%252BInhibitors%26aulast%3DMubeen%26aufirst%3DMuhammad%26date%3D2019%26volume%3D16%26issue%3D8%26spage%3D961%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madhu  Toshniwal</span>, <span class="hlFld-ContribAuthor ">Mahendra  Bundel</span>, <span class="hlFld-ContribAuthor ">Ravikant</span>, <span class="hlFld-ContribAuthor ">Arun  Pareek</span>. </span><span class="cited-content_cbyCitation_article-title">Antifungal Activity of Synthesized Benzothiazole Derivatives using Structure Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Chemistry</span><span> <strong>2019,</strong> <em>31 </em>
                                    (8)
                                     , 1885-1888. <a href="https://doi.org/10.14233/ajchem.2019.21858" title="DOI URL">https://doi.org/10.14233/ajchem.2019.21858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14233/ajchem.2019.21858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14233%2Fajchem.2019.21858%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Chemistry%26atitle%3DAntifungal%252BActivity%252Bof%252BSynthesized%252BBenzothiazole%252BDerivatives%252Busing%252BStructure%252BActivity%252BRelationship%26aulast%3DToshniwal%26aufirst%3DMadhu%26date%3D2019%26date%3D2019%26volume%3D31%26issue%3D8%26spage%3D1885%26epage%3D1888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Kevin L.  Otipoby</span>, <span class="hlFld-ContribAuthor ">Urjana  Poreci</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (13)
                                     , 2905-2913. <a href="https://doi.org/10.1016/j.bmc.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bnovel%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%252Bidentified%252Busing%252BTethering-fragment-based%252Bscreens%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2019%26volume%3D27%26issue%3D13%26spage%3D2905%26epage%3D2913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Chen</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Yibin  Ren</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xia  Qin</span>, <span class="hlFld-ContribAuthor ">Longmiao  Hu</span>, <span class="hlFld-ContribAuthor ">Jing  Fu</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>, <span class="hlFld-ContribAuthor ">Yifeng  Chai</span>, <span class="hlFld-ContribAuthor ">Zheng‐gang  Liu</span>, <span class="hlFld-ContribAuthor ">Haibing  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Cai</span>, <span class="hlFld-ContribAuthor ">Hong‐yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of the Raf kinase inhibitor TAK‐632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2019,</strong> <em>176 </em>
                                    (12)
                                     , 2095-2108. <a href="https://doi.org/10.1111/bph.14653" title="DOI URL">https://doi.org/10.1111/bph.14653</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14653%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DIdentification%252Bof%252Bthe%252BRaf%252Bkinase%252Binhibitor%252BTAK%2525E2%252580%252590632%252Band%252Bits%252Banalogues%252Bas%252Bpotent%252Binhibitors%252Bof%252Bnecroptosis%252Bby%252Btargeting%252BRIPK1%252Band%252BRIPK3%26aulast%3DChen%26aufirst%3DXiaofei%26date%3D2019%26date%3D2019%26volume%3D176%26issue%3D12%26spage%3D2095%26epage%3D2108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmine  Ostacolo</span>, <span class="hlFld-ContribAuthor ">Veronica  Di Sarno</span>, <span class="hlFld-ContribAuthor ">Gianluigi  Lauro</span>, <span class="hlFld-ContribAuthor ">Giacomo  Pepe</span>, <span class="hlFld-ContribAuthor ">Simona  Musella</span>, <span class="hlFld-ContribAuthor ">Tania  Ciaglia</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Vestuto</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Autore</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Bifulco</span>, <span class="hlFld-ContribAuthor ">Stefania  Marzocco</span>, <span class="hlFld-ContribAuthor ">Pietro  Campiglia</span>, <span class="hlFld-ContribAuthor ">Isabel M.  Gomez-Monterrey</span>, <span class="hlFld-ContribAuthor ">Alessia  Bertamino</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of an indol-based multi-target kinase inhibitor through phenotype screening and target fishing using inverse virtual screening approach. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 61-75. <a href="https://doi.org/10.1016/j.ejmech.2019.01.066" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.066%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ban%252Bindol-based%252Bmulti-target%252Bkinase%252Binhibitor%252Bthrough%252Bphenotype%252Bscreening%252Band%252Btarget%252Bfishing%252Busing%252Binverse%252Bvirtual%252Bscreening%252Bapproach%26aulast%3DOstacolo%26aufirst%3DCarmine%26date%3D2019%26volume%3D167%26spage%3D61%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hoyong  Jung</span>, <span class="hlFld-ContribAuthor ">Jinwoong  Kim</span>, <span class="hlFld-ContribAuthor ">Daseul  Im</span>, <span class="hlFld-ContribAuthor ">Hyungwoo  Moon</span>, <span class="hlFld-ContribAuthor ">Jung-Mi  Hah</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (4)
                                     , 534-538. <a href="https://doi.org/10.1016/j.bmcl.2019.01.003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bin%252Bvitro%252Bevaluation%252Bof%252BN-%2525283-%2525283-alkyl-1H-pyrazol-5-yl%252529%252Bphenyl%252529-aryl%252Bamide%252Bfor%252Bselective%252BRAF%252Binhibition%26aulast%3DJung%26aufirst%3DHoyong%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D534%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evan R.  Abt</span>, <span class="hlFld-ContribAuthor ">Ethan W.  Rosser</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Durst</span>, <span class="hlFld-ContribAuthor ">Soumya  Poddar</span>, <span class="hlFld-ContribAuthor ">Vincent  Lok</span>, <span class="hlFld-ContribAuthor ">Liu  Wei</span>, <span class="hlFld-ContribAuthor ">Woosuk  Kim</span>, <span class="hlFld-ContribAuthor ">Janet  Song</span>, <span class="hlFld-ContribAuthor ">Joseph R.  Capri</span>, <span class="hlFld-ContribAuthor ">Thuc M.  Le</span>, <span class="hlFld-ContribAuthor ">Roger  Slavik</span>, <span class="hlFld-ContribAuthor ">Michael E.  Jung</span>, <span class="hlFld-ContribAuthor ">Robert  Damoiseaux</span>, <span class="hlFld-ContribAuthor ">Johannes  Czernin</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Donahue</span>, <span class="hlFld-ContribAuthor ">Arnon  Lavie</span>, <span class="hlFld-ContribAuthor ">Caius G.  Radu</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. </span><span class="cited-content_cbyCitation_journal-name">SSRN Electronic Journal</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.2139/ssrn.3389530" title="DOI URL">https://doi.org/10.2139/ssrn.3389530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2139/ssrn.3389530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2139%2Fssrn.3389530%26sid%3Dliteratum%253Aachs%26jtitle%3DSSRN%2520Electronic%2520Journal%26atitle%3DMetabolic%252BModifier%252BScreen%252BReveals%252BSecondary%252BTargets%252Bof%252BProtein%252BKinase%252BInhibitors%252Bwithin%252BNucleotide%252BMetabolism%26aulast%3DAbt%26aufirst%3DEvan%2BR.%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna Rita  Virzì</span>, <span class="hlFld-ContribAuthor ">Alessandra  Gentile</span>, <span class="hlFld-ContribAuthor ">Silvia  Benvenuti</span>, <span class="hlFld-ContribAuthor ">Paolo M.  Comoglio</span>. </span><span class="cited-content_cbyCitation_article-title">Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2018,</strong> <em>115 </em>
                                    (40)
                                     , 10058-10063. <a href="https://doi.org/10.1073/pnas.1721147115" title="DOI URL">https://doi.org/10.1073/pnas.1721147115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1721147115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1721147115%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DReviving%252Boncogenic%252Baddiction%252Bto%252BMET%252Bbypassed%252Bby%252BBRAF%252B%252528G469A%252529%252Bmutation%26aulast%3DVirz%25C3%25AC%26aufirst%3DAnna%2BRita%26date%3D2018%26date%3D2018%26volume%3D115%26issue%3D40%26spage%3D10058%26epage%3D10063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Usama M.  Ammar</span>, <span class="hlFld-ContribAuthor ">Mohammed S.  Abdel-Maksoud</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 144-166. <a href="https://doi.org/10.1016/j.ejmech.2018.09.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bof%252BRAF%252B%252528rapidly%252Baccelerated%252Bfibrosarcoma%252529%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DAmmar%26aufirst%3DUsama%2BM.%26date%3D2018%26volume%3D158%26spage%3D144%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiawan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhan  Yao</span>, <span class="hlFld-ContribAuthor ">Philip  Jonsson</span>, <span class="hlFld-ContribAuthor ">Amy N.  Allen</span>, <span class="hlFld-ContribAuthor ">Alice Can Ran  Qin</span>, <span class="hlFld-ContribAuthor ">Sharmeen  Uddin</span>, <span class="hlFld-ContribAuthor ">Ira J.  Dunkel</span>, <span class="hlFld-ContribAuthor ">Mary  Petriccione</span>, <span class="hlFld-ContribAuthor ">Katia  Manova</span>, <span class="hlFld-ContribAuthor ">Sofia  Haque</span>, <span class="hlFld-ContribAuthor ">Marc K.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">David J.  Pisapia</span>, <span class="hlFld-ContribAuthor ">Neal  Rosen</span>, <span class="hlFld-ContribAuthor ">Barry S.  Taylor</span>, <span class="hlFld-ContribAuthor ">Christine A.  Pratilas</span>. </span><span class="cited-content_cbyCitation_article-title">A Secondary Mutation in
              BRAF
              Confers Resistance to RAF Inhibition in a
              BRAF
              V600E
              -Mutant Brain Tumor. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2018,</strong> <em>8 </em>
                                    (9)
                                     , 1130-1141. <a href="https://doi.org/10.1158/2159-8290.CD-17-1263" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-17-1263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-17-1263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-17-1263%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DA%252BSecondary%252BMutation%252Bin%252BBRAF%252BConfers%252BResistance%252Bto%252BRAF%252BInhibition%252Bin%252Ba%252BBRAF%252BV600E%252B-Mutant%252BBrain%252BTumor%26aulast%3DWang%26aufirst%3DJiawan%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D9%26spage%3D1130%26epage%3D1141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleksii S.  Rukhlenko</span>, <span class="hlFld-ContribAuthor ">Fahimeh  Khorsand</span>, <span class="hlFld-ContribAuthor ">Aleksandar  Krstic</span>, <span class="hlFld-ContribAuthor ">Jan  Rozanc</span>, <span class="hlFld-ContribAuthor ">Leonidas G.  Alexopoulos</span>, <span class="hlFld-ContribAuthor ">Nora  Rauch</span>, <span class="hlFld-ContribAuthor ">Keesha E.  Erickson</span>, <span class="hlFld-ContribAuthor ">William S.  Hlavacek</span>, <span class="hlFld-ContribAuthor ">Richard G.  Posner</span>, <span class="hlFld-ContribAuthor ">Silvia  Gómez-Coca</span>, <span class="hlFld-ContribAuthor ">Edina  Rosta</span>, <span class="hlFld-ContribAuthor ">Cheree  Fitzgibbon</span>, <span class="hlFld-ContribAuthor ">David  Matallanas</span>, <span class="hlFld-ContribAuthor ">Jens  Rauch</span>, <span class="hlFld-ContribAuthor ">Walter  Kolch</span>, <span class="hlFld-ContribAuthor ">Boris N.  Kholodenko</span>. </span><span class="cited-content_cbyCitation_article-title">Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cell Systems</span><span> <strong>2018,</strong> <em>7 </em>
                                    (2)
                                     , 161-179.e14. <a href="https://doi.org/10.1016/j.cels.2018.06.002" title="DOI URL">https://doi.org/10.1016/j.cels.2018.06.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cels.2018.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cels.2018.06.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Systems%26atitle%3DDissecting%252BRAF%252BInhibitor%252BResistance%252Bby%252BStructure-based%252BModeling%252BReveals%252BWays%252Bto%252BOvercome%252BOncogenic%252BRAS%252BSignaling%26aulast%3DRukhlenko%26aufirst%3DOleksii%2BS.%26date%3D2018%26volume%3D7%26issue%3D2%26spage%3D161%26epage%3D179.e14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelli M.  Morris</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Mhyre</span>, <span class="hlFld-ContribAuthor ">Savanna S.  Carmack</span>, <span class="hlFld-ContribAuthor ">Carrie H.  Myers</span>, <span class="hlFld-ContribAuthor ">Connor  Burns</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Ye</span>, <span class="hlFld-ContribAuthor ">Marc  Ferrer</span>, <span class="hlFld-ContribAuthor ">James M.  Olson</span>, <span class="hlFld-ContribAuthor ">Richard A.  Klinghoffer</span>. </span><span class="cited-content_cbyCitation_article-title">A modified gene trap approach for improved high-throughput cancer drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2018,</strong> <em>37 </em>
                                    (31)
                                     , 4226-4238. <a href="https://doi.org/10.1038/s41388-018-0274-4" title="DOI URL">https://doi.org/10.1038/s41388-018-0274-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-018-0274-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-018-0274-4%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DA%252Bmodified%252Bgene%252Btrap%252Bapproach%252Bfor%252Bimproved%252Bhigh-throughput%252Bcancer%252Bdrug%252Bdiscovery%26aulast%3DMorris%26aufirst%3DShelli%2BM.%26date%3D2018%26date%3D2018%26volume%3D37%26issue%3D31%26spage%3D4226%26epage%3D4238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro  Leonetti</span>, <span class="hlFld-ContribAuthor ">Francesco  Facchinetti</span>, <span class="hlFld-ContribAuthor ">Giulio  Rossi</span>, <span class="hlFld-ContribAuthor ">Roberta  Minari</span>, <span class="hlFld-ContribAuthor ">Antonia  Conti</span>, <span class="hlFld-ContribAuthor ">Luc  Friboulet</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">David  Planchard</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2018,</strong> <em>66 </em>, 82-94. <a href="https://doi.org/10.1016/j.ctrv.2018.04.006" title="DOI URL">https://doi.org/10.1016/j.ctrv.2018.04.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2018.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2018.04.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DBRAF%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%25253A%252BPickaxing%252Banother%252Bbrick%252Bin%252Bthe%252Bwall%26aulast%3DLeonetti%26aufirst%3DAlessandro%26date%3D2018%26volume%3D66%26spage%3D82%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Ramírez</span>, <span class="hlFld-ContribAuthor ">Julio  Caballero</span>. </span><span class="cited-content_cbyCitation_article-title">Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (5)
                                     , 1038. <a href="https://doi.org/10.3390/molecules23051038" title="DOI URL">https://doi.org/10.3390/molecules23051038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23051038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23051038%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIs%252BIt%252BReliable%252Bto%252BTake%252Bthe%252BMolecular%252BDocking%252BTop%252BScoring%252BPosition%252Bas%252Bthe%252BBest%252BSolution%252Bwithout%252BConsidering%252BAvailable%252BStructural%252BData%25253F%26aulast%3DRam%25C3%25ADrez%26aufirst%3DDavid%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D5%26spage%3D1038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoi  Karoulia</span>, <span class="hlFld-ContribAuthor ">Evripidis  Gavathiotis</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>. </span><span class="cited-content_cbyCitation_article-title">New perspectives for targeting RAF kinase in human cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Cancer</span><span> <strong>2017,</strong> <em>17 </em>
                                    (11)
                                     , 676-691. <a href="https://doi.org/10.1038/nrc.2017.79" title="DOI URL">https://doi.org/10.1038/nrc.2017.79</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Cancer%26atitle%3DNew%252Bperspectives%252Bfor%252Btargeting%252BRAF%252Bkinase%252Bin%252Bhuman%252Bcancer%26aulast%3DKaroulia%26aufirst%3DZoi%26date%3D2017%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D676%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuening  Wang</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Harrison</span>, <span class="hlFld-ContribAuthor ">George P.  Studzinski</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Steroid Biochemistry and Molecular Biology</span><span> <strong>2017,</strong> <em>173 </em>, 139-147. <a href="https://doi.org/10.1016/j.jsbmb.2016.09.009" title="DOI URL">https://doi.org/10.1016/j.jsbmb.2016.09.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsbmb.2016.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsbmb.2016.09.009%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Steroid%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DBRAF%252Bsignals%252Bto%252Bpro-apoptotic%252BBIM%252Bto%252Benhance%252BAraC%252Bcytotoxicity%252Binduced%252Bin%252BAML%252Bcells%252Bby%252BVitamin%252BD-based%252Bdifferentiation%252Bagents%26aulast%3DWang%26aufirst%3DXuening%26date%3D2017%26volume%3D173%26spage%3D139%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maja  Cindrić</span>, <span class="hlFld-ContribAuthor ">Samy  Jambon</span>, <span class="hlFld-ContribAuthor ">Anja  Harej</span>, <span class="hlFld-ContribAuthor ">Sabine  Depauw</span>, <span class="hlFld-ContribAuthor ">Marie-Hélène  David-Cordonnier</span>, <span class="hlFld-ContribAuthor ">Sandra  Kraljević Pavelić</span>, <span class="hlFld-ContribAuthor ">Grace  Karminski-Zamola</span>, <span class="hlFld-ContribAuthor ">Marijana  Hranjec</span>. </span><span class="cited-content_cbyCitation_article-title">Novel amidino substituted benzimidazole and benzothiazole benzo[ b ]thieno-2-carboxamides exert strong antiproliferative and DNA binding properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 468-479. <a href="https://doi.org/10.1016/j.ejmech.2017.05.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bamidino%252Bsubstituted%252Bbenzimidazole%252Band%252Bbenzothiazole%252Bbenzo%25255B%252Bb%252B%25255Dthieno-2-carboxamides%252Bexert%252Bstrong%252Bantiproliferative%252Band%252BDNA%252Bbinding%252Bproperties%26aulast%3DCindri%25C4%2587%26aufirst%3DMaja%26date%3D2017%26volume%3D136%26spage%3D468%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Mao</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>130 </em>, 86-106. <a href="https://doi.org/10.1016/j.ejmech.2017.02.041" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.02.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.02.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.02.041%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bderivatives%252Bbased%252Bon%252Bpyrimidine%252Bscaffold%252Bas%252Bpotent%252BPan-Raf%252Binhibitors%252Bto%252Bovercome%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2017%26volume%3D130%26spage%3D86%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Selt</span>, <span class="hlFld-ContribAuthor ">Juliane  Hohloch</span>, <span class="hlFld-ContribAuthor ">Thomas  Hielscher</span>, <span class="hlFld-ContribAuthor ">Felix  Sahm</span>, <span class="hlFld-ContribAuthor ">David  Capper</span>, <span class="hlFld-ContribAuthor ">Andrey  Korshunov</span>, <span class="hlFld-ContribAuthor ">Diren  Usta</span>, <span class="hlFld-ContribAuthor ">Sebastian  Brabetz</span>, <span class="hlFld-ContribAuthor ">Johannes  Ridinger</span>, <span class="hlFld-ContribAuthor ">Jonas  Ecker</span>, <span class="hlFld-ContribAuthor ">Ina  Oehme</span>, <span class="hlFld-ContribAuthor ">Jan  Gronych</span>, <span class="hlFld-ContribAuthor ">Viktoria  Marquardt</span>, <span class="hlFld-ContribAuthor ">David  Pauck</span>, <span class="hlFld-ContribAuthor ">Heidi  Bächli</span>, <span class="hlFld-ContribAuthor ">Charles D.  Stiles</span>, <span class="hlFld-ContribAuthor ">Andreas  von Deimling</span>, <span class="hlFld-ContribAuthor ">Marc  Remke</span>, <span class="hlFld-ContribAuthor ">Martin U.  Schuhmann</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Pfister</span>, <span class="hlFld-ContribAuthor ">Tilman  Brummer</span>, <span class="hlFld-ContribAuthor ">David T.W.  Jones</span>, <span class="hlFld-ContribAuthor ">Olaf  Witt</span>, <span class="hlFld-ContribAuthor ">Till  Milde</span>. </span><span class="cited-content_cbyCitation_article-title">Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (7)
                                     , 11460-11479. <a href="https://doi.org/10.18632/oncotarget.14004" title="DOI URL">https://doi.org/10.18632/oncotarget.14004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.14004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.14004%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DEstablishment%252Band%252Bapplication%252Bof%252Ba%252Bnovel%252Bpatient-derived%252BKIAA1549%25253ABRAF-driven%252Bpediatric%252Bpilocytic%252Bastrocytoma%252Bmodel%252Bfor%252Bpreclinical%252Bdrug%252Btesting%26aulast%3DSelt%26aufirst%3DFlorian%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D7%26spage%3D11460%26epage%3D11479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiang  Shao</span>, <span class="hlFld-ContribAuthor ">Zhijian  Xu</span>, <span class="hlFld-ContribAuthor ">Jinan  Wang</span>, <span class="hlFld-ContribAuthor ">Jiye  Shi</span>, <span class="hlFld-ContribAuthor ">Weiliang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Energetics and structural characterization of the “DFG-flip” conformational transition of B-RAF kinase: a SITS molecular dynamics study. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2017,</strong> <em>19 </em>
                                    (2)
                                     , 1257-1267. <a href="https://doi.org/10.1039/C6CP06624K" title="DOI URL">https://doi.org/10.1039/C6CP06624K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6CP06624K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6CP06624K%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DEnergetics%252Band%252Bstructural%252Bcharacterization%252Bof%252Bthe%252B%2525E2%252580%25259CDFG-flip%2525E2%252580%25259D%252Bconformational%252Btransition%252Bof%252BB-RAF%252Bkinase%25253A%252Ba%252BSITS%252Bmolecular%252Bdynamics%252Bstudy%26aulast%3DShao%26aufirst%3DQiang%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D2%26spage%3D1257%26epage%3D1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (16)
                                     , 3455-3465. <a href="https://doi.org/10.1039/C7OB00518K" title="DOI URL">https://doi.org/10.1039/C7OB00518K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00518K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00518K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRational%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252BPan-Raf%252Binhibitors%252Bto%252Bovercome%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D16%26spage%3D3455%26epage%3D3465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda  Tse</span>, <span class="hlFld-ContribAuthor ">Gennady M.  Verkhivker</span>, . </span><span class="cited-content_cbyCitation_article-title">Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2016,</strong> <em>11 </em>
                                    (11)
                                     , e0166583. <a href="https://doi.org/10.1371/journal.pone.0166583" title="DOI URL">https://doi.org/10.1371/journal.pone.0166583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0166583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0166583%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DExploring%252BMolecular%252BMechanisms%252Bof%252BParadoxical%252BActivation%252Bin%252Bthe%252BBRAF%252BKinase%252BDimers%25253A%252BAtomistic%252BSimulations%252Bof%252BConformational%252BDynamics%252Band%252BModeling%252Bof%252BAllosteric%252BCommunication%252BNetworks%252Band%252BSignaling%252BPathways%26aulast%3DTse%26aufirst%3DAmanda%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3De0166583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoi  Karoulia</span>, <span class="hlFld-ContribAuthor ">Yang  Wu</span>, <span class="hlFld-ContribAuthor ">Tamer A.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Qisheng  Xin</span>, <span class="hlFld-ContribAuthor ">Julien  Bollard</span>, <span class="hlFld-ContribAuthor ">Clemens  Krepler</span>, <span class="hlFld-ContribAuthor ">Xuewei  Wu</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Gideon  Bollag</span>, <span class="hlFld-ContribAuthor ">Meenhard  Herlyn</span>, <span class="hlFld-ContribAuthor ">James A.  Fagin</span>, <span class="hlFld-ContribAuthor ">Amaia  Lujambio</span>, <span class="hlFld-ContribAuthor ">Evripidis  Gavathiotis</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>. </span><span class="cited-content_cbyCitation_article-title">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2016,</strong> <em>30 </em>
                                    (3)
                                     , 485-498. <a href="https://doi.org/10.1016/j.ccell.2016.06.024" title="DOI URL">https://doi.org/10.1016/j.ccell.2016.06.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DAn%252BIntegrated%252BModel%252Bof%252BRAF%252BInhibitor%252BAction%252BPredicts%252BInhibitor%252BActivity%252Bagainst%252BOncogenic%252BBRAF%252BSignaling%26aulast%3DKaroulia%26aufirst%3DZoi%26date%3D2016%26volume%3D30%26issue%3D3%26spage%3D485%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaokai  Li</span>, <span class="hlFld-ContribAuthor ">Jiayi  Shen</span>, <span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Huimin  Cheng</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zhou</span>, <span class="hlFld-ContribAuthor ">Jie  Ma</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of  N -(4-aminopyridin-2-yl)amides as B-Raf V600E  inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (12)
                                     , 2760-2763. <a href="https://doi.org/10.1016/j.bmcl.2016.04.076" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.04.076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.04.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.04.076%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252BN%252B-%2525284-aminopyridin-2-yl%252529amides%252Bas%252BB-Raf%252BV600E%252Binhibitors%26aulast%3DLi%26aufirst%3DXiaokai%26date%3D2016%26volume%3D26%26issue%3D12%26spage%3D2760%26epage%3D2763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf Kareem  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Ju-Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Nam-Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>115 </em>, 201-216. <a href="https://doi.org/10.1016/j.ejmech.2016.02.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bpotent%252Banticancer%252Bbenzothiazole%252Bamides%252Band%252Bureas%252Bfeaturing%252Bpyridylamide%252Bmoiety%252Band%252Bpossessing%252Bdual%252BB-RafV600E%252Band%252BC-Raf%252Bkinase%252Binhibitory%252Bactivities%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BKareem%26date%3D2016%26volume%3D115%26spage%3D201%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longbin  Liu</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Lee</span>, <span class="hlFld-ContribAuthor ">Joseph L.  Kim</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">Howard  Bregman</span>, <span class="hlFld-ContribAuthor ">Zihao  Hua</span>, <span class="hlFld-ContribAuthor ">Richard T.  Lewis</span>, <span class="hlFld-ContribAuthor ">Matthew W.  Martin</span>, <span class="hlFld-ContribAuthor ">Nobuko  Nishimura</span>, <span class="hlFld-ContribAuthor ">Michele  Potashman</span>, <span class="hlFld-ContribAuthor ">Kevin  Yang</span>, <span class="hlFld-ContribAuthor ">Shuyan  Yi</span>, <span class="hlFld-ContribAuthor ">Karina R.  Vaida</span>, <span class="hlFld-ContribAuthor ">Linda F.  Epstein</span>, <span class="hlFld-ContribAuthor ">Carol  Babij</span>, <span class="hlFld-ContribAuthor ">Manory  Fernando</span>, <span class="hlFld-ContribAuthor ">Josette  Carnahan</span>, <span class="hlFld-ContribAuthor ">Mark H.  Norman</span>. </span><span class="cited-content_cbyCitation_article-title">Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (10)
                                     , 2215-2234. <a href="https://doi.org/10.1016/j.bmc.2016.03.055" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.03.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.03.055%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPurinylpyridinylamino-based%252BDFG-in%25252F%2525CE%2525B1C-helix-out%252BB-Raf%252Binhibitors%25253A%252BApplying%252Bmutant%252Bversus%252Bwild-type%252BB-Raf%252Bselectivity%252Bindices%252Bfor%252Bcompound%252Bprofiling%26aulast%3DLiu%26aufirst%3DLongbin%26date%3D2016%26volume%3D24%26issue%3D10%26spage%3D2215%26epage%3D2234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan J.  Sullivan</span>. </span><span class="cited-content_cbyCitation_article-title">The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Oncology</span><span> <strong>2016,</strong> <em>28 </em>
                                    (2)
                                     , 185-191. <a href="https://doi.org/10.1097/CCO.0000000000000271" title="DOI URL">https://doi.org/10.1097/CCO.0000000000000271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CCO.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCCO.0000000000000271%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Oncology%26atitle%3DThe%252Brole%252Bof%252Bmitogen-activated%252Bprotein%252Btargeting%252Bin%252Bmelanoma%252Bbeyond%252BBRAFV600%26aulast%3DSullivan%26aufirst%3DRyan%2BJ.%26date%3D2016%26volume%3D28%26issue%3D2%26spage%3D185%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuzhen  Niu</span>, <span class="hlFld-ContribAuthor ">Shuyan  Li</span>, <span class="hlFld-ContribAuthor ">Dabo  Pan</span>, <span class="hlFld-ContribAuthor ">Huanxiang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2016,</strong> <em>18 </em>
                                    (7)
                                     , 5622-5629. <a href="https://doi.org/10.1039/C5CP06257H" title="DOI URL">https://doi.org/10.1039/C5CP06257H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5CP06257H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5CP06257H%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DComputational%252Bstudy%252Bon%252Bthe%252Bunbinding%252Bpathways%252Bof%252BB-RAF%252Binhibitors%252Band%252Bits%252Bimplication%252Bfor%252Bthe%252Bdifference%252Bof%252Bresidence%252Btime%25253A%252Binsight%252Bfrom%252Brandom%252Bacceleration%252Band%252Bsteered%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DNiu%26aufirst%3DYuzhen%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D7%26spage%3D5622%26epage%3D5629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven R.  Whittaker</span>, <span class="hlFld-ContribAuthor ">Glenn S.  Cowley</span>, <span class="hlFld-ContribAuthor ">Steve  Wagner</span>, <span class="hlFld-ContribAuthor ">Flora  Luo</span>, <span class="hlFld-ContribAuthor ">David E.  Root</span>, <span class="hlFld-ContribAuthor ">Levi A.  Garraway</span>. </span><span class="cited-content_cbyCitation_article-title">Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2015,</strong> <em>14 </em>
                                    (12)
                                     , 2700-2711. <a href="https://doi.org/10.1158/1535-7163.MCT-15-0136-T" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-15-0136-T</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-15-0136-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-15-0136-T%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCombined%252BPan-RAF%252Band%252BMEK%252BInhibition%252BOvercomes%252BMultiple%252BResistance%252BMechanisms%252Bto%252BSelective%252BRAF%252BInhibitors%26aulast%3DWhittaker%26aufirst%3DSteven%2BR.%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D12%26spage%3D2700%26epage%3D2711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Uehling</span>, <span class="hlFld-ContribAuthor ">Philip A.  Harris</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on MAP kinase pathway inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (19)
                                     , 4047-4056. <a href="https://doi.org/10.1016/j.bmcl.2015.07.093" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bprogress%252Bon%252BMAP%252Bkinase%252Bpathway%252Binhibitors%26aulast%3DUehling%26aufirst%3DDavid%2BE.%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4047%26epage%3D4056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Chun  Liu</span>, <span class="hlFld-ContribAuthor ">San-Zhi  Tang</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Yan-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">An-Yang  Xu</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Ya-Dong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as  Potent Dual B-RafV600E/KDR Inhibitors Using Docking  and 3D-QSAR Approaches. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2015,</strong> <em>16 </em>
                                    (10)
                                     , 24451-24474. <a href="https://doi.org/10.3390/ijms161024451" title="DOI URL">https://doi.org/10.3390/ijms161024451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms161024451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms161024451%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStudies%252Bon%252B%25255B5%25252C6%25255D-Fused%252BBicyclic%252BScaffolds%252BDerivatives%252Bas%252BPotent%252BDual%252BB-RafV600E%25252FKDR%252BInhibitors%252BUsing%252BDocking%252Band%252B3D-QSAR%252BApproaches%26aulast%3DLiu%26aufirst%3DHai-Chun%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D10%26spage%3D24451%26epage%3D24474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>, <span class="hlFld-ContribAuthor ">James R.  Henry</span>, <span class="hlFld-ContribAuthor ">Michael D.  Kaufman</span>, <span class="hlFld-ContribAuthor ">Wei-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Bryan D.  Smith</span>, <span class="hlFld-ContribAuthor ">Subha  Vogeti</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Rutkoski</span>, <span class="hlFld-ContribAuthor ">Scott  Wise</span>, <span class="hlFld-ContribAuthor ">Lawrence  Chun</span>, <span class="hlFld-ContribAuthor ">Youyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Robert D.  Van Horn</span>, <span class="hlFld-ContribAuthor ">Tinggui  Yin</span>, <span class="hlFld-ContribAuthor ">Xiaoyi  Zhang</span>, <span class="hlFld-ContribAuthor ">Vipin  Yadav</span>, <span class="hlFld-ContribAuthor ">Shih-Hsun  Chen</span>, <span class="hlFld-ContribAuthor ">Xueqian  Gong</span>, <span class="hlFld-ContribAuthor ">Xiwen  Ma</span>, <span class="hlFld-ContribAuthor ">Yue  Webster</span>, <span class="hlFld-ContribAuthor ">Sean  Buchanan</span>, <span class="hlFld-ContribAuthor ">Igor  Mochalkin</span>, <span class="hlFld-ContribAuthor ">Lysiane  Huber</span>, <span class="hlFld-ContribAuthor ">Lisa  Kays</span>, <span class="hlFld-ContribAuthor ">Gregory P.  Donoho</span>, <span class="hlFld-ContribAuthor ">Jennie  Walgren</span>, <span class="hlFld-ContribAuthor ">Denis  McCann</span>, <span class="hlFld-ContribAuthor ">Phenil  Patel</span>, <span class="hlFld-ContribAuthor ">Ilaria  Conti</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Plowman</span>, <span class="hlFld-ContribAuthor ">James J.  Starling</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Flynn</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2015,</strong> <em>28 </em>
                                    (3)
                                     , 384-398. <a href="https://doi.org/10.1016/j.ccell.2015.08.002" title="DOI URL">https://doi.org/10.1016/j.ccell.2015.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DInhibition%252Bof%252BRAF%252BIsoforms%252Band%252BActive%252BDimers%252Bby%252BLY3009120%252BLeads%252Bto%252BAnti-tumor%252BActivities%252Bin%252BRAS%252Bor%252BBRAF%252BMutant%252BCancers%26aulast%3DPeng%26aufirst%3DSheng-Bin%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D384%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan  Sullivan</span>, <span class="hlFld-ContribAuthor ">Patricia  LoRusso</span>, <span class="hlFld-ContribAuthor ">Scott  Boerner</span>, <span class="hlFld-ContribAuthor ">Reinhard  Dummer</span>. </span><span class="cited-content_cbyCitation_article-title">Achievements and Challenges of Molecular Targeted Therapy in Melanoma. </span><span class="cited-content_cbyCitation_journal-name">American Society of Clinical Oncology Educational Book</span><span> <strong>2015,</strong> <em> </em>
                                    (35)
                                     , 177-186. <a href="https://doi.org/10.14694/EdBook_AM.2015.35.177" title="DOI URL">https://doi.org/10.14694/EdBook_AM.2015.35.177</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14694/EdBook_AM.2015.35.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14694%2FEdBook_AM.2015.35.177%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%2520Educational%2520Book%26atitle%3DAchievements%252Band%252BChallenges%252Bof%252BMolecular%252BTargeted%252BTherapy%252Bin%252BMelanoma%26aulast%3DSullivan%26aufirst%3DRyan%26date%3D2015%26issue%3D35%26spage%3D177%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weimin  Yang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yazhou  Gu</span>, <span class="hlFld-ContribAuthor ">Wenqi  Qian</span>, <span class="hlFld-ContribAuthor ">Fan  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Han</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 581-596. <a href="https://doi.org/10.1016/j.ejmech.2014.10.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.10.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.10.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bbis-aryl%252Bureas%252Band%252Bamides%252Bbased%252Bon%252B2-amino-3-purinylpyridine%252Bscaffold%252Bas%252BDFG-out%252BB-Raf%252Bkinase%252Binhibitors%26aulast%3DYang%26aufirst%3DWeimin%26date%3D2015%26volume%3D89%26spage%3D581%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rangappa S.  Keri</span>, <span class="hlFld-ContribAuthor ">Mahadeo R.  Patil</span>, <span class="hlFld-ContribAuthor ">Siddappa A.  Patil</span>, <span class="hlFld-ContribAuthor ">Srinivasa  Budagumpi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 207-251. <a href="https://doi.org/10.1016/j.ejmech.2014.10.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.10.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.10.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Breview%252Bin%252Bcurrent%252Bdevelopments%252Bof%252Bbenzothiazole-based%252Bmolecules%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DKeri%26aufirst%3DRangappa%2BS.%26date%3D2015%26volume%3D89%26spage%3D207%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolina  Hertzman Johansson</span>, <span class="hlFld-ContribAuthor ">Suzanne  Egyhazi Brage</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF inhibitors in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2014,</strong> <em>142 </em>
                                    (2)
                                     , 176-182. <a href="https://doi.org/10.1016/j.pharmthera.2013.11.011" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2013.11.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2013.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2013.11.011%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DBRAF%252Binhibitors%252Bin%252Bcancer%252Btherapy%26aulast%3DHertzman%2BJohansson%26aufirst%3DCarolina%26date%3D2014%26volume%3D142%26issue%3D2%26spage%3D176%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xilei  Xie</span>, <span class="hlFld-ContribAuthor ">Yu  Yan</span>, <span class="hlFld-ContribAuthor ">Ning  Zhu</span>, <span class="hlFld-ContribAuthor ">Gang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Benzothiazoles exhibit broad-spectrum antitumor activity: Their potency, structure–activity and structure–metabolism relationships. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>76 </em>, 67-78. <a href="https://doi.org/10.1016/j.ejmech.2014.02.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzothiazoles%252Bexhibit%252Bbroad-spectrum%252Bantitumor%252Bactivity%25253A%252BTheir%252Bpotency%25252C%252Bstructure%2525E2%252580%252593activity%252Band%252Bstructure%2525E2%252580%252593metabolism%252Brelationships%26aulast%3DXie%26aufirst%3DXilei%26date%3D2014%26volume%3D76%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoyue  Xiang</span>, <span class="hlFld-ContribAuthor ">Jin  Qi</span>, <span class="hlFld-ContribAuthor ">Qian  He</span>, <span class="hlFld-ContribAuthor ">Min  Jiang</span>, <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>, <span class="hlFld-ContribAuthor ">Lianfu  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-C-substituted benzothiazoles via a copper-promoted domino condensation/S-arylation/heterocyclization process. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2014,</strong> <em>12 </em>
                                    (26)
                                     , 4633. <a href="https://doi.org/10.1039/c4ob00564c" title="DOI URL">https://doi.org/10.1039/c4ob00564c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c4ob00564c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc4ob00564c%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2-C-substituted%252Bbenzothiazoles%252Bvia%252Ba%252Bcopper-promoted%252Bdomino%252Bcondensation%25252FS-arylation%25252Fheterocyclization%252Bprocess%26aulast%3DXiang%26aufirst%3DHaoyue%26date%3D2014%26volume%3D12%26issue%3D26%26spage%3D4633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akito  Nakamura</span>, <span class="hlFld-ContribAuthor ">Takeo  Arita</span>, <span class="hlFld-ContribAuthor ">Shuntarou  Tsuchiya</span>, <span class="hlFld-ContribAuthor ">Jill  Donelan</span>, <span class="hlFld-ContribAuthor ">Jouhara  Chouitar</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Carideo</span>, <span class="hlFld-ContribAuthor ">Katherine  Galvin</span>, <span class="hlFld-ContribAuthor ">Masanori  Okaniwa</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Sei  Yoshida</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2013,</strong> <em>73 </em>
                                    (23)
                                     , 7043-7055. <a href="https://doi.org/10.1158/0008-5472.CAN-13-1825" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-13-1825</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DAntitumor%252BActivity%252Bof%252Bthe%252BSelective%252BPan-RAF%252BInhibitor%252BTAK-632%252Bin%252BBRAF%252BInhibitor-Resistant%252BMelanoma%26aulast%3DNakamura%26aufirst%3DAkito%26date%3D2013%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D7043%26epage%3D7055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of RAF inhibitors including [1,3]thiazolo[5,4-<i>b</i>]pyridine derivative <b>1</b> and 1,3-benzothiazole derivative <b>2</b> as lead compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural differences in the adenine sites of BRAF and VEGFR2 bound to RAF/VEGFR2 inhibitor <b>1</b>. The BRAF structure (4DBN) is shown in green and the VEGFR2 stucture (3VNT) in purple.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of designed <i>C</i>-7-substituted 1,3-benzothiazole derivatives and their predicted binding mode to the DFG-out conformation of BRAF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design approaches employed for the ring A moiety and the ring B–linker–ring C moiety. (A) Ring A moiety: introduction of an R<sup>1</sup> group at the <i>C</i>-7 position for targeting a BRAF-selectivity pocket adjacent to Phe595. (B) Ring B–linker–ring C moiety targeting the hydrophobic back pocket of BRAF: ureide derivatives <b>4</b>–<b>6</b> (linker: NHCONH) and acetamide derivatives <b>7</b>–<b>9</b> (linker: NHCOCH<sub>2</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Strategy for the Preparation of <i>C</i>-7-Substituted 1,3-Benzothiazole Intermediates <b>11</b> by the Regioselective Cyclization of Aniline <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 25–80 °C, 12–18 h (70–98%); (b) Fe(0), CaCl<sub>2</sub>, EtOH/H<sub>2</sub>O (9:1), 80–100 °C (82–99%); (c) H<sub>2</sub>, 10% Pd/C, NMP/MeOH/THF (2:4:1), room temp., 14 h (92%); (d) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 16 h (82%).</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopropanecarbonyl chloride, pyridine, room temp., 2–4 h (68–79%); (b) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, room temp., 12 h (54%); (c) <i>iso</i>-butyl chloroformate, Et<sub>3</sub>N, THF, 0°C, 0.5 h; then, NaBH<sub>4</sub>, THF, MeOH, room temp., 2 h (55% in 2 steps).</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>16A</b>,<b>B</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 25–60 °C, 2–4 h (66–100%); (b) TFAA, THF, room temp., 1–1.5 h (67–93%); (c) H<sub>2</sub>, 10% Pd/C, MeOH, room temp., 2–8 h (99%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp., 12 h (81–85%); (e) cyclopropanecarbonyl chloride, pyridine, THF room temp., 6–16 h (55–82%); (f) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (1:1:1), room temp., 18 h (95%); (g) NaBH<sub>4</sub>, MeOH (2.4 v/v%), EtOH, room temp., 0.5 h (85%); (h) phenyl isocyanate, DMF, room temp., 12 h (28–94%); (i) phenyl acetic acid, HATU, pyridine, 85 °C, 4 h (57–74%).</p></p></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray cocrystal structure of <b>8B</b> bound to BRAF (2.93 Å resolution).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray cocrystal structures of BRAF bound to acetamide derivative <b>8B</b> and of BRAF bound to the corresponding ureide derivative <b>5B</b>. (A) Trifluoromethyl-substituted benzene of <b>8B</b> in the back pocket region. (B) Trifluoromethyl-substituted benzene of the corresponding ureide <b>5B</b> in the back pocket region. (C) Binding mode of acetamide <b>8B</b> with Glu501 and Asp594 (2.93 Å resolution). (D) Binding mode of ureide <b>5B</b> with Glu501 and Asp594 (3.30 Å resolution).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mean (<i>n</i> = 3; *<i>P</i> ≤ 0.025 compared with vehicle by the Shirley–Williams’ test) phosphorylated ERK1/2 levels in the tumor in a human melanoma A375 (<i>BRAF</i><sup>V600E</sup> mutant) xenograft model in rats, at 8 h after oral administration of <b>8B</b>. Data were detected by Western blotting. The solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate = 20:80) was delivered in distilled water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antitumor activity of a solid dispersion of <b>8B</b> (p.o., b.i.d.) in human melanoma A375 (<i>BRAF</i><sup>V600E</sup> mutant) bearing F344 nude rats (A) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) tumor volumes. (B) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) body weight change. The solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate =20:80) was delievered in distilled water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/medium/jm-2013-00778d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antitumor activity of a solid dispersion of <b>8B</b> in human melanoma HMVII (<i>NRAS</i><sup>Q61K</sup>/<i>BRAF</i><sup>G469V</sup> mutant) bearing F344 nude rats (A) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) tumor volumes. (B) Mean (<i>n</i> = 4; *<i>P</i> ≤ 0.025 compared with the vehicle at day 14 by a one-tailed Shirley Williams’ test) body weight change. The solid dispersion formulation (<b>8B</b>/hydroxypropyl methylcellulose phthalate = 20:80) was delievered in distilled water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-16/jm400778d/production/images/large/jm-2013-00778d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400778d&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i66">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Maurer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarini, M.</span><span> </span><span class="NLM_article-title">Raf kinases in cancer-roles and therapeutic opportunities</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3477</span><span class="NLM_x">–</span> <span class="NLM_lpage">3488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=3477-3488&author=G.+Maurerauthor=B.+Tarkowskiauthor=M.+Baccarini&title=Raf+kinases+in+cancer-roles+and+therapeutic+opportunities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DG.%26aulast%3DTarkowski%26aufirst%3DB.%26aulast%3DBaccarini%26aufirst%3DM.%26atitle%3DRaf%2520kinases%2520in%2520cancer-roles%2520and%2520therapeutic%2520opportunities%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D3477%26epage%3D3488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0liZ7ogthqMxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">For the BRIM-3 Study Group. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=For+the+BRIM-3+Study+Group.+Improved+survival+with+Vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0liZ7ogthqMxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DFor%2520the%2520BRIM-3%2520Study%2520Group.%2520Improved%2520survival%2520with%2520Vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">BRAF targeted therapy changes the treatment paradigm in melanoma</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnrclinonc.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=21606968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=426-433&author=A.+Ribasauthor=K.+T.+Flaherty&title=BRAF+targeted+therapy+changes+the+treatment+paradigm+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF targeted therapy changes the treatment paradigm in melanoma</span></div><div class="casAuthors">Ribas, Antoni; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">426-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target.  The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clin. data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.  After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.  The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them.  In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling mol. shown efficacy from early clin. testing.  Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their resp. phase I, II, and III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJ5nnopldxbVg90H21EOLACvtfcHk0lgqxekMqL_zAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D&md5=710ef1d3ccb02a0c80bf7f9b3fe935a7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DBRAF%2520targeted%2520therapy%2520changes%2520the%2520treatment%2520paradigm%2520in%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D426%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaempgen, E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Algarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaszewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarion-Sileni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirakhur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckert, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0lgqxekMqL_zAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lgEBv2lfdmbDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Anforth, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumetti, T. C. M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolyer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kossard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Peñas, P.</span><span> </span><span class="NLM_article-title">Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1111%2Fj.1365-2133.2012.11155.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=22804352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ShtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1153-1160&author=R.+M.+Anforthauthor=T.+C.+M.+P.+Blumettiauthor=R.+F.+Keffordauthor=R.+Sharmaauthor=R.+A.+Scolyerauthor=S.+Kossardauthor=G.+V.+Longauthor=P.+Fernandez-Pe%C3%B1as&title=Cutaneous+manifestations+of+dabrafenib+%28GSK2118436%29%3A+a+selective+inhibitor+of+mutant+BRAF+in+patients+with+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma</span></div><div class="casAuthors">Anforth, R. M.; Blumetti, T. C. M. P.; Kefford, R. F.; Sharma, R.; Scolyer, R. A.; Kossard, S.; Long, G. V.; Fernandez-Penas, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1153-1160</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Inhibitors of mutant BRAF are emerging as std. of care in patients with metastatic melanoma carrying relevant oncogenic mutations.  Cutaneous reactions are frequent and significant.  We conducted a systematic prospective dermatol. review of all patients enrolled at a single institution in the phase I/II clin. trial of the mutant BRAF inhibitor dabrafenib (GSK2118436).  Objectives: To identify the cutaneous manifestations of the BRAF inhibitor dabrafenib; to form diagnostic criteria to standardize the diagnosis of verrucal keratotic squamoproliferative lesions; and to bring awareness to the medical community of the importance of dermatol. assessment of patients taking dabrafenib.  Methods: Patients enrolled in the phase I/II trial (n = 43) were monitored for the development of new skin lesions.  Each new lesion was photographed, a clin. diagnosis recorded and, where appropriate, a biopsy taken.  Human papillomavirus (HPV) and p16 immunohistochem. analyses were performed.  Results: The most frequently obsd. lesions were verrucal keratotic squamoproliferative lesions (49%), Grover's disease (27%) and reactive hyperkeratotic lesions on the soles, at points of friction (22%).  Eighteen squamous cell carcinomas (SCCs) occurred in 20% of patients.  Most SCCs appeared between weeks 6 and 24 following commencement of therapy on both sun-damaged and nonsun-damaged skin.  All SCCs were well differentiated, five were of the keratoacanthoma type, and two were SCC in situ.  Other lesions obsd. included seborrhoeic keratoses, epidermal cysts, acneiform eruptions, hair loss and changes in hair structure.  HPV was neg. in 15 of the 16 tissues studied and p16 expression was higher in SCCs compared with verrucal keratoses.  Conclusions: Administration of the mutant BRAF inhibitor dabrafenib is assocd. with induction of keratinocytic proliferation, which in some cases develops features of low-grade malignancy.  Highly oncogenic HPV infection is unlikely to be a contributor to the formation of SCCs or verrucal keratoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJUWGMM-LFa7Vg90H21EOLACvtfcHk0lgEBv2lfdmbDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ShtbnP&md5=4f5e528a4419a1711320b82bd85d3478</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2012.11155.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2012.11155.x%26sid%3Dliteratum%253Aachs%26aulast%3DAnforth%26aufirst%3DR.%2BM.%26aulast%3DBlumetti%26aufirst%3DT.%2BC.%2BM.%2BP.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DScolyer%26aufirst%3DR.%2BA.%26aulast%3DKossard%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFernandez-Pe%25C3%25B1as%26aufirst%3DP.%26atitle%3DCutaneous%2520manifestations%2520of%2520dabrafenib%2520%2528GSK2118436%2529%253A%2520a%2520selective%2520inhibitor%2520of%2520mutant%2520BRAF%2520in%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2012%26volume%3D167%26spage%3D1153%26epage%3D1160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Falchook, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span> </span><span class="NLM_article-title">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x"> (</span><span class="NLM_issue">9829</span><span class="NLM_x">) </span> <span class="NLM_fpage">1893</span><span class="NLM_x">–</span> <span class="NLM_lpage">1901</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1893-1901&issue=9829&author=G.+S.+Falchookauthor=G.+V.+Longauthor=R.+Kurzrockauthor=K.+B.+Kimauthor=T.+H.+Arkenauauthor=M.+P.+Brownauthor=O.+Hamidauthor=J.+R.+Infanteauthor=M.+Millwardauthor=A.+C.+Pavlickauthor=S.+J.+O%E2%80%99Dayauthor=S.+C.+Blackmanauthor=C.+M.+Curtisauthor=P.+Lebowitzauthor=B.+Maauthor=D.+Ouelletauthor=R.+F.+Kefford&title=Dabrafenib+in+patients+with+melanoma%2C+untreated+brain+metastases%2C+and+other+solid+tumours%3A+a+phase+1+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DArkenau%26aufirst%3DT.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26aulast%3DCurtis%26aufirst%3DC.%2BM.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26atitle%3DDabrafenib%2520in%2520patients%2520with%2520melanoma%252C%2520untreated%2520brain%2520metastases%252C%2520and%2520other%2520solid%2520tumours%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26issue%3D9829%26spage%3D1893%26epage%3D1901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hall-Jackson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyers, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plant, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedge, P.</span><span> </span><span class="NLM_article-title">Paradoxical activation of Raf by a novel Raf inhibitor</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">568</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1016%2FS1074-5521%2899%2980088-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=10421767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=559-568&author=C.+A.+Hall-Jacksonauthor=P.+A.+Eyersauthor=P.+Cohenauthor=M.+Goedertauthor=F.+T.+Boyleauthor=N.+Hewittauthor=H.+Plantauthor=P.+Hedge&title=Paradoxical+activation+of+Raf+by+a+novel+Raf+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Paradoxical activation of raf by a novel raf inhibitor</span></div><div class="casAuthors">Hall-Jackson, Clare A.; Eyers, Patrick A.; Cohen, Philip; Goedert, Michel; Boyle, F. Tom; Hewitt, Neil; Plant, Helen; Hedge, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-568</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">Raf is a proto-oncogene that is activated in response to growth factors or phorbol esters, and is thought to activate MAP kinase kinase-1 (MKK1) and hence the classical MAP kinase (MAPK) cascade.  The compd. ZM 336372 is identified as a potent and specific inhibitor of Raf isoforms in vitro.  Paradoxically, exposure of cells to ZM 336372 induces > 100-fold activation of c-Raf (measured in the absence of compd.), but without triggering any activation of MKK1 or p42 MAPK/ERK2.  The ZM 336372-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras and is not prevented by inhibition of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase.  ZM 336372 does not prevent growth factor or phorbol ester induced activation of MKK1 or p42 MAPK/ERK2, or reverse the phenotype of Ras- or Raf-transformed cell lines.  The only other protein kinase inhibited by ZM 336372 out of 20 tested was SAPK2/p38.  Although ZM 336372 is structurally unrelated to SB 203580, a potent inhibitor of SAPK2/p38, the mutation of Thr106→Met made SAPK2/p38 insensitive to ZM 336372 as well as to SB 203580.  Raf appears to suppress its own activation by a novel feedback loop, such that inhibition is always counterbalanced by reactivation.  These observations imply that some agonists reported to trigger the cellular activation of c-Raf might actually be inhibitors of this enzyme, and that compds. which inhibit the kinase activity of Raf might not be useful as anticancer drugs.  The binding sites for ZM 336372 and SB 203580 on Raf and SAPK2/p38 are likely to overlap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo23oQKXswmRbVg90H21EOLACvtfcHk0lhKrlmdaOUsQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D&md5=93aa7dbc301a6f798be138df3e5a075c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980088-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980088-X%26sid%3Dliteratum%253Aachs%26aulast%3DHall-Jackson%26aufirst%3DC.%2BA.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DHewitt%26aufirst%3DN.%26aulast%3DPlant%26aufirst%3DH.%26aulast%3DHedge%26aufirst%3DP.%26atitle%3DParadoxical%2520activation%2520of%2520Raf%2520by%2520a%2520novel%2520Raf%2520inhibitor%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26spage%3D559%26epage%3D568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0lhKrlmdaOUsQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signalling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trunzer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spleiss, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kockx, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1056%2FNEJMoa1105358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=22256804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=207-215&issue=3&author=F.+Suauthor=A.+Virosauthor=C.+Milagreauthor=K.+Trunzerauthor=G.+Bollagauthor=O.+Spleissauthor=J.+S.+Reis-Filhoauthor=X.+Kongauthor=R.+C.+Koyaauthor=K.+T.+Flahertyauthor=P.+B.+Chapmanauthor=M.+J.+Kimauthor=R.+Haywardauthor=M.+Martinauthor=H.+Yangauthor=Q.+Wangauthor=H.+Hiltonauthor=J.+S.+Hangauthor=J.+Noeauthor=M.+Lambrosauthor=F.+Geyerauthor=N.+Dhomenauthor=I.+Niculescu-Duvazauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=N.+Preeceauthor=L.+Robertauthor=N.+J.+Otteauthor=S.+Mokauthor=D.+Keeauthor=Y.+Maauthor=C.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=H.+Nguyenauthor=M.+Kockxauthor=L.+Andriesauthor=B.+Lestiniauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=J.+L.+Troyauthor=R.+Gonzalezauthor=T.+E.+Hutsonauthor=I.+Puzanovauthor=B.+Chmielowskiauthor=C.+J.+Springerauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=R.+S.+Loauthor=A.+Ribasauthor=R.+Marais&title=RAS+mutations+in+cutaneous+squamous-cell+carcinomas+in+patients+treated+with+BRAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span></div><div class="casAuthors">Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.  METHODS: We performed a mol. anal. to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.  An anal. of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.  RESULTS: Among 21 tumor samples, 13 had RAS mutations (12 in HRAS).  In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS).  Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L.  Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was assocd. with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription.  In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analog PLX4720 was not an initiator or a.promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor.  CONCLUSIONS: Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.  The mol. mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplrkvSEAdDG7Vg90H21EOLACvtfcHk0ljgOHSw0lgx5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D&md5=6c813dc23344a8eedcc7a289d2326f4f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105358%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DF.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DTrunzer%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSpleiss%26aufirst%3DO.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DHayward%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BS.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKockx%26aufirst%3DM.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DTroy%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DRAS%2520mutations%2520in%2520cutaneous%2520squamous-cell%2520carcinomas%2520in%2520patients%2520treated%2520with%2520BRAF%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D3%26spage%3D207%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x"> (</span><span class="NLM_issue">7287</span><span class="NLM_x">) </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ljgOHSw0lgx5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Heidorn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&issue=2&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0ljgOHSw0lgx5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D2%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schostack, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simcox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span> </span><span class="NLM_article-title">RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5518</span><span class="NLM_x">–</span> <span class="NLM_lpage">5527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5518-5527&author=H.+Yangauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=Z.+Goauthor=R.+Iyerauthor=S.+Kolisauthor=S.+Zhaoauthor=R.+Leeauthor=J.+F.+Grippoauthor=K.+Schostackauthor=M.+E.+Simcoxauthor=D.+Heimbrookauthor=G.+Bollagauthor=F.+Su&title=RG7204+%28PLX4032%29%2C+a+selective+BRAFV600E+inhibitor%2C+displays+potent+antitumor+activity+in+preclinical+melanoma+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DGo%26aufirst%3DZ.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DKolis%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DSchostack%26aufirst%3DK.%26aulast%3DSimcox%26aufirst%3DM.%2BE.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DF.%26atitle%3DRG7204%2520%2528PLX4032%2529%252C%2520a%2520selective%2520BRAFV600E%2520inhibitor%252C%2520displays%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520melanoma%2520models%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5518%26epage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. -C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3452</span><span class="NLM_x">–</span> <span class="NLM_lpage">3478</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300126x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3452-3478&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Imadaauthor=T.+Ohashiauthor=Y.+Hayashiauthor=T.+Miyazakiauthor=T.+Aritaauthor=M.+Yabukiauthor=K.+Kakoiauthor=J.+Katoauthor=T.+Takagiauthor=T.+Kawamotoauthor=S.+Yaoauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=H.+Okiauthor=B.+-C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors.+1.+Exploration+of+%5B5%2C6%5D-fused+bicyclic+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm300126x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300126x%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DKakoi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DJ.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2B-C.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors.%25201.%2520Exploration%2520of%2520%255B5%252C6%255D-fused%2520bicyclic%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3452%26epage%3D3478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4680</span><span class="NLM_x">–</span> <span class="NLM_lpage">4692</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4680-4692&author=M.+Okaniwaauthor=T.+Imadaauthor=T.+Ohashiauthor=T.+Miyazakiauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=K.+Higashikawaauthor=T.+Takagiauthor=T.+Kawamotoauthor=Y.+Inuiauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors%3A+2.+Synthesis+and+characterization+of+a+novel+imide-type+prodrug+for+improving+oral+absorption"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DHigashikawa%26aufirst%3DK.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors%253A%25202.%2520Synthesis%2520and%2520characterization%2520of%2520a%2520novel%2520imide-type%2520prodrug%2520for%2520improving%2520oral%2520absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4680%26epage%3D4692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hirose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-<i>d</i>]pyrimidine and thiazolo[5,4-<i>b</i>]pyridine derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5600</span><span class="NLM_x">–</span> <span class="NLM_lpage">5615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5600-5615&author=M.+Hiroseauthor=M.+Okaniwaauthor=T.+Miyazakiauthor=T.+Imadaauthor=T.+Ohashiauthor=Y.+Tanakaauthor=T.+Aritaauthor=M.+Yabukiauthor=T.+Kawamotoauthor=S.+Tsutsumiauthor=A.+Sumitaauthor=T.+Takagiauthor=B.+C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors%3A+3.+Evaluation+of+5-amino-linked+thiazolo%5B5%2C4-d%5Dpyrimidine+and+thiazolo%5B5%2C4-b%5Dpyridine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors%253A%25203.%2520Evaluation%2520of%25205-amino-linked%2520thiazolo%255B5%252C4-d%255Dpyrimidine%2520and%2520thiazolo%255B5%252C4-b%255Dpyridine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D5600%26epage%3D5615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>For BRAF, DOI: <span class="refDoi"> DOI: 10.2210/pdb4dbn/pdb</span> . For VEGFR2, DOI:<span class="refDoi"> DOI: 10.2210/pdb3vnt/pdb</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.2210%2Fpdb4dbn%2Fpdb" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+BRAF%2C+DOI%3A+10.2210%2Fpdb4dbn%2Fpdb.+For+VEGFR2%2C+DOI%3A+10.2210%2Fpdb3vnt%2Fpdb."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2210%2Fpdb4dbn%2Fpdb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.2210%252Fpdb4dbn%252Fpdb%26sid%3Dliteratum%253Aachs%26doi%3D10.2210%2Fpdb4dbn%2Fpdb%26doi%3D10.2210%2Fpdb3vnt%2Fpdb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kaufmann, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span> </span><span class="NLM_article-title">Arzneimittelsynthetische studien IV. Synthese schwefelhaltiger verbindungen</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1929</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1002%2Fardp.19292670304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1929&pages=192-211&author=H.+P.+Kaufmannauthor=E.+Weber&title=Arzneimittelsynthetische+studien+IV.+Synthese+schwefelhaltiger+verbindungen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic drug studies. IV. Synthesis of sulfur-containing preparations</span></div><div class="casAuthors">Kaufmann, H. P.; Weber, E.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft</span>
        (<span class="NLM_cas:date">1929</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-211</span>CODEN:
                <span class="NLM_cas:coden">APBDAJ</span>;
        ISSN:<span class="NLM_cas:issn">0376-0367</span>.
    </div><div class="casAbstract">An exptl. study confined mainly to the introduction of the SCN group into, and the influence of such groups, on certain antipyretics (aniline, phenetidine and phenylhydrazinc) and disinfectants (thymol, cresols and hydroxyquinolines).  The method of introducing SCN into the above compds. involves treatment in a suitable solvent with NaSCN and Br.  Among the new compds. prepd. and characterized were the following: p-rhodanacelanilide, C9H8ON2S, needles m. 188°;  1-amino-2-rhodan-4-ethoxybenzene, C9H10ON2S, silky needles m. 67-8°, easily convertible to 2-amino-6-ethoxybenzthiazol; C9H10ON2S, needles m. 161°;  2-diacetylamino-6-ethoxybenzthiazol, C13H14O3N2S, m. 245°;  bis(1-amino-4-ethoxy)2-disulfide, C16H20O2S2, m. 101°; sym.-formyl-(p-rhodanphenyl) hydrazine, C8H7ON3S, needles m. 132°; sym.-Ac(p-rhodanphenyl), C9H9ON3S, m. 171°; sym.-benzoyl-(p-rhodanphenyl)hydrazine, C14H11ON3S, m. 164°; sym.-phthalyl-(p-rhodanphenyl)hydrazine, C15H9O2N3S, m. 213°; sym.-acetyl-bis(p-rhodanphenyl)hydrazine, C15H12ON4S2, needles m. 160°; sym.-benzoyl-bis(p-rhodanphenyl)hydrazine, C21H14ON4S2, m. 160°; α-hydroxy-γ-rhodanquinoline (4-rhodancarbostyrile), C10H6ON2S, yellowish needles m. 141°; γ-rhodan-o-hydroxyquinoline, C10H6ON2S, m. 134°; 1-methyl-4-isopropyl-3-hydroxy-6-rhodanbenzene (3-methyl-4-rhodan-6-isopropylphenol), needles m. 105°; 1-methyl-2-hydroxy-5-rhodanbenzene (o-methyl-p-rhodanphenol), C8H7ONS, m. 71°; 1-methyl-3-hydroxy-5-rhodanbenzene (o-methyl-m-rhodanphenol), C8H7ONS, needles m. 76°; 1-methyl-4-hydroxy-3-rhodanbenzene, C8H7ONS, m. 105°, yields with alc.  HCl a N-free compd., C8H6O2S, m. 83°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRUByAzB_wf7Vg90H21EOLACvtfcHk0lib68B6PvRJXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D&md5=f514b2d36023e1c8ed30c16b08dfeff8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fardp.19292670304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19292670304%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DH.%2BP.%26aulast%3DWeber%26aufirst%3DE.%26atitle%3DArzneimittelsynthetische%2520studien%2520IV.%2520Synthese%2520schwefelhaltiger%2520verbindungen%26jtitle%3DArch.%2520Pharm.%26date%3D1929%26spage%3D192%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Stuckwisch, C. G.</span><span> </span><span class="NLM_article-title">Derivatives of 2-amino-6-methoxybenzothiazole</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1949</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3417</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja01178a043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1949&pages=3417&author=C.+G.+Stuckwisch&title=Derivatives+of+2-amino-6-methoxybenzothiazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja01178a043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01178a043%26sid%3Dliteratum%253Aachs%26aulast%3DStuckwisch%26aufirst%3DC.%2BG.%26atitle%3DDerivatives%2520of%25202-amino-6-methoxybenzothiazole%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1949%26volume%3D71%26spage%3D3417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ismail, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chedekel, M. R.</span><span> </span><span class="NLM_article-title">Synthesis of benzothiazoles. α-Amino-(4-hydroxy-6-benzothiazolyl)propionic acid</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2243</span><span class="NLM_x">–</span> <span class="NLM_lpage">2246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01299a041" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=2243-2246&author=I.+A.+Ismailauthor=D.+E.+Sharpauthor=M.+R.+Chedekel&title=Synthesis+of+benzothiazoles.+%CE%B1-Amino-%284-hydroxy-6-benzothiazolyl%29propionic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo01299a041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01299a041%26sid%3Dliteratum%253Aachs%26aulast%3DIsmail%26aufirst%3DI.%2BA.%26aulast%3DSharp%26aufirst%3DD.%2BE.%26aulast%3DChedekel%26aufirst%3DM.%2BR.%26atitle%3DSynthesis%2520of%2520benzothiazoles.%2520%25CE%25B1-Amino-%25284-hydroxy-6-benzothiazolyl%2529propionic%2520acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D2243%26epage%3D2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Charris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monasterios, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Castro, N.</span><span> </span><span class="NLM_article-title">Synthesis of some 5-nitro-2-furfurylidene derivatives and their antibacterial and antifungal activities</span> <span class="citation_source-journal">Heterocycl. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1515%2FHC.2002.8.3.275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvFGjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=275-280&issue=3&author=J.+Charrisauthor=M.+Monasteriosauthor=J.+Dominguezauthor=W.+Infanteauthor=N.+De+Castro&title=Synthesis+of+some+5-nitro-2-furfurylidene+derivatives+and+their+antibacterial+and+antifungal+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some 5-nitro-2-furfurylidene derivatives and their antibacterial and antifungal activities</span></div><div class="casAuthors">Charris, Jaime; Monasterios, Melina; Dominguez, Jose; Infante, Wilson; De Castro, Norma</div><div class="citationInfo"><span class="NLM_cas:title">Heterocyclic Communications</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-280</span>CODEN:
                <span class="NLM_cas:coden">HCOMEX</span>;
        ISSN:<span class="NLM_cas:issn">0793-0283</span>.
    
            (<span class="NLM_cas:orgname">Freund Publishing House Ltd.</span>)
        </div><div class="casAbstract">New 5-nitro-2-furfurylidene derivs. I (R1 = Me, Ph; R2 = H, NO2; R3 = H, 6-F, 6-Cl, 6-OMe, 5,6-F2, etc.) were synthesized by reaction of 2-methyl-4-(5-nitro-2-furfurylmethylidene)-Δ2-oxazolin-5-one or 2-phenyl-4-(2-furfurylmethylidene)-Δ2-oxazolin-5-one with 2-aminobenzothiazoles.  The compds. synthesized were identified by 1H-NMR, IR, MS and microanal.  All products were screened for their in vitro antibacterial and antifungal activities against the std. strains: Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, and the yeast Candida albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIH2MfHRtP8bVg90H21EOLACvtfcHk0lib68B6PvRJXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvFGjurw%253D&md5=3990df645756e422dab165a5d22d85a4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1515%2FHC.2002.8.3.275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FHC.2002.8.3.275%26sid%3Dliteratum%253Aachs%26aulast%3DCharris%26aufirst%3DJ.%26aulast%3DMonasterios%26aufirst%3DM.%26aulast%3DDominguez%26aufirst%3DJ.%26aulast%3DInfante%26aufirst%3DW.%26aulast%3DDe%2BCastro%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520some%25205-nitro-2-furfurylidene%2520derivatives%2520and%2520their%2520antibacterial%2520and%2520antifungal%2520activities%26jtitle%3DHeterocycl.%2520Commun.%26date%3D2002%26volume%3D8%26issue%3D3%26spage%3D275%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Tomasi, A.; Morgan, B. P.; McDonald, A.; Roof, D.; Maxon, M.</span><span> </span><span class="NLM_article-title">Compounds, Compositions, and Methods</span>. WIPO Patent Application WO 2004/098494, Nov 18,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+Tomasi&author=B.+P.+Morgan&author=A.+McDonald&author=D.+Roof&author=M.+Maxon&title=Compounds%2C+Compositions%2C+and+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTomasi%26aufirst%3DA.%26atitle%3DCompounds%252C%2520Compositions%252C%2520and%2520Methods%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Malik, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manvi, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanjwade, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span> </span><span class="NLM_article-title">Synthesis and screening of some new 2-amino substituted-benzothiazole derivatives for antifungal activity</span> <span class="citation_source-journal">Drug Invention Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1eqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=32-34&issue=1&author=J.+K.+Malikauthor=F.+V.+Manviauthor=B.+K.+Nanjwadeauthor=S.+Singh&title=Synthesis+and+screening+of+some+new+2-amino+substituted-benzothiazole+derivatives+for+antifungal+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and screening of some new 2-amino substituted-benzothiazole derivatives for antifungal activity</span></div><div class="casAuthors">Malik, Jitender K.; Manvi, F. V.; Nanjwade, B. K.; Singh, Sanjiv</div><div class="citationInfo"><span class="NLM_cas:title">Drug Invention Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-34</span>CODEN:
                <span class="NLM_cas:coden">DITRCZ</span>;
        ISSN:<span class="NLM_cas:issn">0975-7619</span>.
    
            (<span class="NLM_cas:orgname">Drug Invention Today</span>)
        </div><div class="casAbstract">Some new 2-Amino substituted-benzothiazole were synthesized by treating with KSCN in presence of glacial acetic acid and with different substituted aniline.  Structures of the synthesized compds. were established on the basis of M.p., TLC, and IR spectral data.  The anti-fungal activity of the synthesized compds. was evaluated by disk diffusion method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tsvkyOHXLrVg90H21EOLACvtfcHk0lib68B6PvRJXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1eqtLs%253D&md5=434175a9fde3bb926ffdf23b4e7f7fec</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DJ.%2BK.%26aulast%3DManvi%26aufirst%3DF.%2BV.%26aulast%3DNanjwade%26aufirst%3DB.%2BK.%26aulast%3DSingh%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520screening%2520of%2520some%2520new%25202-amino%2520substituted-benzothiazole%2520derivatives%2520for%2520antifungal%2520activity%26jtitle%3DDrug%2520Invention%2520Today%26date%3D2009%26volume%3D1%26issue%3D1%26spage%3D32%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Schnur, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fliri, A. F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kajiji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis Lung carcinoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00107a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=914-918&author=R.+C.+Schnurauthor=A.+F.+J.+Fliriauthor=S.+Kajijiauthor=V.+A.+Pollack&title=N-%285-fluorobenzothiazol-2-yl%29-2-guanidinothiazole-4-carboxamide.+A+novel%2C+systemically+active+antitumor+agent+effective+against+3LL+Lewis+Lung+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00107a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00107a007%26sid%3Dliteratum%253Aachs%26aulast%3DSchnur%26aufirst%3DR.%2BC.%26aulast%3DFliri%26aufirst%3DA.%2BF.%2BJ.%26aulast%3DKajiji%26aufirst%3DS.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26atitle%3DN-%25285-fluorobenzothiazol-2-yl%2529-2-guanidinothiazole-4-carboxamide.%2520A%2520novel%252C%2520systemically%2520active%2520antitumor%2520agent%2520effective%2520against%25203LL%2520Lewis%2520Lung%2520carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D914%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sledge, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Q. H.</span><span> </span><span class="NLM_article-title">Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">8599</span><span class="NLM_x">–</span> <span class="NLM_lpage">8607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=8599-8607&issue=24&author=M.+Wangauthor=M.+Gaoauthor=B.+H.+Mockauthor=K.+D.+Millerauthor=G.+W.+Sledgeauthor=G.+D.+Hutchinsauthor=Q.+H.+Zheng&title=Synthesis+of+carbon-11+labeled+fluorinated+2-arylbenzothiazoles+as+novel+potential+PET+cancer+imaging+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMock%26aufirst%3DB.%2BH.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DHutchins%26aufirst%3DG.%2BD.%26aulast%3DZheng%26aufirst%3DQ.%2BH.%26atitle%3DSynthesis%2520of%2520carbon-11%2520labeled%2520fluorinated%25202-arylbenzothiazoles%2520as%2520novel%2520potential%2520PET%2520cancer%2520imaging%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26issue%3D24%26spage%3D8599%26epage%3D8607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wang, M.; Jiang, S.; Hou, X.</span><span> </span><span class="NLM_article-title">[1,2,3] Piazthiole-7-formhydrazide Derivative as I-Type Plant Disease-Resisting Revulsive.</span> SIPO Patent Application CN 1389114, Jan 08,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+Wang&author=S.+Jiang&author=X.+Hou&title=%5B1%2C2%2C3%5D+Piazthiole-7-formhydrazide+Derivative+as+I-Type+Plant+Disease-Resisting+Revulsive."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26atitle%3D%255B1%252C2%252C3%255D%2520Piazthiole-7-formhydrazide%2520Derivative%2520as%2520I-Type%2520Plant%2520Disease-Resisting%2520Revulsive.%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Gyorkos, A. C.; Corrette, C. P.; Cho, S. Y.; Turner, T. M.; Pratt, S. A.; Aso, K.; Kori, M.; Gyoten, M.</span><span> </span><span class="NLM_article-title">Preparation of Nitrogen-Containing Fused Heterocyclic Compounds Like Benzimidazoles and Benzothiazoles as CRF Receptor Antagonists</span>. WIPO Patent Application WO 2005/044793, May 19,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+C.+Gyorkos&author=C.+P.+Corrette&author=S.+Y.+Cho&author=T.+M.+Turner&author=S.+A.+Pratt&author=K.+Aso&author=M.+Kori&author=M.+Gyoten&title=Preparation+of+Nitrogen-Containing+Fused+Heterocyclic+Compounds+Like+Benzimidazoles+and+Benzothiazoles+as+CRF+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGyorkos%26aufirst%3DA.%2BC.%26atitle%3DPreparation%2520of%2520Nitrogen-Containing%2520Fused%2520Heterocyclic%2520Compounds%2520Like%2520Benzimidazoles%2520and%2520Benzothiazoles%2520as%2520CRF%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession code 4KSP for BRAF with <b>8B</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bondi, A.</span><span> </span><span class="NLM_article-title">van der Waals volumes and radii</span> <span class="citation_source-journal">J. Phys. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/doi/10.1021/j100785a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1964&pages=441-451&author=A.+Bondi&title=van+der+Waals+volumes+and+radii"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">van der Waals volumes and radii</span></div><div class="casAuthors">Bondi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-51</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">Intermol. van der Waals radii of the nonmetallic elements were assembled into a list of recommended values for vol. calcns.  These values were arrived at by selecting from the most reliable x-ray diffraction data those which could be reconciled with crystal d. at 0°K. (to give reasonable packing d.), gas kinetic collision cross section, crit. d., and with liquid state properties.  A qual. understanding of the nature of van der Waals radii is provided by correlation with the de Broglie wavelength of the outermost valence electron.  Tentative values for the van der Waals radii of metallic elements in organometallic compds. are proposed.  A list of increments for the vol. of mols. impenetrable to thermal collision, the so-called van der Waals vol., and of the corresponding increments in area per mol. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHeueZoao997Vg90H21EOLACvtfcHk0lh3Q3dP6Y9niA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D&md5=0f25964afae4e9f761e0d314151444a5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fj100785a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100785a001%26sid%3Dliteratum%253Aachs%26aulast%3DBondi%26aufirst%3DA.%26atitle%3Dvan%2520der%2520Waals%2520volumes%2520and%2520radii%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1964%26volume%3D68%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession code 4KSQ for BRAF with <b>5B</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci7002494" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1-24&issue=1&author=K.+A.+Brameldauthor=B.+Kuhnauthor=D.+C.+Reuterauthor=M.+Stahl&title=Small+molecule+conformational+preferences+derived+from+crystal+structure+data.+A+medicinal+chemistry+focused+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule conformational preferences derived from crystal structure data. a medicinal chemistry focused analysis</span></div><div class="casAuthors">Brameld, Ken A.; Kuhn, Bernd; Reuter, Deborah C.; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Based on torsion angle distributions of frequently occurring substructures, conformation preferences of druglike mols. are presented, accompanied by a review of the relevant literature.  First, the relevance of the Cambridge Structural Database (CSD) for drug design is demonstrated by comparing substructures present in compds. entering clin. trials with those found in the CSD and protein-bound ligands in the Protein Data Bank (PDB).  Next, we briefly highlight preferred conformations of elementary acyclic systems, followed by a discussion of sulfonamide conformations.  Due to their central role in medicinal chem., we discuss properties of aryl ring substituents in depth, including biaryl systems and systems of two aryl rings connected by two acyclic bonds.  For a subset of torsion motifs, we also compare torsion angle histograms derived from CSD structures with those derived from ligands in the PDB.  Furthermore, selected properties of some six- and seven-membered ring systems are discussed.  The article closes with a section on attractive sulfur-oxygen contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBrdvMrRvKirVg90H21EOLACvtfcHk0lh3Q3dP6Y9niA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D&md5=289969338dcb94a145ce736d19d05cf4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fci7002494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci7002494%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DReuter%26aufirst%3DD.%2BC.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DSmall%2520molecule%2520conformational%2520preferences%2520derived%2520from%2520crystal%2520structure%2520data.%2520A%2520medicinal%2520chemistry%2520focused%2520analysis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26issue%3D1%26spage%3D1%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haass, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproesser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+Smalleyauthor=D.+Fongauthor=Y.+L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lgIr-PGF8UORg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%2BL.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">Aunique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=Aunique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DAunique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span> </span><span class="NLM_article-title">Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi101777f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=738-751&author=H.+Iwataauthor=S.+Imamuraauthor=A.+Horiauthor=M.+S.+Hixonauthor=H.+Kimuraauthor=H.+Miki&title=Biochemical+characterization+of+TAK-593%2C+a+novel+VEGFR%2FPDGFR+inhibitor+with+a+two-step+slow+binding+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fbi101777f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi101777f%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHixon%26aufirst%3DM.%2BS.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DBiochemical%2520characterization%2520of%2520TAK-593%252C%2520a%2520novel%2520VEGFR%252FPDGFR%2520inhibitor%2520with%2520a%2520two-step%2520slow%2520binding%2520mechanism%26jtitle%3DBiochemistry%26date%3D2011%26volume%3D50%26spage%3D738%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&issue=9&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lj6XMj7k3OGwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D9%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">The Ministry of Health, Labour and Welfare</span><span class="NLM_x">. </span><span> </span><span class="NLM_article-title">The Ministry of Health, Labour and Welfare Ministerial Notification No. 285. General Tests/Reagents, Test Solutions</span>.  <span class="citation_source-book">The Japanese Pharmacopoeia</span>, English version, <span class="NLM_publisher-name">Ministry of Health, Labour and Welfare</span>: <span class="NLM_publisher-loc">Tokyo, Japan</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">15</span>, p.  <span class="NLM_fpage">239</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=239&author=The+Ministry+of+Health%2C+Labour+and+Welfare&title=The+Japanese+Pharmacopoeia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520Ministry%2520of%2520Health%252C%2520Labour%2520and%2520Welfare%2520Ministerial%2520Notification%2520No.%2520285.%2520General%2520Tests%252FReagents%252C%2520Test%2520Solutions%26btitle%3DThe%2520Japanese%2520Pharmacopoeia%26pub%3DMinistry%2520of%2520Health%252C%2520Labour%2520and%2520Welfare%26date%3D2006%26volume%3D15%26spage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Lavoie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thevakumaran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavory, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padeganeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, D. Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, M.</span><span> </span><span class="NLM_article-title">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&issue=7&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+L.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+that+stabilize+a+closed+RAF+kinase+domain+conformation+induce+dimerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0lj6XMj7k3OGwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%2BL.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520that%2520stabilize%2520a%2520closed%2520RAF%2520kinase%2520domain%2520conformation%2520induce%2520dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D7%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">2410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400778d&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm400778d&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400778d&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-2410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0lj6XMj7k3OGwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Galvin, K.</span>MLN2480: A Novel pan-RAF Inhibitor for Treatment of BRAF Mutant and Wild-Type Tumors, 103rd Annual Meeting of American Association for Cancer Research (AACR), Chicago, IL, Mar 31–Apr 4,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Abstract.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=K.+Galvin&title=MLN2480%3A+A+Novel+pan-RAF+Inhibitor+for+Treatment+of+BRAF+Mutant+and+Wild-Type+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGalvin%26aufirst%3DK.%26jtitle%3DMLN2480%253A%2520A%2520Novel%2520pan-RAF%2520Inhibitor%2520for%2520Treatment%2520of%2520BRAF%2520Mutant%2520and%2520Wild-Type%2520Tumors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN','PDB','4DBN'); return false;">PDB: 4DBN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT','PDB','3VNT'); return false;">PDB: 3VNT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP','PDB','4KSP'); return false;">PDB: 4KSP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSQ','PDB','4KSQ'); return false;">PDB: 4KSQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i60"><a href="/doi/suppl/10.1021/jm400778d">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_73337"></div></div></div></div></div><hr /></hr><p class="last">Information related to the feedback activation in fibroblast CsFb cells, reported regioselective/nonselective <i>C</i>-7 substituted 1,3-benzothiazole ring formation reaction of meta-substituted anilines and regioselective cyclization of meta-substituted thioureides, and assay protocols used in kinase enzyme assays, cellular assays, SPR assay, in vivo studies, solubility study, pharmacokinetic studies, and structural biology studies. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400778d/suppl_file/jm400778d_si_001.pdf">jm400778d_si_001.pdf (381.5 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB accession codes are 4KSP for BRAF with <b>8B</b> and 4KSQ for BRAF with <b>5B</b>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400778d&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-16%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm400778d" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400778d" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b5ea5fc9192e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
